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ABSTRACT

The Clinical Significance of HPRT as a Diagnostic and Therapeutic
Biomarker for Hematological and Solid Malignancies
Michelle Hannah Townsend
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy
An estimated 1,735,350 new cancer diagnosis and 609,640 cancer related deaths are
predicted to occur in the United States in 2018. To improve patient prognosis, biomarkers are
needed to identify cancer in early stages. When diagnosed at an early stage, cancer is more likely
to respond to treatments and patients have a higher survival rate. Consequently, there is an everpresent need to identify biomarkers that can aid in the detection of cancer. Additionally, there is
a paradigm shift in the field of cancer treatment towards immunotherapy. Traditional cancer
treatments include chemotherapy, radiation, and hormone therapy and are not cancer-specific,
which leads to bystander effects on the patient’s normal organs that often harm the patient and
create unnecessary hardship. To alleviate this, immunotherapy utilizes a patient’s own immune
cells to attack and destroy cancer cells via cancer-specific biomarkers. These biomarkers are
ideally on the surface of cancer cells and absent from the patient’s normal cells to avoid healthy
tissue destruction. With this new therapy, there is a recent push to find surface antigens for
immunotherapy techniques.
This dissertation describes the characterization of HPRT as a diagnostic and therapeutic
biomarker for the detection and possible treatment of hematological and solid malignancies. We
describe the general upregulation of HPRT upon malignancy and show that this elevation in
protein expression is independent of stage, which indicates that it would be useful as an early
stage diagnostic companion tool. We have preliminarily linked the elevation in HPRT to a
mutation in one of its prime transcription factors, p53. Specific mutation in p53 called Gain of
Function mutations have shown to influence salvage pathway enzyme expression, and we have
shown that mutations in p53 are relevant to the elevated levels of HPRT within several cancer
types. In addition, we also found that HPRT associates significantly with the membrane of
several cancer cell lines as well as patient samples. We found that HPRT has insignificant
expression on normal cells, which suggests it may be useful as a targetable biomarker for
immunotherapy. Throughout our analysis, we also determined that HPRT might have a role in
immune regulation as an elevation of the protein correlates to the decrease of several proinflammatory genes involved in immune activation. The knowledge gained from the data
presented in this dissertation have opened up new functions for HPRT outside of simple
nucleotide production and have confirmed that HPRT has a unique role in cancer that has not
been previously reported.
Keywords: Hypoxanthine Guanine Phosphoribosyltransferase, HPRT1 or HGPRT, cancer
biomarker, salvage enzyme
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SUMMARY OF CHAPTERS/APPENDICES
Summary of Introduction Chapter
Chapter 1 contains two publications that outline the purpose of my research. The first
publication provides background information of HPRT and its relation to health and disease. The
second publication provides a comprehensive look into the current biomarkers in clinical trials
for CAR T cell therapy. These two publications provide insights into why we are analyzing
HPRT as a possible biomarker for immunotherapy. Published paper in Medical Oncology (DOI:
10.1007/212032-018-1144-1) and published paper in the Journal of Experimental and Clinical
Cancer Research (DOI: 10.1186/s13046-018-0817-0).
Summary of Research Chapters
Chapter 2 describes the initial project I completed upon entering the lab, which focused
on the carcinogenicity of a common herbicide, Glyphosate. There has been substantial debate
recently into the safety of using glyphosate as an herbicide in agriculture. With this in mind, we
wanted to evaluate the DNA damaging effects of various levels of glyphosate to determine
whether there was a significant increase in DNA damage, and at what concentration level this
damage occurred. We showed that at physiological levels within the body, glyphosate had no
increase in DNA damage on human cancer cell lines, but at levels above 100mM there was
significant increases in DNA damage. We also determined that for mid-level concentration of
1mM the cells showed significant repair and following 2 hours of incubation, the cells were able
to fully recover. We showed that glyphosate poses little threat to DNA at physiologic
concentrations and cells are able to recover subsequent damage caused by the chemical when
initial damage occurs. Paper published in Regulatory Toxicology and Pharmacology (DOI:
10.1016/j.yrtph.2017.02.002).
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Chapter 3 evaluates the changes in IL-10 and TGF-β expression between primary tumors
and metastatic tumors to determine if there is an increase level of anti-inflammatory cytokines
that aid in a cancer cells ability to colonize other organ sites and avoid immune surveillance. We
found no significant changes in TGF-β expression within malignant tumors compared to normal
controls but did find that IL-10 exhibited variability among the various patients, with a higher
percentage of metastatic patients showing elevated IL-10. These results suggest that IL-10 may
play a role in metastatic potential of the cancer cells and that tumors with an immunosuppressive
microenvironment may be more successful at invading other tissue. Paper published in Cancer
Biology and Therapy (DOI: 10.1080/15384047.2017.1360453).
In Chapter 4 we conducted a pedagogical study to evaluate whether student performance
and concept mastery increased utilizing think pair share quizzes over traditional multiple-choice
quizzes in class in response to a Teaching Enhancement Grant Funding proposal. We found that
TPS questions are easily implemented into lecture-style classrooms and promote student
communication and group learning, which then corresponds to a better understanding of the
material being taught. Based on test scores and student feedback, TPS quizzes were preferred
over standard quizzes and showed a clear improvement in classroom atmosphere and fostered a
collaborative environment. Paper under review.
Chapter 5 explores the expression of HPRT on the cell surface of two non-small cell lung
cancer cell lines: NCI-H460 and A549. In addition, we also evaluated the upregulation of the
protein in lung cancer tissue. We showed that HPRT has a significant localization to the
membrane of both NCI-H460 cells and, to a lesser extent, A549 cells. We also found that
YHPRT was significantly elevated in approximately 50% of lung cancer patients. These data
suggest that HPRT could be used as not only a therapeutic biomarker due to its surface
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expression on malignant cells, but also as a diagnostic biomarker of developing malignancy.
Paper published in OncoTargets and Therapy (DOI: https://doi.org/10.2147/OTT.S128416).
Chapter 6 evaluates the expression of HPRT on the surface of cancer cell lines (SW480,
SW620, Colo205 and HT-29), normal colon tissue, and malignant patient tissue. We found that
SW480, SW620, and HT-29 cells all had significant expression of HPRT on the cell surface,
while Colo205 cells had insignificant expression. In patients, we found that normal colon
samples had no significant presence on the cell surface, but 1 of the 2 malignant samples
analyzed had surface presentation of HPRT. To confirm the variable nature of HPRT
upregulation and surface presentation, we found that 59% of patients had an upregulation of
HPRT in their tumors when compared to normal colon samples. These data show that HPRT
surface expression is not restricted to cancer cell lines as it is present in patient samples.
Additionally, data presented in this publication show the variable nature of HPRT presentation
and expression as not all of the colon cancer cell lines or patients evaluated had surface
expression. Paper published in Molecular and Cellular Oncology (DOI:
https://doi.org/10.1080/23723556.2018.1481810).
Chapter 7 thoroughly analyzes the expression of HPRT in patient tissue to determine
whether it could be used as a diagnostic biomarker for early stage detection of malignancy. We
found that in lung, breast, colon, and prostate tissue, HPRT was elevated in 35%-55% of patients
analyzed. In addition, we also found the same variability in RNA-sequencing data from TCGA
as HPRT experienced a general trend of increased expression in cancer patients. The
upregulation of the protein within malignant tissue was independent of cancer stage, which
indicate that the cause of the upregulation is most likely mutational in nature. The stage
independence also shows that HPRT could be used as an early stage diagnostic biomarker. Paper
published in Cancer and Clinical Oncology (DOI: https://doi.org/10.5539/cco.v6n2p19).
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Chapter 8 describes an investigation into the use of HPRT as a standard endogenous
control for cancer-related studies. We had observed and published that HPRT was upregulated in
a majority of malignant tissue, yet it is widely used as a normalization control for gene
expression analysis. The purpose of this project was to show that HPRT should not be used as a
control and provide sufficient evidence to suggest its removal from use as a standard control. We
found that on the level of RNA, protein, and tissue the expression of HPRT is too variable to be
utilized as a standard. Paper under review.
Chapter 9 elaborates on the surface expression of HPRT in B cell malignancies in
addition to determining possible molecular mechanisms behind the elevation of HPRT within
malignant samples. We found that HPRT is found on the surface of both Raji cells and in seven
of the nine ALL patient samples we analyzed. Following this, we also ranked every B cell line
according to their HPRT expression and found that genes with a positive correlation to HPRT
expression were involved in DNA replication/repair and proliferation, but half of the genes with
a negative correlation to HPRT expression were pro-inflammatory cytokines. This suggests that
HPRT may have an influence on the immune system by downregulating pro-inflammatory
cytokine production. Paper under review.
Chapter 10 explores the expression of four target genes in endometrial cancer to
determine if they would be valuable as diagnostic and therapeutic biomarkers. We found that all
four genes, JAG2, AURKA, PGK1, and HPRT1, had elevated expression in malignant tissue
when compared to normal tissue. In addition, PGK1 and HPRT1 had a stage dependence. In
addition, we also found that HPRT1 and AURKA expression had the most significant impact on
patient survival with higher expressing patients showing a lower overall survival. Subsequently,
we evaluated the drugs that had the highest impact on the gene expression of all target genes and
found that MEK and Topo I inhibitors had the best impact on reducing HPRT1 expression, while
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drugs that had an impact on AURKA elevation were inhibitors of microtubule function. Paper
under review.
Summary of Appendices
Appendix 1 describes the presence of HPRT on the surface of some prostate cancer cells
and determines a preliminary association between HPRT expression and a gain of function
mutation in p53. We found that HPRT is not universally localized to the surface of cancer cells
and determine that DU145 cells have surface presentation while PC3 cancer cells do not. As PC3
cells are null for p53 expression and DU145 cells have a mutated form of p53 we determined
that there is differential expression of HPRT in several cancers with mutations in the p53
transcription factor. Paper in preparation.
Appendix 2 describes the initial association HPRT has with the immune system. We
determined that HPRT elevation corresponds significantly with the downregulation of several
cytokines and both pro-inflammatory and anti-inflammatory genes. We also determined that
HPRT has a significant impact on the survival of several cancer types. This may be a result of
decreased tumor infiltration by immune cells in high expressing patients that we observed in
several cancer types. We hypothesized the effects that elevated HPRT has on immune cells is
directly caused by an increase in guanosine production upon HPRT elevation. To test this we
treated different immune cell subsets with guanosine and adenosine and measured their
activation. We found that in T cells there was no influence with guanosine treatment, while B
cells showed a reduction in activation similar to adenosine treatment. This data indicates that
HPRT may be elevated in the tumor microenvironment as a method to control immune invasion
and afford protection for the tumor. Paper in preparation.
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General Overview
We have found that HPRT expression is variable between cancer patients and has a
significant elevation in several malignancies. This overexpression is also manifest as surface
localization of the protein as HPRT expresses on the cell membrane of several cancer types. We
hypothesize this surface expression to be directly caused by a GOF mutation in p53, but this is
still under investigation. In addition, we have also shown that HPRT has an impact on immune
regulation and acts to downregulate several immune-regulatory cytokines. We have preliminarily
linked this role to the over-production of guanosine, which has been shown to have
immunomodulatory functions in the CNS. All together the data presented in this dissertation
implicate HPRT as a significant contributor to the tumor microenvironment and also as a
potential target for immunotherapy.
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CHAPTER 1
The Biology and Clinical use of HPRT as a Biomarker for Immunotherapy

A Review of HPRT and its Emerging Role in Cancer
Michelle H. Townsend, Richard A. Robison, and Kim L. O’Neill
Citation: Townsend, M.T., Robison, R.A., O’Neill K.L., A Review of HPRT and its Emerging
Role in Cancer. Medical Oncology. 2018. DOI: 10.1007/212032-018-1144-1
The following is taken from an article published in the Journal of Cancer Research and Clinical
Oncology. All content and figures have been formatted for this dissertation.

Abstract
Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) is a common salvage
housekeeping gene with a historically important role in cancer as a mutational biomarker. As an
established and well known human reporter gene for the evaluation of mutational frequency
corresponding to cancer development, HPRT is most commonly used to evaluate cancer risk
within individuals and determine potential carcinogens. In addition to its use as a reporter gene,
HPRT also has important functionality in the body in relation to purine regulation as
demonstrated by Lesch-Nyhan patients whose lack of functional HPRT leads to significant
purine overproduction and further neural complications. This regulatory role, in addition to an
established connection between other salvage enzymes and cancer development, points to HPRT
as an emerging influence in cancer. Recent work has shown that not only is the enzyme upregulated within malignant tumors, it also has significant surface localization within some cancer
cells. With this is mind, HPRT has the potential to become a significant biomarker not only for
the characterization of cancer, but also for its potential treatment.
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Nucleotide Synthesis Pathways
Nucleotides are an integral component of cellular life due to their versatility and
abundance1. Their functional flexibility is demonstrated as ATP and GTP are utilized in both
DNA and RNA synthesis and maintenance, while simultaneously act as energy sources for the
cell2,3. Because the cell is reliant on their correct synthesis, the processes that regulate nucleotide
production are tightly structured and controlled4. These mechanisms are responsible for
maintaining adequate nucleotide levels at all times within the cell, which elevate as high as 5 to
10 fold increases during G1 and S phases of the cell cycle5.
There are two distinct biological pathways eukaryotic cells utilize to synthesize
nucleotides: de novo synthesis and the salvage pathway. De novo synthesis is an energetically
expensive 15 step process that requires up to 28 enzymes to synthesize nucleotides from raw
materials within the cell6. The enzymes involved specifically in purine biosynthesis are
responsible for converting organic glucose into phosphoribosyl pyrophosphate (PRPP), which
can then be converted into GTP and ATP7. Because it requires extensive energy, this anabolic
pathway is primarily used when the demand for nucleotides is the most prominent: during G1
and S phase8. Although complex in nature, this process is highly conserved between organisms,
suggesting that it is ancient in origin9.
The second mechanism, the salvage pathway, has several derived mechanisms that
synthesize nucleotides from used materials within the cell9. While de novo synthesis creates the
components of nucleotides, the salvage pathway utilizes a clever approach that ‘recycles’ parts
from old nucleotides and pieces them together to form complete nucleotides. Due to the
recycling nature of the salvage pathway, it is the chosen nucleotide synthesis mechanism
throughout the cell cycle for both purines and pyrimidines as it aids in conserving valuable
energy. Specifically, for purine synthesis, it is estimated that 90% of free purines in humans are
2

recycled10. Therefore, the enzymes involved in this process are responsible for providing
necessary purine nucleotides for DNA synthesis and maintenance.

Figure 1-1A. An Overview of the HPRT enzyme function. HPRT is responsible for the transfer of a ribose
monophosphate from PRPP to hypoxanthine and guanine to form inosine monophosphate (IMP) and guanine
monophosphate (GMP), respectively. Pyrophosphate is the byproduct from this reaction. After IMP and GMP are
synthesized they are converted to functional nucleotides used in DNA synthesis and repair

Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) is a salvage pathway enzyme
responsible for the formation of IMP and GMP from precursors within the cell to eventually
form Inosine and Guanine, respectively (Figure 1-1A)11. HPRT transfers phosphoribose from
PRPP to hypoxanthine and guanine bases10,12. The enzyme is composed of ten beta strands and
six alpha helices with residues 37-189 forming the core of the enzyme13. Depending on the pH of
the surrounding tissue, the protein can exist as either a dimer or a tetramer with identical
subunits13–15. The molecular weight of each of the protein subunits is 48.9 kDa and the molecule
has an instability index of 21.69, classifying the protein as stable. The functional homo tetramer
contains four subunits labeled A, A’, B, and B’ (Figure 1-2A)13.

3

The HPRT enzyme consists of several regions that each have distinct functions in
substrate recognition and reactivity. The carboxy terminal end of the central beta sheet is
primarily involved in substrate recognition. The core region of the protein contains twisted
parallel beta sheets with five beta strands that are surrounded by four alpha helices. Residues 6574 form the most flexible portion of the protein as they create a loop that will bind
pyrophosphate. The residues of the enzyme that will bind PRPP substrate are 129-140, which are
located on the floor of the active site. In order for enzymatic activity in the active site to be
successful the metal ion Mg2+ is required13,15.

Figure 1-2A. HPRT Protein Structure. The homo tetramer structure of human HPRT. The homo tetramer structure
of human HPRT. A) The protein consists of only 27% alpha helices and 27% beta sheets, which indicates that the
remaining 46% of the enzyme consists of beta turns and random coils. B) Individual subunit labeling is indicated by
the altering colors. Each subunit is identical and is translated from the same mRNA message.

The hprt locus
The hprt gene is 47,827bp and resides on the long arm of the X chromosome (Figure 13A). The gene is relatively large, especially considering that only a small portion of the
transcribed DNA is eventually translated. There are 9 exons that code for a 217 amino acid
protein, which represents only 1.3% of the original genomic message 10,16,17. Because the final
protein product is involved in cellular maintenance, the control sequences upstream of the hprt
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gene contain the hallmarks of a mammalian housekeeping gene; there is an absence of 5’
transcriptional sequences including the TATA and CAAT boxes and there are exceptionally GCrich sequences with many GC hexanucleotide motifs along the 5’ end of the gene18. As a
housekeeping gene, hprt is found in all somatic tissue in low levels19. In a majority of human
cells hprt mRNA transcripts comprise only 0.005 to 0.01% of the total mRNA within the cell20.
The only exception is in central nervous tissue where there is an unusually elevated level of
HPRT expression ranging from 0.02 to 0.04% of the total mRNA, which is a 4 fold increase in
comparison to other somatic tissue20,21. This elevated expression is not fully understood because
cells in the central nervous system (CNS) are not stimulated to divide and would therefore
require less machinery for nucleotide synthesis. In addition, the human genome contains nonfunctional HPRT homologous regions in the autosomal DNA of chromosomes 5, 11, and 1316.
These DNA sequences are not known to be transcribed and are most likely pseudogenes, but
their exact origin and expression is not well understood22.

Figure 1- 3A. The HPRT locus. The HPRT gene contains 9 exons coding for a 657bp coding mRNA and a resulting
217 amino acid protein.
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HPRT regulatory role: Examples from Lesch-Nyhan Syndrome
As an essential housekeeping protein, a deficiency of HPRT results in a spectrum of
diseases that directly correspond with the availability of the protein. Individuals with a complete
lack of functional HPRT develop Lesch-Nyhan syndrome, while individuals with a partial
deficiency develop gout-like symptoms characteristic of Kelley-Seegmiller syndrome21. Because
the gene is located on the X chromosome, it is an X-linked recessive condition that
predominantly affects males of diseased families. A common thread that connects these distinct
diseases is the presence of hyperuricemia in patients. The excess of uric acid within the plasma,
usually ranging between 9 and 12 grams per liter, contributes to many of the underlying
symptoms typical of HPRT deficiency22. These symptoms are not present in individuals who are
deficient in any of the other salvage pathway enzymes despite having the same function in
nucleotide synthesis.
Lesch-Nyhan syndrome is primarily characterized by severe neurological illnesses.
Patients suffer from dystonia, choreoathetosis, twisting and writhing, akathisia, akinesia, and
several other motor neuron disorders that make successful voluntary motion incredibly difficult
and frequently impossible. Along with motor neuron dysfunction, patients also suffer from
severe self-injurious behavior that can lead to self-mutilation22–28. Along with improper neural
development, Lesch-Nyhan patients also show significant purine overproduction. This
overproduction indicates that HPRT is crucial in not only the synthesis of purines, but also the
regulation of their production21.
When patients have a reduced level of HPRT rather than a complete deficiency they
develop gout-like manifestations and eventual gouty arthritis, distinctive of Kelley-Seegmiller
syndrome21. Partial HPRT deficiency usually develops from a point mutation resulting in a single
amino acid substitution within the protein22. Many such mutants have been characterized and are
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often present in the amino-terminal domain of the protein27. These mutations generally stay
within family lineages, and it is rare that two separate families share the same mutation.
Symptoms are directly related to, and caused by, the excess production of uric acid within the
body. Diseased individuals pass large amounts of urate crystals into the urine for a majority of
their early life, and after approximately 20 years of chronic hyperuricemia an inflammatory
response develops that leads to arthritis17. In Lesch-Nyhan Syndrome and Kelley-Seegmiller
syndrome the regulatory nature of HPRT is demonstrated as the lack of the protein results in an
over-production of purines. We suggest a possible negative feedback loop controlling purine
production that may be regulated by the availability of HPRT within the cell: as cells have
sufficient purines, HPRT is utilized to halt further purine synthesis.
Relationship between other salvage pathway enzymes and cancer
Involved in the same salvage pathway nucleotide synthesis pathway as HPRT, Thymidine
Kinase 1 (TK1), previously known as fetal TK, is an enzyme that controls pyrimidine synthesis
of thymine. TK1 catalyzes the conversion of thymidine to deoxythymidine monophosphate
(dTMP)29. Due to its presence in the serum of cancer patients, TK1 is known as a proliferative
biomarker in cancer development and as a biomarker to monitor recurrence30–35. The serum
detection of TK1 is an early step in cancer growth and has been used as an early detection system
for cancer prevention as elevated serum levels have been shown to correspond with tumor
aggressiveness30,36–38. It has also been suggested that TK1 could be used to distinguish between
slowly growing tumors and more aggressive, fast growing tumors39. In addition, TK1 has been
established as a cancer biomarker for multiple cancers including leukemia, colorectal cancer,
lung cancer, breast cancer, and prostate cancers37,40. As an established biomarker for cancer
development, TK1 demonstrates the relationship between cancer proliferation and the control of
salvage enzymes.
7

HPRT as a reporter gene
The role HPRT has played within the realm of cancer has been largely limited to its use
as an established human reporter gene. The hprt gene is currently used to assess somatic
mutations and mutagenesis in in vitro and in vivo studies evaluating potential carcinogens and
cancer therapies41–45. As the first human somatic gene mutation assay developed, the HPRT
assay has been thoroughly used to identify and select mutant cells by taking advantage of the
biochemical pathways used to synthesize DNA within cells46–48. Mutations in the hprt locus are
carefully monitored in studies of individuals exposed to both potential mutagens and
carcinogenic agents to determine the effects of exposure to DNA integrity and resulting cancer
risk49–53 Using this mutational biomarker, researchers have found significant correlations
between HPRT mutations and increased cancer risk45,50,52–58. Gladd and Tindall used the hprt
locus to determine the mutation rate of various cancer cell lines with mismatch repair-gene
defects59. While Branda et al. utilized the hprt locus to monitor the DNA mutation rate of women
with breast cancer treated with tamoxifen, radiotherapy, or chemotherapy54. As such as
influential biomarker for cancer development, the utilization of hprt has led to significant
contributions to the cancer community.
Emerging role in cancer
Recently, new evidence has indicated an emerging role for HPRT within cancer.
Researchers have found that HPRT has elevated expression specifically within cancer cells.
Muller et al., using quantitative PCR, found that HPRT was present in breast cancer cell lines
(MDA-MB-231), primary tumors, and tumor-infiltrated lungs of SCID mice injected with MDAMB-231 breast cancer cells. Yet, they found no detectable amount of the enzyme in normal lungs
from healthy mice counterparts. Additionally, Muller et al. found that the mRNA levels of hprt
directly correlated with the tumor load of the tested mouse, indicating that the level of HPRT
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within the mouse was related to the size of the tumor60. Furthermore, evaluation of HPRT
expression in cancer patients via immunohistochemistry shows significant variability between
cancer patients61. Overall, HPRT is generally over-expressed within cancer patients as data from
both tissue and RNA-seq shows significant increases in protein levels within malignant
samples61. While there is an overall increase in malignancy, HPRT over-expression is not a
consistent trend within all patients, and only a cohort of cancer patients experience an upregulation61. This indicates that the regulation of HPRT synthesis is compromised within those
patients. As previously discussed, HPRT has a regulatory function within the cell that may
contribute to this apparent lack of transcriptional control within malignant cells. As a protein
with differential expression, HPRT has the potential to be used as a characterization tool when
assessing patient tumors and evaluating treatment options.
In addition to showing unique expression profiles within malignant tumors, HPRT also
has been implicated as a possible surface biomarker. Recent work has shown that HPRT colocalizes with the plasma membrane of certain cancer cell lines62. As a potential cancerassociated antigen, HPRT could become a target for emerging immunotherapies designed to
attack cancer cells displaying unique surface proteins. As the expression of the enzyme is
generally consistent and extremely low within normal cells, HPRT could become a useful tool
for those patients who experience an upregulation. We propose that HPRT is involved in some
regulatory pathway monitoring and controlling nucleotide synthesis and protein production and
within a malignant environment this regulation is lost and HPRT becomes over-expressed
allowing cancer cells to bypass pathways controlled or regulated by strict HPRT production.
Further work is required to solidify HPRT as a significant biomarker for cancer identification,
characterization, and possible targeting, but the enzyme has recently shown significant promise
as not only a mutational reporter gene, but also a cancer biomarker and neoantigen.
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Abstract
Biomarkers are an integral part of cancer management due to their use in risk assessment,
screening, differential diagnosis, prognosis, prediction of response to treatment, and monitoring
progress of disease. Recently, with the advent of Chimeric Antigen Receptor (CAR) T cell
therapy, a new category of targetable biomarkers has emerged. These biomarkers are associated
with the surface of malignant cells and serve as targets for directing cytotoxic T cells. The first
biomarker target used for CAR T cell therapy was CD19, a B cell marker expressed highly on
malignant B cells. With the success of CD19, the last decade has shown an explosion of new
targetable biomarkers on a range of human malignancies. These surface targets have made it
possible to provide directed, specific therapy that reduces healthy tissue destruction and
preserves the patient’s immune system during treatment. As of May 2018, there are over 100
clinical trials underway that target over 25 different surface biomarkers in almost every human
tissue. This expansion has led to not only promising results in terms of patient outcome, but has
also led to an exponential growth in the investigation of new biomarkers that could potentially be
utilized in CAR T cell therapy for treating patients. In this review, we discuss the biomarkers
currently under investigation and point out several promising biomarkers in the preclinical stage
of development that may be useful as targets.
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Background
As the new paradigm shift in cancer treatment, immunotherapy is the epitome of
personalized medicine, as a patient’s immune system is enlisted to fight their own cancer.
Originally manifest as monoclonal antibody therapy, immunotherapy now has a broadened
definition that encompasses tumor vaccines, checkpoint blockades, bispecific antibodies, tumor
infiltrating lymphocytes (TILs), and most recently, chimeric antigen receptor (CAR) T cell
therapy. T cells are a critical component of the adaptive immune system as they not only
orchestrate cytotoxic effects, but also provide long term cellular ‘memory’ of specific antigens63.
Commonly, a patient will have TILs specific for their tumor but these cells are often retrained by
the tumor microenvironment to become anergic and nonfunctional64. T cells endogenously
require the interaction between MHC displayed peptides and their TCR to activate65, but CAR T
cells have been engineered to activate via an antibody fragment towards a tumor-associated or
tumor-specific antigen (TAA and TSA, respectively). CAR T cells are a “living drug” comprised
of a single chain variable fragment (scFv) fused to the signaling domain of a T cell. Upon
recognition and binding to the scFv target, the T cell activates and subsequent target cell killing
is initiated. CAR T cell therapy has been revolutionary in the treatment of hematological
malignancies with the targets CD19 and CD20 but has been unable to translate effectively to
solid tumors. A major drawback for CAR therapy in solid malignancies is the lack of cancerspecific tumor targets. While hematological malignancies do not necessarily require antigen
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target specificity towards cancer cells, solid tumor targets do, and the specific biomarker cannot
be expressed on normal tissue.

Figure 1-1B. Uses of Cancer Biomarkers. Cancer biomarkers have had a historically proven useful for several
different aspects of cancer patient care. With the advent of immunotherapy, surface cancer biomarkers are being
utilized as therapeutic targets to direct and orchestrate an immune response in a cancer-specific fashion.

With over 300 CAR T cell therapy clinical trials ongoing in CAR therapy as of May
2018, there has been an equally impressive effort to identify and characterize TAA or TSA
surface biomarkers in solid tumors. Biomarkers have been an integral component of cancer for
several decades, and with the expansion of CAR T cell therapy, a new category of therapeutic
biomarkers has arisen. These markers can be used to direct CAR T cells to malignant target cells
(Figure 1-1B). The effort to identify and characterize these therapeutic biomarkers has been
substantial and has increased exponentially over the last decade. As a result, 18 surface
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biomarkers are currently being evaluated in clinical trials (Figure 1-2B). In addition, there is also
a significant number of pre-clinical biomarkers that have shown promise as targets for CAR
therapy due to their unique expression on cancer cells. Here, we summarize the biomarkers
currently under investigation in clinical trials for both hematological and solid malignancies,
along with those that may prove useful in future CAR therapies for solid tumors.

Figure 1-2B. Current CAR T cells in clinical trials. From the initial success of CD-19 CAR T cell therapy, several
new biomarker targets have emerged and are being tested in clinical trials. This expansion of targets has expanded
CAR T cell therapy to the treatment of not just hematological malignancies, but also to solid tumors as well.

Surface Biomarkers have expanded significantly over the last decade
CAR T cell therapy was initially conceptualized in 198966 and was recognized as an
effective therapeutic after targeting CD19 for the treatment of lymphomas and leukemias 67–69.
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This led to an exponential growth in CAR therapy and as a direct consequence, in surface
biomarker discovery (Figure 1-3B). In 2012, there were a total of 5 clinical trials, four targeting
CD19 and one targeting Mesothelin. This number has continued to grow and the number of
biomarkers tested in a clinical setting has also expanded from 2 to 25. The year 2017 saw more
clinical trials than any previous year with 111 initiated, targeting 17 different biomarkers (Table
1-1B). This growth demonstrates not only the efficacy of CAR T cell therapy, but also the huge
push in immunotherapy to find new and better targets.

Figure 1-3B. Clinical trial Biomarkers as of May 2018 by year. The expansion of CAR targets is shown as the
diversity and number of clinical trials has exponentially increased from 2012. Not only are there more clinical trials
utilizing CAR T cell therapy, there are also more targets being evaluated.
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Table 1-1B. Current Clinical Trials (as of April 2018)
Target

Name

Function

Disease

Clinical Trials in 2018

CD19

Cluster of
Differentiation
19

Dominant signaling
component on mature B
cells

ALL, B cell lymphoma, leukemia,
Non-Hodgkin lymphoma,

NCT03366350*, NCT03366324*,
NCT02546739*, NCT03448393*,
NCT03467256*, NCT03488160*,
NCT03016377*, NCT03468153*,
NCT03483688*, NCT03398967*,
NCT03229876*, NCT03455972*,
NCT03423706*, NCT03497533*

exact function of
mesothelin in these
normal mesothelial
cells is unclear.

Pancreatic cancer, Cervical Cancer,
Ovarian Cancer, Lung Cancer,
Peritoneal carcinoma, Fallopian
tube cancer, Colorectal Cancer,
Breast Cancer

NCT02930993+, NCT03182803+,
NCT03030001+, NCT02706782+,
NCT01583686+, NCT03356795+,
NCT03054298+, NCT03267173+,
NCT02792114+, NCT02959151+,
NCT02580747+, NCT02414269+,
NCT02465983+, NCT03323944+,

Mesothelin

Her2

Human
Epidermal
Growth Factor
Receptor 2

Activate intracellular
signaling pathways in
response to extracellular
signals.

CNS tumor, Breast Cancer, Ovarian
Cancer, Lung Cancer, Gastric
Cancer, Colorectal Cancer, Glioma,
Pancreatic Cancer, Glioblastoma

NCT03500991*, NCT03423992*,
NCT02713984+, NCT03267173+,
NCT02792114+, NCT02442297+,
NCT00889954+, NCT03423992+,
NCT01109095+, NCT02706392+,
NCT00902044+, NCT03389230+,

PSCA

Prostate Stem
Cell Antigen

Not well understood

Pancreatic cancer, lung cancer

CT03198052+, NCT02744287+,
NCT03267173+

CEA

Carcinoembryoni
c antigen

Cell adhesion

Liver metastases, lung cancer,
colorectal cancer, gastric cancer,
breast cancer, pancreatic cancer,

NCT02850536+, NCT02349724+,
NCT03267173+, NCT02959151,

CD33

Siglec-3

Transmembrane receptor
on myeloid lineage

Myeloid leukemia,

NCT03473457*, NCT02958397+,
NCT03126864+, NCT03222674+,

GAP

GTPaseactivating
protein

Terminating G protein
signaling

Solid tumors

NCT02932956*

GD2

Ganglioside G2

Glioma, Cervical cancer, sarcoma,
neuroblastoma,

NCT03423992*, NCT03356795+,
NCT02992210+, NCT01953900+,
NCT02761915, NCT03373097+,
NCT02765243+, NCT03423992+,
NCT03294954+, NCT03356782+,
NCT02919046+,

CD5

Cluster of
differentiation 5

TCR inhibitory molecule

T cell acute lymphoblastic
lymphoma, T-non-Hodgkin
lymphoma,

NCT03081910+,

PSMA
(PSMA/TGF
β)

Prostate specific
membrane
antigen

Transmembrane protein

Cervical cancer, Prostate cancer,
Bladder cancer

NCT03356795+, NCT03089203+ (TGFβ), NCT03185468+,
NCT01140373+

ROR1

Receptor
Tyrosine Kinase
like Orphan
Receptor 1

Modulates neurite growth
in the CNS

Breast cancer, lung cancer,
lymphoblastic leukemia,

NCT02706392+,

CD123

IL-3RA

Involved in hematopoietic
progenitor cell
differentiation and
proliferation

AML, Leukemia,

NCT03473457*, NCT03125577+,
NCT02937103+, NCT03114670+,
NCT02159495+, NCT03098355+,
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NCT03222674+, NCT03203369+,
NCT03190278+,
CD70

Cluster of
differentiation
70

Induces proliferation of
costimulated T cells

B cell malignancies, pancreatic
cancer, renal cell cancer, breast
cancer, melanoma, ovarian cancer

NCT03125577+, NCT02830724+,

CD38

Cluster of
differentiation
38

Cell adhesion, signal
transduction, and calcium
signaling

Myeloma,

NCT03464916*, NCT03473496*,
NCT03473457*, NCT03125577+,
NCT03222674+, NCT03271632+,

BCMA

B cell maturation
antigen

Mediates the survival of
plasma cells

Myeloma

NCT03448978*, NCT03473496*,
NCT03430011*, NCT03455972*,
NCT02954445+, NCT03322735+,
NCT03338972+, NCT03318861+,
NCT02215967+, NCT03093168+,
NCT03274219+, NCT03302403+,
NCT03492268+, NCT03288493+,
NCT03070327+, NCT03196414+,
NCT03448978+, NCT02958410+,
NCT03287804+, NCT03473496+,
NCT03380039+, NCT03430011+,
NCT03361748+, NCT03455972+,
NCT02546167+, NCT03271632+

Muc1

Mucin 1

Mucous barrier formation
on epithelial surfaces

Sarcoma, Leukemia, Pancreatic
cancer, cervical cancer, lung
cancer, hepatocellular carcinoma,
breast cancer, glioma, colorectal
cancer, gastric cancer

NCT03179007+, NCT02587689+,
NCT02617134+, NCT03198052+,
NCT03356795+, NCT03267173+,
NCT03222674+, NCT03356782+

EphA2

Ephrin type-A
receptor 2
precursor

Eph-ephrin bidirectional
signaling pathway of
mammalian cells

Glioma

NCT03423992*

EGFRVIII

Epidermal
growth factor
receptor variant
III

Cell differentiation and
proliferation

Glioblastoma

NCT03283631*

IL13Ra2

Interleukin 13
receptor, alpha 2

Signal processing via JakSTAT

Glioma

NCT02208362+

CD133

Prominin-1

unknown

Glioma, AML, Liver Cancer,
Pancreatic Cancer, Ovarian Tumor,
Colorectal Cancer, Breast Cancer

NCT03473457*, NCT03356782+,
NCT03423992*

GPC3

Glypican 3

Regulate cell growth,
division, and survival

Heptocellular carcinoma, lung
cancer, Lymphoma, Leukemia,
Pancreatic Cancer, Colorectal
Cancer

NCT02905188*, NCT02932956*,
NCT02715362+, NCT03130712+,
NCT02395250+, NCT02876978+,
NCT03198546+, NCT02723942+,
NCT03084380+, NCT03302403+,
NCT03146234+, NCT02959151+,

EpCam

Epithelial cell
adhesion
molecule
precursor

Embryonic stem cell
proliferation and
differentiation

Breast Cancer, Colon Cancer,
Pancreatic Cancer, Esophageal
Carcinoma, Gastric Cancer,
Prostate Cancer, Hepatic
Carcinoma, Lymphoma, Leukemia

NCT02915445+, NCT03013712+,
NCT02729493+, NCT02725125+,
NCT02728882+, NCT02735291+

FAP

Fibroblast
activation
protein alpha

Neuropeptide regulation.
hFGF21 inactivation

Pleural Mesothelioma

NCT01722149+

Note. +; indicate trials ongoing/active, *; indicate trials that started in 2018
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Current Clinical Targets for Hematological Malignancies
As the most studied and researched target for CAR therapy, CD19 has shown impressive
success in clinical settings to treat Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin
Lymphoma (NHL), and Chronic Lymphocytic Leukemia (CLL)70. Despite the high levels of
complete response rates in patients, relapse from CD19 CAR therapy can occur via a suppressive
tumor microenvironment or antigen escape71–73. With this in mind, new targets are being
identified and evaluated to treat hematological malignancies. Among these new targets are CD5,
CD123, CD33, CD70, CD38, and BCMA. These same targets have already shown promise using
drug-conjugated antibodies, and several have been FDA approved for treatment (Figure 1-4B).
These biomarkers are now being evaluated as targets for adoptive T cell CAR therapy to treat
hematological malignancies.
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Figure 1-4B. Biomarker targets for hematological malignancies. The endogenous function of each of A) CD5, B)
BCMA, C) CD33. D) CD38, E) CD70, and F) IL13Rα2 are shown. These targets are all being utilized to treat
hematological malignancies in clinical trials. They are not cancer-specific and do have expression on normal cells
but have an elevation within cancer that is being used for targeting.
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CD5
CD5 is a negative regulator of TCR signaling and is expressed on the surface of most T
cells and on a specific subpopulation of B cells (B-1) found most commonly in fetal cells74
(Figure 1-4A-B). CD5 has high expression in approximately 80% of T-cell acute lymphoblastic
leukemia (T-ALL) and T cell lymphomas along and also has significant expression on B-cell
lymphomas75. CD5 was first utilized as an immunotherapy treatment via immunotoxinconjugated antibodies76–82 that aided in the depletion of malignant T cell populations in treated
patients. More recently, CD5 has been utilized as a CAR target to treat T cell malignancies
directly. As CD5 is not cancer specific, this treatment results in T cell aplasia83,84. While this is
not ideal for long term patient immune functionality, the therapy is effective in eliminating
malignant T cell populations and prolonging patient survival.
IL13Rα2
Interleukin-3 receptor alpha chain (IL13Rα2 or CD123) is a surface receptor found
overexpressed in several hematological malignancies including blastic plasmacytoid dendritic
cell neoplasm (BPDCN)85, hairy cell leukemia86,87, B-cell acute lymphocytic leukemia (B-ALL)
86,88

, and Acute myeloblastic leukemia (AML)89,90. As the receptor expression is limited on

hematopoietic stem cells, the receptor has promising use as a targetable biomarker for CAR
therapy90,91 (Figure 1-4F-B). Initial targeting of IL13Rα2 was conducted utilizing the natural
ligand, IL-3, but CAR T cell approaches are now being utilized to further target this receptor to
treat primarily AML patients. Initial trials with CD123 CAR cells showed potent cytotoxicity
against AML cells within mice92–95 and in human patients96. This preliminary success has led to
its further testing in clinical trials, evaluating this therapy for both safety and efficacy against
AML. IL13Rα2, like CD5, is not cancer specific, and the consequence of CD5 CAR T cells is
severe myeloablation97.
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CD33
CD33 is a transmembrane receptor that binds sialic acid and causes inhibition of
activation. The protein is expressed on AML blasts and normal myeloid progenitors98–102 (Figure
1-4C-B). Because CD33 is absent in adult pluripotent hematopoietic stem cells and has elevated
expression on approximately 85-90% of AML patients, the antigen has gained clinical
significance as a TAA103–105. In initial trials testing the efficacy of CD33 CAR T cells, patients
showed signs of an inflammatory reaction in response to infused CAR T cells: chills, fever, and
elevated cytokine levels. This resulted in reduced blasts within the bone marrow following two
weeks of therapy106. Following these preliminary tests, clinical trials are ongoing to determine if
CD33 is a safe and effective treatment for myeloid leukemia.
CD70
CD70 is a target that is being utilized to treat both hematological malignancies as well as
solid tumors (Table 1-1B). CD70 is the membrane-bound ligand of the CD27 receptor (TNF
superfamily)107–109 (Figure 1-4E-B). Expression of CD70 is limited to diffuse large B-cell and
follicular lymphomas, as well as Hogkins lymphoma, multiple myeloma, and EBV-associated
malignancies110–114. Additionally, CD70 is also expressed on other malignancies such as
glioma115–118, breast cancer119,120, renal cell carcinoma110,121–123, ovarian cancer124–126, and
pancreatic cancer124,127. Targeting this antigen is feasible as CD70/CD27 signaling is not
essential for the development of a functional immune system as CD27-/- mice recover from
infection in a similar time frame as CD27WT mice128,129. Targeting was first performed using
monoclonal antibodies against CD70, and this showed promise in animal models110,130,131. CD70
CAR T cell treatments are unique because an antibody fragment against CD70 is not being
utilized; instead, the CAR signaling domain is attached to the human CD27 protein, the natural
binding partner of CD70, which functions with similar specificity as an scFv107.
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CD38
CD38 is a glycoprotein associated within lipid rafts and is specific to cell surface
receptors that function to regulate calcium flux and mediate signal transduction in both lymphoid
and myeloid cells132–134. While CD38 is expressed consistently on myeloma cells132,135, it’s
expression is limited on normal lymphoid and myeloid cells136 (Figure 1-4D-B). As a TAA,
CD38 has been used as a target via monoclonal antibody treatment (Daratumumab)132, which
was approved by the FDA in 2015 for patients with multiple myeloma137. Daratumumab showed
an overall response rate of 31%, which demonstrates the success of utilizing CD38 as a target.
CD38 CAR T cells have shown similar efficacy against double-hit lymphoma cells (MYC
rearrangement along with BCL2 or BCL6 rearrangement)138. With promising data, CD38 CAR T
cells are currently in phase I trials against myeloma to test safety and dosing.
BCMA
B cell maturation antigen (BCMA) is a TNF receptor that binds B-cell activating factor
(BAFF) and is universally expressed on myeloma cells but has insignificant expression on major
adult organs139 (Figure 1-4B-B). BCMA is exclusively expressed in B-cell lineage cells, and is
expressed during plasma cell differentiation140. In preclinical models, anti-BCMA CAR T cells
have shown effective killing of myeloma cells both in vitro and in vivo141,142. Following Phase I
safety studies, some patients experienced neurotoxicity and cytokine release syndrome, which
are common side effects of CAR T cell treatment143. Other side effects of targeting BCMA are
similar to those of other hematological malignancies, as patients suffer from partial or complete
B cell aplasia.
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Current clinical targets for solid tumors
While CAR T cell therapy has been very successful against hematological malignancies,
it has been challenging to apply this technology to solid tumors. This challenge has resulted in a
strong effort to discover biomarkers for solid malignancies. As such, there are 17 biomarkers
currently in clinical trials for solid tumors (Figure 1-5B).

Figure 1-5B. Biomarker targets for solid malignancies. Over 14 different organ types are currently being targeted
using a variety of different biomarkers. Many biomarker targets have expression in several different cancer types.

Mesothelin
Mesothelin (MSLN), the second most frequently targeted biomarker after CD19, has
emerged as an attractive target for cancer immunotherapy. MSLN is a cell-surface glycoprotein
with presence in the sera of cancer patients as soluble MSLN-related peptide (SMRP). Within
normal tissue, the expression of MSLN is restricted to mesothelial cells lining the pericardium,
peritoneum, and pleura. Yet, in cancer cells, MSLN is overexpressed on nearly a third of human
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malignancies144. Elevated levels of MSLN have been reported on ovarian cancers145,146, nonsmall-cell lung cancers147,148, breast cancers149,150, esophageal cancers151, colon and gastric
cancers152, and pancreatic cancers153. In addition, Lamberts et al. reported MSLN expression in
other solid tumors such as thyroid cancer, renal cancer, and synovial sarcoma154. The biological
function of MSLN is nonessential given that MSLN-/- mice do not show any phenotypic
abnormalities155. However, the overexpression of MSLN has been associated with cancer cell
proliferation, increased local invasion and metastasis, and resistance to apoptosis induced by
cytotoxic agents150,156–158. MSLN-CAR T cells have been created and tested against ovarian
cancer, and lung cancer156. These CAR T cells have shown significant increases in T cell
proliferation, T cell redistribution to metastatic sites, reduction in tumor burden, and increased
overall survival. This promising pre-clinical data has led to several Phase I clinical trials to test
the safety and efficacy of MSLN CAR T cell therapy against several tumors (Table 1-2B). Initial
Phase I clinical trials have shown transient expression of the MSLN-CAR T cells and minimal
cytokine release syndrome or on-target, off-tumor effects (NCT01355965, NCTO 02159716 &
NCTO01897415). A single infusion of MSLN-CAR T cells resulted in decreased tumor burden
and patients had no signs of long-term toxicities 1-2 months post infusion159.
Table 1-2B. Mesothelin CAR T cell clinical trials (as of April 2018)
Title

Recruitment

Conditions

Phases

NCT number

1

Anti-mesothelin CAR T Cells for
Patients with Recurrent or
Metastatic Malignant Tumors

Recruiting

Mesothelin Positive
Tumors

Phase 1

NCT02930993

2

PD-1 Antibody Expressing CAR
T Cells for Mesothelin Positive
Advanced Malignancies

Recruiting

Advanced Solid Tumor

Phase 1,
Phase 2

NCT03030001

3

A Study of Mesothelin
Redirected Autologous T Cells
for Advanced Pancreatic
Carcinoma

Recruiting

Pancreatic Cancer

Phase 1

NCT02706782
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4

CTLA-4 and PD-1 Antibodies
Expressing Mesothelin-CAR-T
Cells for Mesothelin Positive
Advanced Solid Tumor

Recruiting

Advanced Solid Tumor

Phase 1,
Phase 2

NCT03182803

5

Pilot Study of Autologous Tcells in Patients with
Metastatic Pancreatic Cancer

Completed

Pancreatic Cancer

Phase 1

NCT02465983

6

Intervention of CAR-T Against
Cervical Cancer

Recruiting

Cervical Cancer

Phase 1,
Phase 2

NCT03356795

7

Autologous Redirected RNA
Meso CAR T Cells for
Pancreatic Cancer

Completed

Metastatic Pancreatic
Ductal
Adenocarcinoma (PDA)

Phase 1

NCT01897415

8

Evaluate the Safety and
Efficacy of CAR-T in the
Treatment of Pancreatic
Cancer.

Recruiting

Pancreatic Cancer

Early Phase
1

NCT03267173

9

CART-meso in Mesothelin
Expressing Cancers

Completed

Metastatic Pancreatic
(Ductal)
Adenocarcinoma,
Epithelial Ovarian
Cancer, Malignant
Epithelial Pleural,
Mesothelioma

Phase 1

NCT02159716

10

CAR T Cells in Mesothelin
Expressing Cancers

Active, not
recruiting

Lung Adenocarcinoma,
Ovarian Cancer,
Peritoneal Carcinoma,
Fallopian Tube Cancer,
Mesotheliomas
Pleural, Mesothelioma
Peritoneum

Phase 1

NCT03054298

11

Treatment of Relapsed and/or
Chemotherapy Refractory
Advanced Malignancies by
CART-meso

Recruiting

Malignant
Mesothelioma,
Pancreatic Cancer,
Ovarian Tumor, Triple
Negative Breast
Cancer, Endometrial
Cancer, Other
Mesothelin Positive
Tumors

Phase 1

NCT02580747

12

Autologous CARTmeso/19
Against Pancreatic Cancer

Active, not
recruiting

Pancreatic Cancer

Early Phase
1

NCT03497819

13

Malignant Pleural Disease
Treated with Autologous T
Cells Genetically Engineered to

Recruiting

Malignant Pleural
Disease,
Mesothelioma, Lung
Cancer, Breast Cancer

Phase 1

NCT02414269
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Target the Cancer-Cell Surface
Antigen Mesothelin
14

A Study of Chimeric Antigen
Receptor T Cells Combined
with Interventional Therapy in
Advanced Liver Malignancy

Recruiting

Hepatocellular
Carcinoma, Metastatic
Pancreatic Cancer
Metastatic Colorectal
Cancer

Phase 1,
Phase 2

NCT02959151

15

CAR T Cell Receptor
Immunotherapy Targeting
Mesothelin for Patients with
Metastatic Cancer

Recruiting

Cervical Cancer,
Pancreatic Cancer,
Ovarian Cancer,
Mesothelioma, Lung
Cancer

Phase 1,
Phase 2

NCT01583686

16

CAR T Cell Immunotherapy for
Pancreatic Cancer

Active, not
recruiting

Pancreatic Cancer

Phase 1

NCT03323944

17

Autologous Redirected RNA
Meso-CIR T Cells

Completed

Malignant Pleural
Mesothelioma

Phase 1

NCT01355965

18

T-Cell Therapy for Advanced
Breast Cancer

Recruiting

Breast Cancer,
Metastatic HER2negative Breast

Phase 1

NCT02792114

Her2
HER2 (Human epidermal growth factor 2) is a transmembrane tyrosine kinase in the
ERBB family. The HER2 receptor plays an important role in normal cell growth and
differentiation, activating PI3K/Akt and RAS/Raf/MEK/MAPK pathways160. Studies have
reported HER2 protein overexpression, gene amplification, and mutation in many cancers
including breast, lung, colorectal, brain, ovarian, and pancreas161. Overexpression of HER2 has
been found to be associated with increased tumor cell proliferation and invasion162, decreased
response to hormonal treatment163, and resistance to apoptosis164. HER2 has been targeted
utilizing DNA vaccines, peptide vaccines, and dendritic vaccines which have shown promising
results in both preclinical and early clinical studies165,166. Trastuzumab, a humanized monoclonal
antibody developed to target overexpressed HER2 receptor, has also shown success as an
immunotherapy treatment. Transtuzumab, along with chemotherapy, has increased overall
survival and risk of recurrence compared to chemotherapy alone in HER2 overexpressing breast
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cancer patients167. Several groups have reported the anti-tumor activity, persistence, and
application feasibility of HER2 CAR T cells preclinically in HER2 overexpressing cancer as an
alternative targeted therapy168–170. The success of preclinical experiments of HER2 CAR T cell
has led to the initiation of several clinical trials for the treatment of various cancers (Table 13B)171–173.
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Table 1-3B. HER2 CAR T cell clinical trials (As of April 2018).
Title

Recruitment

Conditions

Phases

NCT Number

1

HER2-specific CAR T Cell
Locoregional Immunotherapy
for HER2-positive
Recurrent/Refractory Pediatric
CNS Tumors

Not yet
recruiting

Central Nervous
System Tumor

Phase 1

NCT03500991

2

A Clinical Research of CAR T
Cells Targeting HER2 Positive
Cancer

Recruiting

Breast Cancer,
Ovarian Cancer, Lung
Cancer, Gastric
Cancer, Colorectal
Cancer, Glioma,
Pancreatic Cancer

Phase 1,
Phase 2

NCT02713984

3

Chimeric Antigen ReceptorModified T Cells for Breast
Cancer

Completed

Breast Cancer

Phase 1,
Phase 2

NCT02547961

4

T Cells Expressing HER2specific Chimeric Antigen
Receptors(CAR) for Patients
with Glioblastoma

Recruiting

Glioblastoma

Phase 1

NCT02442297

5

Memory-Enriched T Cells in
Treating Patients with
Recurrent or Refractory Grade
III-IV Glioma

Not yet
recruiting

Glioblastoma,
Malignant Glioma

Phase 1

NCT03389230

7

Evaluate the Safety and
Efficacy of CAR-T in the
Treatment of Pancreatic
Cancer.

Recruiting

Pancreatic Cancer

Early
Phase 1

NCT03267173

8

Her2 Chimeric Antigen
Receptor Expressing T Cells in
Advanced Sarcoma

Recruiting

Sarcoma

Phase 1

NCT00902044

9

CMV-specific Cytotoxic T
Lymphocytes Expressing CAR
Targeting HER2 in Patients
With GBM

Active, not
recruiting

Glioblastoma
Multiforme (GBM)

Phase 1

NCT01109095

10

T-Cell Therapy for Advanced
Breast Cancer

Recruiting

Breast Cancer,
Metastatic HER2negative Breast

Phase 1

NCT02792114

11

Personalized Chimeric Antigen
Receptor T Cell
Immunotherapy for Patients
with Recurrent Malignant
Gliomas

Recruiting

Malignant Glioma of
Brain

Phase 1

NCT03423992

12

Treatment of Chemotherapy
Refractory Human
Epidermalgrowth Factor

Unknown
status

Advanced HER-2
Positive Solid Tumors

Phase 1,
Phase 2

NCT01935843
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Receptor-2(HER-2) Positive
Advanced Solid Tumors
13

Her2 and TGFβ CTLs in
Treatment of Her2 Positive
Malignancy

Active, not
recruiting

HER2 Positive
Malignancies

Phase 1

NCT00889954

14

Genetically Modified T-Cell
Therapy in Treating Patients
with Advanced ROR1+
Malignancies

Recruiting

Recurrent Adult Acute
Lymphoblastic
Leukemia, Recurrent
Mantle Cell
Lymphoma,
Refractory Chronic
Lymphocytic
Leukemia, Non-Small
Cell Lung Cancer,
Triple-Negative
Breast Carcinoma

Phase 1

NCT02706392

GD2
GD2 is a ganglioside antigen that is expressed on the surface of several malignancies
including neuroblastoma174, glioma, cervical cancer, and sarcoma175,176. The normal expression
of the protein is limited to neurons, melanocytes, and peripheral nerve fibers176–178. One of the
most successful trial reports for CARs in solid tumors has been using GD2 as a target for
neuroblastoma179–182. Not only did GD-2 CAR T cells induce a response in 30% of patients,
including a complete remission in 3 patients, but researchers found long term persistence of the
CAR T cells post treatment, which subsequently reduced tumor recurrence/progression 182.
Meanwhile, GD2 monoclonal antibodies (Dinutuximab) have been effective for the control of
neuroblastoma176,183–185 and this product is currently FDA approved for that application. There
have been some observed cytotoxicities associated with targeting GD2, such as sensorimotor
demyelinating polyneuropathy caused by anti-GD2 biding to peripheral myelin in the posterior
pituitary177. In preclinical models, severe lethal CNS toxicity caused by CAR T cell infiltration
and proliferation within the brain resulted in neuronal destruction186. Therefore, although there
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has been success utilizing CAR therapy in patients, necessary precautions need to be taken to
avoid neurotoxicity as GD2 has expression in normal neural cells. GD2, as of May 2018, has 10
ongoing clinical CAR T cell trials targeting primarily neuroblastoma (Table 1-4B). A majority of
these clinical trials are in phase I status to determine the safety of the treatment. One of the
clinical trials (NCT02765243) is testing the incorporation of a kill switch, which is an engineered
suicide gene (iCasp9) to help avoid neurotoxicity.
Table 1-4B. GD2 CAR T cell clinical trials (as of April 2018)
Title
Anti-GD2 CAR T Cells in Pediatric
Patients Affected by High Risk
and/or Relapsed/Refractory
Neuroblastoma
Anti-GD2 4th Generation CART
Cells Targeting Refractory and/or
Recurrent Neuroblastoma
A Phase I Trial of T Cells
Expressing an Anti-GD2 Chimeric
Antigen Receptor in Children and
Young Adults with GD2+ Solid
Tumors
CAR-T Cell Immunotherapy for
GD2 Positive Glioma Patients

Recruitment
Recruiting

Conditions
Neuroblastoma

Phases
Phase 1,
Phase 2

NCT Number
NCT03373097

Recruiting

Neuroblastoma

Phase 2

NCT02765243

Completed

Sarcoma,
Osteosarcoma,
Neuroblastoma
, Melanoma

Phase 1

NCT02107963

Completed

GD2 Positive
Glioma

Phase 1,
Phase 2

NCT03252171

Study Evaluating the Efficacy and
Safety With CAR-T for Relapsed or
Refractory Neuroblastoma in
Children
A Cancer Research UK Trial of
Anti-GD2 T-cells (1RG-CART)

Recruiting

Relapsed or
Refractory
Neuroblastoma

Not
Applicable

NCT02919046

Recruiting

Phase 1

NCT02761915

7

Study on GD2 Positive Solid
Tumors by 4SCAR-GD2

Recruiting

Relapsed or
Refractory
Neuroblastoma
Solid Tumor

Phase 1,
Phase 2

NCT02992210

8

Intervention of CAR-T Against
Cervical Cancer

Recruiting

Cervical
Cancer

Phase 1,
Phase 2

NCT03356795

9

Safety and Efficacy Evaluation of
4th Generation Safety-engineered
CAR T Cells Targeting Sarcomas

Recruiting

Phase 1,
Phase 2

NCT03356782

10

iC9-GD2-CAR-VZVCTLs/Refractory or Metastatic
GD2-positive Sarcoma/VEGAS

Active, not
recruiting

Sarcoma,
Osteoid
Sarcoma,
Ewing
Sarcoma
Sarcomas

Phase 1

NCT01953900

1

2
3

4
5

6
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MUC1
MUC1 is a large transmembrane glycoprotein that is transcriptionally upregulated in
breast and ovarian tumors187,188. MUC1 expression is confined to normal luminal epithelium, and
the expression is lost upon transformation189–193. MUC1 has recently become an interesting target
in cancer immunotherapy because of the overexpression of aberrantly glycosylated MUC1 in
most solid tumors and several hematological malignancies. This is in addition to the role of
MUC1 in cancer progression, invasion, metastasis, angiogenesis, and chemoresistance. Although
expressed significantly on malignant cells, MUC1 targeting presents some complications as
MUC1 is shed and may inhibit tumor antibody binding/recognition194. MUC1 also has the ability
to inhibit T cell function and thereby promotes an anti-inflammatory TME195. CAR T-cell
therapy targeting MUC1 has been beset with several challenges such as steric hindrance and
glycosylation-related epitope heterogeneity196. Following CAR optimization with tripartite
endodomains and high affinity screening for effective ScFv fragments, MUC1-CAR T cells
showed significant delays in tumor growth in mouse xenograft models197. MUC1-CAR T cells
also show enhanced proliferation, increased IFN-ϒ secretion, and enhanced anti-tumor efficacy
when compared to control CAR T cells in vitro198. Based on the success of these preclinical
MUC1-CAR T cells, several clinical trialstargeting MUC1 in several cancer types have begun
(Table 1-5B). Early phase 1 clinical trials revealed no initial adverse side-effects and patient
cytokine levels increased, indicating a positive response as tumor necrosis was observed199.
Table 1-5B. MUC1 CAR T cell clinical trials (as of April 2018)
1

Title
Phase I/II Study of AntiMucin1 (MUC1) CAR T Cells
for Patients with MUC1+
Advanced Refractory Solid
Tumor

Recruitment
Recruiting

Conditions
Hepatocellular
Carcinoma, Non-small
Cell Lung Cancer,
Pancreatic Carcinoma,
Triple-Negative
Invasive Breast
Carcinoma

Phases
Phase 1,
Phase 2

NCT Number
NCT02587689
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Table 5. MUC1 CAR T cell clinical trials (as of April 2018)

2

Anti-MUC1 CAR T Cells and
PD-1 Knockout Engineered T
Cells for NSCLC
CTLA-4 and PD-1 Antibodies
Expressing MUC1-CAR-T
Cells for MUC1 Positive
Advanced Solid Tumor
CAR-T Cell Immunotherapy
in MUC1 Positive Solid
Tumor

Recruiting

PSCA/MUC1/PDL1/CD80/86-CAR-T Cells
Immunotherapy Against
Cancers
Multi-CAR T Cell Therapy for
Acute Myeloid Leukemia

Recruiting

7
8

3

4

5

6

9

Lung Neoplasm
Malignant, Non-small
Cell Lung Cancer
Advanced Solid Tumor

Phase 1,
Phase 2

NCT03525782

Phase 1,
Phase 2

NCT03179007

Malignant Glioma of
Brain, Colorectal
Carcinoma, Gastric
Carcinoma
Lung Cancer

Phase 1,
Phase 2

NCT02617134

Phase 1

NCT03198052

Recruiting

Acute Myeloid
Leukemia

Phase 1,
Phase 2

NCT03222674

Intervention of CAR-T
Against Cervical Cancer

Recruiting

Cervical Cancer

Phase 1,
Phase 2

NCT03356795

Evaluate the Safety and
Efficacy of CAR-T in the
Treatment of Pancreatic
Cancer.
Safety and Efficacy
Evaluation of 4th Generation
Safety-engineered CAR T
Cells Targeting Sarcomas

Recruiting

Pancreatic Cancer

Early
Phase 1

NCT03267173

Recruiting

Sarcoma, Osteoid
Sarcoma, |Ewing
Sarcoma

Phase1,
Phase 2

NCT03356782

Recruiting

Recruiting

GPC3
Glypican-3 (GPC3) is a GPI bound sulfate proteoglycan involved in cellular growth,
differentiation, and migration200,201. GPC3 shows elevated expression in approximately 75% of
hepatocellular carcinoma samples, but had no expression in corresponding normal tissue202,203.
GPC3 is also elevated within breast cancer204, melanoma205, and pancreatic cancer206,207
demonstrating its use across a wide variety of cancer types. GPC3 CAR T cells showed
promising preclinical results targeting tumors in mouse xenograft models208. In human trials
there was minimal toxicity and all patients tolerated the treatment (NCT02395250)209. Further
clinical trials targeting lung cancer, pancreatic cancer, and colorectal cancer are ongoing.
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IL13Rα2
There are currently two clinical trials, one initiated in 2015 and one in 2018, testing the
efficacy and safety of IL13Rα2 directed CAR T cells against glioma patients. IL-13 is a T helper
2 (TH2) derived cytokine involved in immune regulation. IL13Rα2 is an IL-13 receptor that acts
as a decoy by directly competing with the IL13Rα1 receptor to elicit downstream STAT
signaling210,211. IL13Rα2 receptors are upregulated in approximately 50% of glioma patients and
have a strong correlation with poor survival212. As a gene that is highly expressed in tumor
infiltrating macrophages (TIM) and tumor-associated macrophages (TAM), but shows minimal
expression in normal brain tissue, IL13Rα2 has been previously studied as a cancer vaccine, and
more recently as a direct target for CAR therapy. Initially, IL13Rα2 CAR T cells were developed
utilizing a membrane-tethered IL13 ligand mutated at residue 13 (EY)212 as the antigen
recognition domain. Unfortunately, it was determined that these domains also recognized
IL13Rα1 receptors as well, which raised significant safety concerns. New CAR T cell constructs
targeting IL13Rα2 therapy rely on scFv-based targeting. With this modification in antigen
specificity, scFv-based IL13Rα2 CARs induce tumor regression in mouse xenograft models of
glioma and show insignificant recognition of IL13Rα1 receptors213.
PSCA
Prostate stem cell antigen (PSCA) is a serine protease214,215 expressed in the basal cells of
normal prostate cells 216 and is overexpressed in approximately 80% of prostate cancers217–220. In
addition, PSCA expression increases with both high gleason score, and metastasis219. The
expression of PSCA is limited to the basal cell epithelium in the prostatic epithelium217. As a
protein attached to the cell surface via a GPI-anchor, it serves as an ideal target for prostate
cancer and further metastatic sites219. PSCA has also been found expressed on other cancer types
such as gastric cancer, gallbladder adenocarcinoma221–223, non-small-cell lung cancer216,224, ad
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pancreatic cancer225. In humanized mouse models, CAR T cells targeting PSCA induced
significant antitumor activity in pancreatic cancer225. Although initial results have been
promising, preclinical reports have shown that tumors can escape PSCA-CAR T cells and while
treatment does prolong survival, it does not necessarily eradicate PSCA-expressing tumors226,227.
VEGFR2
Vascular endothelial growth factor receptor 2 (VEGFR2) is an important mediator of
tumor angiogenesis228,229. VEGFR2 is involved in microvascular permeability, endothelial cell
proliferation, invasion, migration, and survival230. Overexpression of VEGFR2 has been
associated with increased metastasis in several malignancies231,232, and VEGFR2 expression has
also been shown on squamous cell carcinomas of the head and neck233, colorectal cancer234,235,
breast cancer236,237, and NSCLC238–240. While overexpressed in cancer, the expression of
VEGFR2 in normal tissue is restricted to endothelia and mesothelial241. Initial targeting of
VEGFR2 with monoclonal antibodies has resulted in growth inhibition and decreased micro
vessel density while simultaneously inducing tumor cell apoptosis and necrosis242,243. These
preclinical results have been shown in NSCLC, renal carcinoma, hepatocellular carcinoma,
melanoma, ovarian cancer, and colorectal cancer231,244–248. To date, only one clinical trial has
been enrolled utilizing CAR T cells against VEGFR2 (NCT01218867)249.
CEA
Carcinoembryonic antigen (CEA) is a glycoprotein on the surface of several
carcinomas250. The most studied use for CEA as a surface biomarker has been in liver metastasis,
especially originating from colorectal cancer251–253. CEA is also significantly expressed on the
surface of gastric cancer, pancreatic cancer, ovarian cancer, and lung cancers254. While CEA is
expressed on the surface of some normal cells, including epithelial cells in the pulmonary tract
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and in the gastrointestinal tract, these normal sites of expression are invisible to immune
detection as CEA is restricted to the apical surface of the epithelial cells that face the lumen in
normal adults255,256. As the cells are ‘invisible’ to immune detection it renders CEA an attractive
target with limited bystander cytotoxicity. Following cancer development, epithelial cells lose
apical polarity, which subsequently results in CEA gaining access to the blood stream and into
the serum of the patient257. This renders CEA a useful diagnostic biomarker, as serum detection
can serve to identify cancer development for several cancer types including breast258–260, skin
cancer261, NSCLC262–264, gastric259,265–268, and pancreatic cancer259,269–272. Preclinical testing with
CEA-CAR T cells has shown that lymphodepletion or myeloablation prior to infusion is required
to induce a response in mice with CEA+ tumors255. Initially, CEA was targeted utilizing
engineered TCRs, but trials were halted as patients developed severe colitis as a result of off
target killing of normal epithelial cells273. These same results have yet to be observed with CAR
T cell therapy targeting CEA, but patients are treated with caution to avoid on-target, off-tumor
cytotoxicity.
PSMA
Prostate specific membrane antigen (PSMA), or Glutamate carboxypeptidase II
(GCPII)215, is a glycoprotein274 with three known activities including folate hydrolase275,
NAALADase276, and dipeptidyl peptidase274. While PSMA is expressed in normal prostate
epithelium274, it has been shown in 90% of human prostate tumors including their respective
metastatic sites215,277,278. PSMA has also been expressed in low levels in salivary glands, brain,
and kidneys279–281. In initial pre-clinical models, anti-PSMA CAR T cells were able to effectively
target and eliminate 60% of tumors in treated animals while significantly improving overall
survival in vivo282. Following Phase I clinical trials, no anti-PSMA toxicities were noted and
40% of patients achieved clinical partial responses (PR)283. More recently, PSMA CAR T cells
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have been designed to resist TGFβ suppression, which is commonly found in prostate cancers,
via a negative TGFβ receptor II 284.
ROR1
Receptor tyrosine kinase like orphan receptor 1 (ROR1) is a Wnt5a surface receptor
expressed during embryonic development, but generally absent from adult tissue with the
exception of adipocytes, gut, pancreas, and parathyroid glands285–287. In the case of cancer,
ROR1 has shown high levels in several solid malignancies: pancreatic288,289, ovarian288,290–292,
breast288,293–295, lung288,296,297, gastric cancer298, and colorectal cancer299. High levels of ROR1
have shown strong correlation to poor patient outcome and also to developing metastasis292,300.
There has been some conflicting preclinical studies where CAR T cells targeting ROR1 have
demonstrated severe cytotoxicity as the cells accumulated within the lungs301. Meanwhile, other
studies have shown great success in targeting ROR1, which may be a direct cause of the
specificity of the antibody utilized for the scFv302,303. Currently, ROR1 is being used in clinical
trials to target breast and lung cancers.
FAP
Fibroblast activation protein (FAP) is a transmembrane serine protease with high
expression on cancer-associated stromal cells (CASC) in epithelial cancers304–306. In pancreatic
tumors, FAP shows significant elevation and is correlated with worse clinical outcome307. In
colorectal cancer, patients with high levels of FAP were more likely to develop metastasis,
recurrence, and aggressive disease progression308. FAP does not have this same expression
within normal cells, as most stromal cells have insignificant levels of the protein309–311. As a
therapeutic target, FAP has been utilized as a useful cancer vaccine in inhibiting tumor growth
and increasing cytotoxicity304,312,313. As the biomarker has shown success as a targeting agent,
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CAR T cells targeting FAP have been developed. These FAP CAR T cells show conflicting
results as some groups report limited antitumor efficacy314, while others report significant tumor
cytotoxicity with minimal off-tumor killing315 along with prolonged survival316. While the use of
FAP CAR T cells may extend to many different organ sites, current clinical trials are designed to
treat pleural mesothelioma.
EpCAM
Epithelial cell adhesion molecule (EpCAM or CD326) is a transmembrane glycoprotein
that functions to abrogate E-cadherin-mediated cell adhesion, and functions within
transcriptional complexes inducing c-myc and cycline A & E expression317,318. EpCAM has
shown overexpression in a range of tumors including colon adenocarcinoma, stomach
adenocarcinoma, pancreatic adenocarcinoma, lung adenocarcinoma, ovarian adenocarcinoma,
and breast adenocarcinoma319,320. The protein is found at the basolateral cell membrane of
normal adult tissue 321. EpCAM has shown significance as a biomarker for early cancer
development 322. Like several other biomarker targets described, monoclonal antibody therapy
targeting EpCAM (Catumaxomab) has been used in patients to treat peritoneal carcinomatosis
(PC) which resulted in a slight increase in survival323. Further clinical trials with Catumaxomab
have been used to target bladder cancer324, head and neck cancer325, ovarian cancer326, and
metastatic disease327. These trials resulted in an increase in overall patient survival. EpCAM
specific CAR T cells have been developed to treat prostate, breast, and peritoneal cancers and
have shown suppressed tumor progression/delayed disease as well as CAR T cell trafficking into
the tumor site328–331.
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EGFRvIII
Epidermal growth factor receptor variant III (EGFRvIII) is a gain of function mutated
EGFR that arises from the genomic deletion of exons 2-7. The deletion of these exons leads to a
ligand-independent receptor that endows cells with a significant growth advantage over normal
cells332. EGFRVIII is commonly found within glioblastoma patients, especially in CD133+
glioblastoma cancer stem cells333. As a tumor-specific antigen, EGFRvIII has been targeted
utilizing FDA approved cancer vaccines (Rindopepimut), which result in significant improved
survival334. Due to its success as a cancer vaccine, CAR T cells have been developed to directly
target malignant cells expressing EGFRvIII. These CAR T cell therapies have shown delayed
tumor growth, elimination of EGFRVIII+ tumor cells, and increased pro-inflammatory cytokine
release in an antigen dependent manner335–338. A first-in-human study of intravenous delivery of
a single dose of autologous EGFRvIII-CAR T cells (NCT02209376) had reported that the
infusion of cells was feasible and safe, with no off-tumor toxicity or cytokine release syndrome.
In this study, 10 patients with recurrent glioblastoma (GBM) were treated with EGFRvIII-CAR
T cells. At least one patient achieved stable disease for over 18 months with a single infusion of
CAR T cells. The median overall survival was about 8 months in all patients. The study,
however, found that tumor microenvironment increased the expression of inhibitory molecules
and infiltration by regulatory T cells which suppressed effector CAR T cell functions339. While
there are promising results using this target, there may be suppressive factors that limit its
efficacy in patients. There are nine clinical trials ongoing (as of May 2018) targeting a variety of
tumor types (Table 1-6B).
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Table 1-6B. EGFRvIII CAR T cell clinical trials (as of April 2018)
Title
EGFRvIII CAR T Cells for NewlyDiagnosed WHO Grade IV
Malignant Glioma
Pilot Study of Autologous AntiEGFRvIII CAR T Cells in
Recurrent Glioblastoma
Multiforme
Intracerebral EGFR-vIII CAR-T
Cells for Recurrent GBM

Recruitment
Recruiting

Conditions
Glioblastoma,
Gliosarcoma

Phases
Phase 1

NCT Number
NCT02664363

Recruiting

Glioblastoma
Multiforme

Phase 1

NCT02844062

Not yet
recruiting

Phase 1

NCT03283631

4

4SCAR-IgT Against Glioblastoma
Multiform

Enrolling by
invitation

Recurrent
Glioblastoma
Multiforme,
Recurrent Brain
Tumor
Glioblastoma
Multiforme

Phase 1,
Phase 2

NCT03170141

5

CAR T Cell Receptor
Immunotherapy Targeting
EGFRvIII for Patients with
Malignant Gliomas Expressing
EGFRvIII
Evaluate the Safety and Efficacy of
CAR-T in the Treatment of
Pancreatic Cancer.
Autologous T Cells Redirected to
EGFRVIII-With a Chimeric
Antigen Receptor in Patients With
EGFRVIII+ Glioblastoma

Recruiting

Malignant Glioma,
Glioblastoma,
Gliosarcoma

Phase 1,
Phase 2

NCT01454596

Recruiting

Pancreatic Cancer

Early
Phase 1

NCT03267173

Active, not
recruiting

Not
Applicable

NCT02209376

Personalized Chimeric Antigen
Receptor T Cell Immunotherapy
for Patients with Recurrent
Malignant Gliomas
Long-term Follow-up of Subjects
Exposed to Lentiviral-based
CART-EGFRvIII Gene-modified
Cellular Therapy Products in
Cancer Studies

Recruiting

Patients with
Residual or
Reccurent
EGFRvIII+
Glioma
Malignant Glioma
of Brain

Phase 1

NCT03423992

1
2

3

6
7

8

9

Enrolling by
invitation

A long-term
follow-up study of
CART-EGFRvIII
Infusion

NCT02666248

EphA2
Ephrin type A receptor (EphA2) is a receptor tyrosine kinase that plays a key role in the
development of cancer disease. EphA2 enhances tumorigenesis and progression via interactions
with other cell-surface receptors such as EGFR and HER2/ErbB2, which in turn amplify MAPK,
Akt, and Rho family GTPase activities340–342. EphA2 has shown expression in normal brain, skin,
bone marrow, lung, thymus, spleen, liver, small intestine, colon, bladder, kidney, uterus, testis
and prostate at low levels343,344. Overexpression of EphA2 has been observed in malignant tissue
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which has been linked to poor clinical prognosis345–347. EphA2 has been targeted through a
variety of avenues including viral vectors, RNA interference, small molecule inhibitors,
recombinant proteins, and immunotherapy. Small molecule inhibitors (FDA approved-Dasatinib)
of EphA2 have significantly reduced tumor growth in several cancer types, and have shown antitumor efficacy via the reduction of EphA2 expression and kinase activity upon treatment 348,349.
On the heels of the success of these methods, CAR T cells have been developed to target EphA2
in Lung cancer350, glioma351, and glioblastoma352 which have all demonstrated cytotoxic effects
both in vitro and in vivo353.
Combination therapy with multiple biomarker targets
To aid in providing both specificity and longevitiy of CAR T cells, efforts have been
made to combine different biomarker targets to elicit T cell responses. These CARs are termed
“tandem CARs” and are designed to express two antigen binding domains. Following binding of
both scFv fragments, CAR T cells are able to send an activation signal and elicit target cell
death, but are unable to do this if only one scFv binds354. BCMA CAR T cells have been linked
to CS1-CAR T cells and designed to express both CAR molecules on the cell surface. They
found that this combination elicited potent and specific anti-tumor activity through both antigens
in vitro and in vivo355. HER2/IL-13RA2 CAR T cells have been designed and showed additive T
cell activation when both receptors were engaged, resulting in superior sustained activity356. In
addition, these tandem CARs avoided antigen escape, which is the primary drawback from CAR
therapy as cancer evolves to sequester target antigen expression. CD20/CD19 tandem CARs
have also been developed, but showed no difference between tandem CAR killing and single
antigen specificity CARs in this context357. This demonstrates that only certain combinations of
biomarker targets are effective in a tandem CAR design. CD19 has also been combined with
Her2 and showed the engineered cells could preserve the cytolytic activity of T cells358. This is
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an ongoing worthwhile pursuit to develop CARs that have specific killing with minimal
cytotoxic effects to healthy tissue. By activating upon two ScFv signals, bystander organ killing
could be reduced as different antigen combinations can decrease on-target, off-tumor killing.
In an effort to increase CAR–tumor specificity and reduce off-tumor toxicity inhibitory
chimeric antigen receptors (iCARs) have been developed to ensure healthy tissue is not targeted
by CAR T cells. iCAR cells are designed with an ingrained override signal. When in contact with
only the tumor antigen, CAR T cells elicit a cytotoxic response to the target cell, but when in
contact with normal tissue antigens, the T cells are effectively turned ‘off’ via anti-inflammatory
co-stimulation. This new technique may provide a way for biomarkers to be used in combination
to elicit extremely specific effects within cancer and avoid healthy tissue toxicity359,360.
Up and coming biomarkers
As CAR therapy expands, so does the need for discovering new cancer-specific
biomarkers that can serve as targets. We show some biomarkers with preliminary preclinical data
that may be useful as future CAR targets.
CT antigens
Cancer/testis (CT) antigens have normal expression limited to adult testicular germ cells,
but have shown expression in various tumor cells such as ovarian cancer, lung cancer,
melanoma, breast cancer, glioma, and colon cancer361–368. Because male germ cells are unable to
present antigens to T cells, CT antigens can be targeted with minimal cytotoxicity to normal
tissue. While current efforts to target CT antigens are primarily focused on modified high
specific TCR regions369, there is an opportunity to target these antigens using CAR T cells as
well.
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GUCY2C
Guanylyl cyclase C (GUCY2C) is a membrane-bound protein found on the apical
surfaces of intestinal epithelial cells, but is also a cancer mucosa antigen that is overexpressed in
both primary and metastatic colorectal cancers as well as esophageal and gastric cancers370–375. It
has been determined that CD8+ T cell responses are expanded when cells are vaccinated against
GUCY2C. These cells are effective at eliminating metastatic colorectal tumors376,377. Initial
GUCY2C targeting with CAR T cells has shown promising specificity and demonstrated reduced
tumor number and increased survival in mice with GUCY2C+ tumors. This target shows
potential for the possible CAR T cell treatment of colorectal tumors in human patients.
TAG-72
Tumor associated glycoprotein-72 (TAG-72) is a pancarcinoma antigen that shows
expression in ovarian cancer378, colorectal cancer379, breast cancer380–382, and prostate
cancer383,384. While TAG-72 is present in the normal female reproductive tract, the expression is
limited and generally weaker than that seen in cancer385. While 91% of endometrial
adenocarcinoma samples showed TAG-72 expression, the expression of TAG-72 in normal
tissue appears to be hormone (estrogen and progesterone) dependent, which can be utilized to
prevent expression in normal patient tissue during treatment386. As such, TAG-72 may have
potential as a possible biomarker for the treatment of some cancer types.
HPRT1/TK1
Salvage enzymes Thymidine Kinase 1 (TK1) and Hypoxanthine guanine
phosphoribosyltransferase (HPRT1) have recently shown potential as surface antigens for CAR
T cell therapy. HPRT1 is a salvage pathway enzyme that synthesizes guanine and inosine
throughout the cell cycle10. The protein is a housekeeping protein that is found within all normal
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somatic cells in low levels19. There is an upregulation of HPRT1 in certain cancer types, making
it a promising biomarker for the treatment of these cancers61,387. In addition, the protein has also
been shown to have significant surface localization on certain malignancies such as lung and
colorectal cancer62,388. As HPRT1 expression is limited to the cytosol within normal cells, the
unique surface localization of the protein makes it promising as a targetable biomarker. TK1 is
another salvage enzyme responsible for the synthesis of thymidine in the cell cycle and has been
used as a serum biomarker for cancer detection and recurrence29,32,34,36. Recently, there has been
evidence that shows that TK1 may also be upregulated within some malignancies and displayed
on the surface of the cell389. As proteins normally restricted intracellularly, TK1 and HPRT could
be used as surface antigens for CAR therapy with minimal bystander cytotoxicity.
Conclusions
As CAR T cell therapy expands, so does the search for new biomarker targets for both
hematological and solid malignancies. We have provided an analysis of the biomarker targets
currently under investigation in clinical trials, in addition to those that may show clinical
significance in the future upon further development. Immunotherapy is becoming the new
standard in patient care and has experienced huge growth and expansion over the last decade. As
CAR T cells become more sophisticated and as new biomarkers are discovered to expand
treatment to numerous cancer types, the field of immunotherapy will reach more patients and aid
in the improvement of care.
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Abstract
Glyphosate is a highly used active compound in agriculturally based pesticides. The
literature regarding the toxicity of glyphosate to human cells has been highly inconsistent. We
studied the resulting DNA damage and cytotoxicity of various glyphosate concentrations on
human cells to evaluate DNA damaging potential. Utilizing human Raji cells, DNA damage was
quantiﬁed using the comet assay, while cyto- toxicity was further analyzed using MTT viability
assays. Several glyphosate concentrations were assessed, ranging from 15 mM to 0.1 mM. We
found that glyphosate treatment is lethal to Raji cells at concentrations above 10 mM, yet has no
cytotoxic effects at concentrations at or below 100 mM. Treatment concentrations of 1 mM and 5
mM induce statistically signiﬁcant DNA damage to Raji cells following 30e60 min of treatment,
however, cells show a slow recovery from initial damage and cell viability is unaffected after 2
h. At these same concentrations, cells treated with additional compound did not recover and
maintained high levels of DNA damage. While the cytotoxicity of glyphosate appears to be
minimal for physiologically relevant concentrations, the compound has a deﬁnitive cytotoxic
nature in human cells at high concentrations. Our data also suggests a mammalian metabolic
pathway for the degradation of glyphosate may be present.
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Introduction
Since their inception in 1939 by the Swiss chemist Paul Muller, pesticides have become a
global phenomenon and a standard approach to pest prevention390. The use of pesticides
increased exponentially from 196 million pounds in 1960 to 632 million pounds in 1981, and in
2008 an estimated 516 million pounds were being used yearly391. It is estimated that if pesticides
were banned for a year, the year-ending supplies of corn, wheat, and soybeans would decrease by
73%392,393. As a result, the use of these herbicides has become an integral part of the world- wide
economy392.
A critical component in the majority of pesticides and weed killers is the non-selective
herbicide glyphosate. This chemical targets the shikimate pathway, which is crucial to the
development and growth of plants394. Glyphosate interrupts the function of the enzyme 5enolpyruvylshikimate 3-phosphate synthase, which is responsible for catalyzing the reversible
formation of 5-enolpyruvylshikimate 3-phosphate and inorganic phosphate from the organic
molecules shikimate 3-phosphate and phosphoenolpyruvate395,396. By doing so, glyphosate halts
the synthesis of the aromatic amino acids required for protein synthesis, thereby inhibiting plant
growth.
Recently, there has been substantial debate regarding the non- toxic nature of glyphosate
in humans397–399. Glyphosate was labeled as a “probable carcinogen” by the IARC, and various
studies have shown it to be cytotoxic at high concentrations399,400. These potential side effects
are concerning due to glyphosate's extensive agricultural use worldwide.
Despite being a topical treatment, there is evidence that glyphosate is absorbed into the
soil and water, which causes great concern for consumer health401–403. This concern has led to
multiple studies of glyphosate cytotoxicity and carcinogenicity.
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In vitro studies have yielded inconsistent results regarding glyphosate's cytotoxic
properties. In a study conducted by Gasnier et al., toxicity to HepG2 cells appeared at glyphosate
concentrations as low as 5 ppm during a 24 h incubation period, and concentrations of 120 nM
induced DNA damage after 24 h exposure399. Koller et al. found that in TR146 cell lines,
treatment with Roundup induced lower cell viability, while treatment with the active ingredient
in Roundup, glyphosate, did not induce any signiﬁcant change in cell viability404. Li et al. found
that at concentrations of 15 mM, 25 mM, and 50 mM, glyphosate did not decrease cell viability
in epithelial cell lines RWEP-1, pRNA-1-1, and in normal cells405. Manas et al. (2009)
determined that in Hep-2 cells there was “no statistically signiﬁcant clastogenic effects
quantitatively detected in any glyphosate treatments.” The extensive variation among the
literature has made it difﬁcult to accurately assess the health risk of glyphosate. Recently in
2015, the International Agency for Research on Cancer (IARC) concluded glyphosate induced
signiﬁcant genotoxic effects for both Glyphosate and its metabolite aminomethylphosphonic acid
(AMPA). Although the Expert Panel reviewed the data and concluded glyphosate did not induce
oxidative stress characteristic of carcinogenicity, there remains a substantial level of confusion
with regards to the ‘safe’ nature of glyphosate 406. Due to its high use in agricultural and
consumer settings, continued research is important to ensure the protection of individuals
exposed to the compound407,408.
The purpose of this study was to investigate the concentration- dependent nature of
glyphosate DNA damaging potential in Burkitt's B Cell Lymphoma (Raji) cells using the comet
assay and MTT viability assays400,409–412. We treated cells with concentrations of glyphosate
ranging from 0.1 mM to 15 mM and measured resulting DNA damage and loss of cell viability
after various lengths of exposure. We hypothesized that the discrepancies in past results may be,
in part, due to the utilization of different treatment conditions across protocols. The use of a
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broad range of concentrations and incubation times allowed us to gain a more complete
understanding of glyphosate's cytotoxic and carcinogenic effects in Raji human cells.
Materials and Methods
Chemicals and reagents
Low melting agarose, Glyphosate (95% purity), MTT cell viability assay, and Propidium
Iodide were purchased from Sigma-Aldrich, Inc. (Milwaukee, WI). Hydrogen Peroxide and Lglutamine was purchased from Fisher Scientiﬁc (Pittsburg, PA). Fetal Bovine Serum was
purchased from Hyclone (Logan, UT). RPMI 1640 was purchased from Mediatech, Inc.
(Manassas, VA).
Equipment
A Zeiss Axioscope ﬂuorescence microscope was used to image all Comet experiments.
TriTek CometScore Freeware v1.5 software was utilized to determine tail moment values.
Cell culture
Burkitt's Lymphoma (Raji) cells (ATCC CCL-86) were obtained from American Type
Culture Collection (ATCC) and cultured ac- cording to ATCC recommendations at 37 °C and
5% CO2. Cells were cultured in RPMI 1640 (Mediatech, Inc. Manassas, VA) and supplemented
with 10% FBS and 2 mM L-glutamine (Fisher Scientiﬁc, Pittsburg, PA). Media was replaced
every 48 h. Cells utilized for experimentation were placed in exponential growth and had a
minimum viability of 95% as determined by Trypan blue cell staining. Cells were authenticated
by the University of Arizona Genetics Core in May 2016. Raji cells were utilized for this
analysis because the replication time is 18 h long and allowed the assays to cover the entire cell
cycle.
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Compound preparation
Glyphosate was dissolved initially to a 50 mM stock concentration in PBS. This solution
was then diluted further to create stocks of 25 mM, 15 mM, and 10 mM. These aliquots were
diluted in PBS to the concentrations tested (5 mM, 1 mM, 100 mM, 10 mm, 1 mM, and 0.1 mM).
Aliquots were stored in 15 mL conical vials at 4 °C. For use in MTT viability assays, glyphosate
was diluted in cell culture RPMI media to the ﬁnal test concentrations and stored at 4 °C.
Alkaline comet assay
Raji cells were incubated with either hydrogen peroxide, PBS, or glyphosate. The
concentration and time points varied depending on the experimental run. Time intervals tested
included 10, 20, 30, 40, 50, 60, 75, 90, 105, and 120 min. Concentrations of 0.1 mM, 1 mM, 10
mM, 100 mM, 1 mM, 5 mM, 10 mM, and 15 mM were tested at each of the time points. Cells
were suspended at a concentration of 200,000 cells per 100 mL treatment. Once treated, cells
were washed twice in 4 °C PBS, and then suspended at 200,000 cells per 100 mL of PBS. The
cells were then prepared for the comet assay. Glyphosate treatment was conducted at 37 °C in a
water bath.
Samples were prepared for comet analysis by following the methods described by Xiao et
al. (2014). with slight modiﬁcations. In brief, samples were mixed with low melting point
agarose and layered on double frosted microscope slides 413. The slides were placed in alkaline
lysis buffer for 60 min, rinsed with ddH2O and then placed in alkaline electrophoresis buffer for
20 min. They were then electrophoresed for 30 min at 24 V and 400 mA. Following
electrophoresis, slides were allowed to rest in ddH2O for 15 min, then ﬁxed in 20 °C 100%
ethanol for 5 min and allowed to dry overnight. Slides were then stained with propidium iodide
for 15 min, rinsed with ddH2O, and imaged. All comets were scored using TriTek CometScore
Freeware v1.5. Every experimental run tested a single concentration for multiple time points.
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Each time point contained a minimum of two slides as replicas. Approximately 50 comets were
analyzed per slide, totaling 100 comets per time point per treatment concentration. Each
concentration was replicated multiple times in order to ensure consistency. Comet Assay results
are reported in terms of tail moment. Tail moment is deﬁned as the product of the tail length and
the percentage of DNA in the tail. These values are given as part of the output by the
CometScore software and are widely reported for Comet analysis (Olive et al., 1990).
A similar protocol was utilized to test the effects of secondary glyphosate exposure at 1
mM and 5 mM concentrations. In these experiments, 200 mL additional glyphosate was added to
the cells after 60 min of initial treatment, while 200 mL of PBS was added to the negative
control.
Cell viability assay
Samples were prepared for the MTT cell viability assay by the methods described by
Hamid et al. (2004). with slight modiﬁcations. Glyphosate treatments were diluted in Raji cell
growth media to their ﬁnal test concentrations. Raji cells were incubated in this prepared growth
media for 24 h in a 96-well plate at 37 °C and 5% CO2. The 24 h time period was chosen
because Raji cells divide every 18 h, which ensures the entire cell cycle was taken into account.
After incubation, 10 mL of kit provided MTT reagent at a concentration of 5 mg/mL was added
to each well. Following 3 h of incubation, 100 mL of DMSO detergent was added to each well.
The plate was then incubated on a shaker at 4 °C for 2 h and evaluated at a 570 nm absorbance.
Statistical analysis
Relationships between exposure time and tail moment were modeled statistically using a
natural spline to account for nonlinearity (Parang et al., 2000). The number of knots was selected
based on Akaike Information Criteria (AIC) and parameters were estimated using least squares.
P-Values <0.05 were considered statistically signiﬁcant.
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Results
Cell death at high concentrations of glyphosate
Glyphosate rapidly induced DNA damage and cell death in Raji cells following treatment at
concentrations of 10 mM and 15 mM after only 30 min of treatment. Cells exposed at these
concentrations quickly adopted an apoptotic proﬁle characterized by the lack of a clear head and
the appearance of a long, rounded tail, as shown in Fig. 2-1. Tail moments were signiﬁcant after
just 10 min of glyphosate exposure. After 30 min, the damage was so extensive that comet
analysis was unfeasible due to software restraints.

Figure 2-1. Comet assay analysis of Raji cells exposed to 10 mM glyphosate. Cells at 10 mM and 15 mM
concentrations underwent severe DNA damage and cell death soon after exposure. Dead cells were characterized by
a loss of a deﬁned comet head and a large, fragmented DNA tail. The extensive amount of damage at later time
points made analysis impractical due to software restraints.
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Figure 2- 2. MTT analysis of Raji cells exposed to various glyphosate concentrations. Hydrogen Peroxide (positive)
was utilized as a control to measure thorough cell death, and cells suspended in cell growth media (negative) was
utilized as a control for standard cell death as a result of treatment conditions. Following 24 h of incubation with
glyphosate, there was a signiﬁcant loss of cell viability following treatment with 10 mM and 15 mM glyphosate.
Concentrations of 5 mM and lower did not have a signiﬁcant loss of viability when compared to the negative
control. This indicates the damage to Raji cells at 15 mM and 10 mM glyphosate was enough to sustain complete
cell death, while concentrations at or below 5 mM sustained cell viability.

To conﬁrm that cell death had occurred, cell viability was quantiﬁed using MTT viability
assays. Results, shown in Fig. 2-2, indicate a signiﬁcant loss of cell viability after 24 h treatments
with 10 mM and 15 mM concentrations of glyphosate. A comparison shown in Fig. 2-4 outlines
the difference in appearance of cells that maintain viability to those who undertake severe DNA
damage characteristic of cell death.
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Figure 2-3. Tail moment values of cells treated with various concentrations of glyphosate across 2 h of treatment.
Tail moment values (quantiﬁable measure of DNA damage) are listed on the y-axis (scale varies at different
concentrations), and treatment times are labeled on the x-axis. Each concentration was individually evaluated and
assigned a 95% conﬁdence interval, which is displayed in green, while the mean value is shown in red. A, Cells
exposed to glyphosate concentrations of 15 mM and 10 mM sustained severe DNA damage with tail moments above
25, which was indicative of cell death. Within 30 min of treatment, all cells had adopted the characteristic proﬁle of
a dead cell (Fig. 2-1). B, Raji cells exposed to glyphosate concentrations of 5 mM and 1 mM had statistically
signiﬁcant DNA damage after 60e75 min of treatment. This damage was not present in later time points and cells
were able to recover full viability after 120 min of treatment. C, Cells treated with 100 mM and 10 mM of
glyphosate did not show statistically signiﬁcant DNA damage, and cells retained full viability throughout the full
120-min treatment. D, Physiologically relevant concentrations of glyphosate were exposed to Raji cells over a 120
min period and did not experience any signiﬁcant DNA damage.

Minimal cytotoxicity at low, physiologically relevant concentrations of glyphosate
For concentrations of glyphosate at or below 100 mM, tail mo- ments were not
statistically signiﬁcant at any time point as shown in Fig. 2-3. MTT analysis in Fig. 2-2 likewise
showed no decrease of cell viability following glyphosate treatment at these concentrations.
These ﬁndings indicate a lack of cytotoxicity to Raji cells at low treatment concentrations,
suggesting that the risk of glyphosate exposure at standard physiological levels may be
negligible.
DNA damage and cellular recovery at 1 mM and 5 mM concentrations
Cells exposed to 1 mM and 5 mM concentrations of glyphosate had signiﬁcant tail
moments after 40 min of glyphosate incubation. Tail moments reached a maximum following 60
min and 80 min of treatment for 5 mM and 1 mM concentrations of glyphosate, respectively.
Interestingly, as shown in Fig. 2-3, a steady decrease in tail moment was observed in later time
points and after 2 h of treatment, the DNA damage was no longer signiﬁcant.
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Figure 2-4. Raji cells treated with 1 mM and10 mM glyphosate concentrations experience different damaging
events. A, Following treatment with 10 mM glyphosate, Raji cells showed no signs of DNA damage and the ‘head’
of the cells stayed intact throughout the 2 h treatment time. B, After exposure to 1 mM glyphosate, cells started to
show signs of damage after 60 min of treatment that subsided after 2 h. At the end of the 2 h incubation, cells were
fully viable with no signs of severe DNA damage.

The decrease in tail moment may suggest that the induced DNA damage was insufﬁcient
to trigger cell death, and that cells were able to recover from the damaging event. MTT analysis
supported this hypothesis, showing no signiﬁcant loss of cell viability after 24 h incubations at
either concentration.
In order to further elucidate the comet analysis results at 1 mM and 5 mM, cells were
treated again with glyphosate at these concentrations 1 h after initial treatment. There was a
signiﬁcant difference between cells receiving only primary treatment and cells receiving the
additional treatment (Fig. 2-5). Raji cells exposed to the compound twice did not show the same
pattern of recovery, with tail moments reaching levels above 20 for 1 mM and 25 for 5 mM
glyphosate treatment. Meanwhile, cells with only primary expo- sure to the compound showed a
decrease in DNA damage, with tail moments dropping from 15 to 5.8 for 1 mM and 23.67 to
6.74 for 5 mM treatments of glyphosate.
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Figure 2-5. Tail moments of Raji cells incubated with 1 mM and 5 mM glyphosate concentrations after primary and
secondary exposure to the compound. A, Raji cells were evaluated after initial treatment with 1 mM glyphosate.
Following the same pattern as previously reported, the cells underwent a damaging event (tail moment 15.01) that
was later recovered. At the end of the 2 h incubation, cells had gained viability and maintained a low tail moment
value of 5.82. B, Raji cells receiving both primary and secondary treatment of 1 mM glyphosate did not experience
the same recovery as those only treated with primary glyphosate. At 60 min, Raji cells were again incubated with 1
mM glyphosate. Tail moments in this case were increased slightly and do not show the same decrease as primary
only treated cells and maintained high tail moment values above 20. C, Cells treated with primary 5 mM glyphosate
only showed a pattern of recovery in cell viability with tail moments dropping from 23.67 to 6.74. D, When Raji
cells were incubated with 5 mM glyphosate primary and secondary treatment, there was no recovery observed and
the tail moment increased from 23.67 to 28.03. These data suggest that after primary treatment, Raji cells may be
metabolizing the compound and breaking it down to its less toxic metabolites.
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Discussion
These results show that the DNA damaging and cytotoxic potential of glyphosate is
related to exposure length and treatment concentration, suggesting a dose-dependent relationship
for glyphosate's cytotoxic effects. These data show that glyphosate induced signiﬁcant DNA
damage only when cells are exposed to concentrations several orders of magnitude larger than
those attainable in vivo. Our data support the established evidence that glyphosate is “not
genotoxic” in human cells at physiologically relevant concentrations414. While these data
ultimately support glyphosate's classiﬁcation as a potential carcinogen, they suggest that its
effects are negligible when exposure is minimal. Our results do implicate the need for further
studies of the physiological uptake and bioavailability of glyphosate for agricultural workers,
who may be subject to extended exposure and are thus at higher risk. Further- more, our studies
at 1 mM and 5 mM suggest that cells initially damaged by glyphosate may have the ability to
repair and regain viability if repeated exposure is not experienced.
Another important consideration obtained from this study is the utility of multiple time
points in the comet assay. This aspect of the experimental design allowed for accurate
assessment of the DNA- damaging event that took place. Our results show that incubation times
used in the comet assay can affect results dramatically; the extent of DNA damage changed
drastically across different incubation time points. The 1 mM concentration at 1 h, for example,
showed that severe DNA damage occurred. Yet, at 2 h with the same treatment, no DNA damage
was evident. If cells had only been evaluated at this time, results would suggest that there was no
cytotoxic activity and the initial DNA damaging event would be missed. Cytotoxic activity might
also be underestimated by standard viability assay in which the DNA damage is insufﬁcient to
induce cell death. Because of our analysis across multiple time points, we were able to observe
both the DNA damaging event as well as the ensuing recovery. We recommend that in future
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utilizations of the comet assay or related assays measuring mutagenic or clastogenic events,
incubation times be considered and evaluated.
Conclusion
Human cell exposure to glyphosate has minimal cytotoxicity and DNA damage at
concentrations at or below 100 mM.
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Abstract
Classical anti-inflammatory cytokines are known to play a role in both cancer progression
as well as cancer elimination. We evaluated the anti-inflammatory cytokines IL-10 and TGF-β in
patients with colon adenocarcinoma and metastatic colon adenocarcinoma utilizing
immunohistochemical assays to determine the expression of the cytokines between various
malignant tissues. We found tissues stained with TGF-β showed no significant upregulation
within malignant tumors when compared to normal tissue controls. We observed high levels of
TGF-β presence in most tissues similar to GAPDH expression. Within both colon
adenocarcinoma and metastatic carcinomas there was a significant variability among patients in
the expression of IL-10. While some patients experienced insignificant increases in the cytokine
compared to controls, other patients had a clear upregulation of the protein within their tissue. In
addition, there was an increase in the number of patients positive for IL-10 upregulation within
metastatic tumors when compared to primary tumors. These data indicate that there is substantial
variability between patients in regards to IL-10 expression, which may further aid in
characterizing tumors and evaluating metastatic potential.
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Introduction
Globally, colorectal cancer (CRC) is the third most prevalent cancer and comprises
approximately 10% of diagnosed cancers 415. The majority of individuals at high risk for CRC
development are over 50 years of age, as incidence rates increase 50 fold in patients ages 60-79
when compared to patients younger than 40 416. While there has been noteworthy improvements
in early screening and combinatorial treatment development, in the United States 49,190
individuals died of the disease in 2016 417. As colon cancer grows, mutates, and evolves within
patients, it is important to understand the unique environment surrounding tumor growth and
development, and its ability to evade immune detection 418,419.
As the primary form of communication between cells, cytokines have a powerful impact
on regulating both proliferation and immune responses in the tumor microenvironment 420,421.
Cytokine profiles can induce anti-tumor responses, which often lead to a favorable prognosis, but
can also result in supporting malignancy in conditions of chronic inflammation 422. These
cytokine profiles are assessed by measuring the concentration of both pro- and anti-inflammatory
cytokines and evaluating their expression within malignant cells 423. Cytokines within the tumor
microenvironment are produced by both cancer cells and immune cells that are recruited to the
malignant site 424. Tumors will often skew cytokine profiles to support growth and proliferation
by influencing surrounding cells to secrete potent pro-inflammatory cytokines such as TNF-α,
IL-8, IL-6, and IL-1β 424–426. Cancer cells rely on a pro-inflammatory environment to activate
signaling pathways, such as NF-κB and Ap-1, responsible for supporting cell survival 426. In
order to combat this, several anti-inflammatory drugs have been tested for efficacy in preventing
or treating CRC, such as nonsteroidal anti-inflammatory drugs (NSAIDs), to reduce
inflammation at the tumor site 424–427.
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Known to be widely expressed within a majority of somatic tissue, transforming growth
factor beta (TGF-β) is a cytokine known for its induction of peripheral tolerance and antiinflammatory responses. TGF-β is shown to have a tumor suppressive role within cancers, as it
functions to inhibit cell proliferation, induce apoptosis, and inhibit cell immortalization 428. Yet,
as cancer progresses within some patients, there is an increase in TGF-β levels which leads to the
inhibition of cell adhesion and promotion of angiogenesis, supporting immunosuppression in the
tumor microenvironment, and the degradation of the extracellular matrix 428,429. These factors
contribute to the success of a tumor to metastasize 430. As a result, TGF-β has been implicated as
a factor involved in promoting metastasis. To further clarify the role of TGF-β in colon
adenocarcinoma we investigated its levels within primary tumors and metastatic tumors to
determine whether cancer had an increased ability to metastasize when TGF-β was highly
expressed.
Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine secreted primarily from
Th2 cells. While inhibiting antigen presenting cells, IL-10 is also responsible for suppressing the
production of pro-inflammatory cytokines 420. It has been shown that upon transferring the IL-10
gene into tumors, there was an observed decrease in metastatic ability and an increase in
protective immunity against the tumor 431–433. Yet, other sources claim that secreting IL-10
promotes the suppression of antitumor immune responses and protects the tumor against immune
attack within CRC cells 432. These conflicting results exemplify the pleiotropic nature of IL-10,
especially within the tumor microenvironment, and the alternative roles it can play within cancer
progression.
While there has been extensive investigation into the nature of pro-inflammatory
cytokines within tumor tissue, the expression of these anti-inflammatory cytokines within CRC
tumors is not as well characterized. Specifically, there remains a need to determine anti-

62

inflammatory cytokine production within metastatic CRC tumors to evaluate whether cells
undergo transcriptional changes in cytokine gene expression when relocating to an alternative
environment within the body. The purpose of this study is to evaluate both IL-10 and TGF-β
expression within CRC patients with both colon adenocarcinoma as well as metastatic colon
adenocarcinoma to investigate variability of these anti-inflammatory cytokines within CRC
tumors.
Results
IL-10 has a significant upregulation in 20% of patients with colon adenocarcinoma
When tissues were stained for IL-10, there was a significant upregulation of the cytokine
that occurred within a fifth of the patients when compared to normal controls (Fig 3-1). To aid in
distinguishing this variability, tissues were separated into ‘Adenocarcinoma IL-10 Low’,
representing patients with insignificant IL-10 expression, and ‘Adenocarcinoma IL-10 High’,
representing patients with significant IL-10 expression (Fig 3-2). On average, the gray staining
intensity of IL-10 in Adenocarcinoma IL-10 Low patients was 125.51, while the average staining
intensity in Adenocarcinoma IL-10 High patients was 111.46 (Fig 3-1A). As lower gray values
indicated more antigen binding, this difference was statistically significant (p<0.0001) and
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showed that there was a clear divide among patients in regards to the presence of IL-10 within
their tumors.

Figure 3-1. Statistical analysis of IL-10 expression within colon cancer tissue. (A) Expression of IL-10 within all
tissue types shows statistically significant increases in the cytokine within cancer tissue when compared to controls.
‘Adenocarcinoma IL-10 High’ tissue indicates tissues who had significant Il-10 expression and ‘Adenocarcinoma
IL-10 Low’ tissue indicates tissue who had insignificant IL-10 expression. This same nomenclature is applied to the
metastatic tissues. (B) All tissues [Adenocarcinoma IL-10 Low and Adenocarcinoma Il-10 High] were combined to
determine the overall IL-10 expression within cancer grades. Overall, IL-10 expression had a significant increase in
expression in Grade III tissue. (C) We found no statistically significant changes in IL-10 production between
genders.

Further analysis revealed there was a significant increase (p=0.0049) in IL-10 expression
within Grade III tumors when compared to Grade II tumors (Fig 3-1B). These data indicate IL10 expression may be linked to the differentiation of the cancer cell, as cells that are poorly
differentiated have an increased expression of IL-10. We also evaluated the differences between
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sexes and found no statistically significant (p =0.8778) relationship between IL-10 production
and sex (Fig 3-1C).
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Figure 3-2. IL-10 and TGF-β staining of colon adenocarcinoma tissue. Each tissue is displayed with the gray scale
image, with an applied threshold, in the top right corner of the image. Below each image is the intensity map of the
tissue with the gray values on the Y-axis. Within each of the intensity maps is a graphical representation of the level
of gray staining. The scale bar indicates a magnification of 200. (A) Tissue from a 66-year-old female with Stage
IIB colon adenocarcinoma who showed minimal levels of IL-10 expression characteristic of approximately 80% of
patients. (B) Tissue from a 78-year-old female with stage III adenocarcinoma who experienced a significant
upregulation of IL-10 within her tumor, which was characteristic of approximately 20% of the patients. (C) Tissue
from a 64-year old male with stage III adenocarcinoma. This individual was rare among the samples analyzed as he
had no visible staining of TGF-β. (D) Tissue from a 71-year old male with stage IIB adenocarcinoma, who had
significant levels of TGF-β characteristic of only 13% of the tissues.

Patients with metastatic colorectal adenocarcinoma have an increased proportion of IL-10
upregulation
As with colon adenocarcinomas, metastatic cancer samples had a similar divide between
patients that experienced a significant expression of IL-10 and those that did not. This difference
between patients was skewed in the opposite direction of colon adenocarcinoma tissue: instead
of having a majority of patients with no significant IL-10 expression, a majority of metastatic
samples were positive for IL-10. While 20% of patients with colon adenocarcinoma were
positive for expression, 53% of patients with metastatic adenocarcinoma had elevated levels of
IL-10 (Fig 3-3B). These results indicate that IL-10 may be an important factor contributing to
metastasis and the ability of a metastatic cell to survive.
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Figure 3-3. Statistical analysis of IL-10 expression within metastatic adenocarcinoma. (A) Within metastatic tissue
there was no statistically significant increase in IL-10 presence with changes in grade. (B) While there were positive
tissues within both adenocarcinoma and metastatic adenocarcinoma, patients with metastatic adenocarcinoma had a
more prevalent presence of IL-10. (C) Along with an increase in the amount of patients with elevated IL-10
expression, the average stain intensity of patients with metastatic adenocarcinoma was significantly higher than
patients with primary adenocarcinoma.

Tissue samples were similarly split into ‘Metastatic IL-10 Low’ and ‘Metastatic IL-10
High’ samples (Fig 3-4). The average staining intensity of Metastatic IL-10 Low samples was
119.95, while the average staining of Metastatic IL-10 High samples was 106.42 (Fig 3-1A).
This difference was statistically significant (p<0.0001) and indicates a clear divide between
patients regarding IL-10 production, as lower values indicate more IL-10 within the tissue. In
addition, the average intensity of Metastatic IL-10 High samples was significantly darker than
Adenocarcinoma IL-10 High (p=0.027), indicating a higher expression of IL-10 within
metastatic malignant cells (Fig 3-3C).

Figure 3-4. IL-10 and TGF-β expression within metastatic adenocarcinomas. Each tissue is displayed with the gray
scale image, with an applied threshold, in the top right corner of the image. Below each image is the intensity map
of the tissue with the gray values on the Y-axis. Within each of the intensity maps is a graphical representation of
the level of gray staining. The scale bar indicates a magnification of 200. (A) Tissue from a 43-year-old male with
grade 2 metastatic adenocarcinoma from the colon had minimal levels of IL-10 expression representative of 44% of
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patients. (B) Tissue from a 51-year-old female with metastatic adenocarcinoma who had significantly upregulated
expression of IL-10 representative of 55% of tissue evaluated. (C) Tissue from a 58-year-old male with metastatic
adenocarcinoma stained with TGF-β. All metastatic tissues exhibited this same level of TGF-β staining. This level
of staining was consistent through all of the tissue types.

While there was a statistically significant difference within colon adenocarcinoma
samples in regards to grade, there was no statistically significant change in IL-10 expression
within metastatic adenocarcinomas when considering grade (Fig 3-3A). As metastatic tumors are
very commonly poorly differentiated, we expected to see no clear divide between any
determined grades.
To determine whether the observed IL-10 increase in metastatic tumors was also seen
within individual patients upon metastasis we examined a small cohort (n = 13) of individuals
with expression data from both primary tumor sites and matching metastatic tumor sites. Within
this small cohort there was no statistically significant difference in overall IL-10 expression
between primary tumors and metastatic tumors. However, one patient had a significantly
elevated expression of IL-10 within their metastatic tumor when compared to their primary
tumor (Fig 3-5B). Additionally, we analyzed IL-10 expression data in a larger set of metastatic
tumors to determine the general distribution of the cytokine within metastasis. We found that
there were generally low levels of the cytokine as observed within tissue. However, the
expression profile showed a right skewed pattern with a small fraction of patients showing
considerably highly elevation of IL-10, and several other patients who had a general upregulation
(Fig 3-5A). For patients who experience this upregulation, it may be beneficial to target IL-10 to
reduce metastatic potential.
TGF-β expression is generally consistent throughout all patient tissue
While IL-10 showed variable expression within tumors when compared to normal
controls, there was no significant changes in expression within tissue stained for TGF-β. Four
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patients experienced very low levels of TGF-β uncharacteristic of any other tissue samples (Fig
3-5B & 3-2C). These patients had an average staining intensity of 110.95, which is significant
(p<0.0001) when compared to both cancerous tissue and normal tissue, which had an average
staining intensity of 87.82 (Fig 3-5A). These patients represented a fraction of the samples, and
the unusual lack of expression may be used as an additional tool for characterizing individual
tumors and mutations within patients.

Figure 3-5. IL-10 and TGF-β expression profiles in patients from TCGA. (A) 396 metastatic tumors were analyzed
for IL-10 expression. The number of patients is plotted against the Expression profile in transcripts per million. (B)
IL-10 expression within primary and metastatic tumors was plotted to show differences within the same individual.
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On patient experienced significantly elevated IL-10 and is shown in green. This same cohort was utilized to also
evaluate (C) TGF-β expression between primary and metastatic tumors.

The expression of TGF-β did not experience any changes in staining intensity between
metastatic adenocarcinomas or colon adenocarcinomas. (Fig 3-2D & 3-4C) In addition, while
analyzing a small cohort of patients with both primary tumor and metastatic tumor samples, there
was no statistically significant difference between the two sites in regards to TGF-β expression
(Figure 3-5C).

Figure 3-6. Statistical analysis of TGF-β expression within colon cancer tissue. (A) TGF-β showed a consistent level
of expression across all tissue types, including normal tissue, with the exception of 4 patients who had insignificant
levels of TGF-β expression. (B) Number of patients with positive expression of TGF-β and negative levels of TGFβ. There was a small proportion of patients that had no TGF-β expression. (C) There was no significant difference in
TGF-β expression between tissue grades in colon adenocarcinoma samples or metastatic adenocarcinoma samples.

Discussion
These results show that immunosuppressive cytokine levels of IL-10 have variable
expression within different colon adenocarcinoma tumors and may provide insights into the
strategies tumors utilize in order to avoid immune detection. Both anti-inflammatory cytokines
as well as pro-inflammatory cytokines are known to be involved in contributing to positive and
negative patient outcome and help to establish the complexity of the tumor microenvironment.
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The complexity of the tumor microenvironment is supported by the cytokines secreted
within the tumor site and is often protective for cancer cells and provides an atmosphere optimal
for cancer cell growth. This supportive environment is no longer present as individual metastatic
cancer cells break off from the primary tumor to invade other tissue. Instead of being nurtured by
a very well organized, structured tumor site, metastatic cells are faced with several challenges
where they often have to alter gene expression in order to survive.
A critical target for IL-10 is the inhibition of antigen presenting cells. IL-10 functions to
down-regulated MHC expression and co-stimulatory molecules critical for the activation of
effector T cells 434–436. In addition, IL-10 contributes to the expression of Foxp3 and TGF-β,
which sustain Treg populations 434,437. Tregs are influential in the success of a tumor to
metastasize as they aid in tumor cell survival within the circulation. Because cancer cells are
escaping from a well-established environment, a vast majority of cells released do not
successfully establish metastatic sites. Those cells that successfully avoid destruction within
circulation make changes to the transcriptional control of genes to promote an environment that
supports immune evasion 438. These transcriptional changes often involve increasing levels of IL10 in order to elevate the number of Tregs within the surrounding environment. By increasing
Treg differentiation, metastatic cells can increase their chance of survival when breaking away
from the primary tumor. Our results show that within metastatic tumors there is a significant
increase in the number of patients with elevated IL-10 when compared to primary tumors. This
indicates that IL-10 may play a role in promoting metastasis and controlling the immune
environment to support metastatic tumor cell escape.
Within the primary tumor site, IL-10 production can both support and interfere with
cancer cell survival, which may explain why the levels of IL-10 are so variable between CRC
patients. IL-10 can function to stimulate the immune system by increasing the frequency of
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cytotoxic CD8+ T cells and natural killer cells depending on the other cytokines present within
the tumor microenvironment (IL-2 for T cell activation and IL-19 for Natural killer cell
activation) 439,440. The anti-tumor effects of IL-10 are also demonstrated as IL-10 modifies and
efficiently regulates the quality of antigen presentation 434. The effects of IL-10 within the
primary tumor are modulated by the surrounding cytokine profile and expression of the protein
can provide insights into approaches the tumor takes to skew the immune response to either antiinflammatory or pro-inflammatory.
We did not find a significant increase in TGF-β when comparing metastatic tumors to
endogenous tumors. Our results show that the levels of TGF-β do not vary significantly between
normal colon tissue and malignant colon tissue, indicating its role within cellular maintenance is
essential for all tissue. Yet, we did observe tissue from 4 patients with insignificant levels of
TGF-β which may provide physicians with a targeted treatment for those individuals who lack
the protein, as this phenomenon was only experienced within patients with malignant tissue.
Classical anti-inflammatory cytokines exhibit complex effects on tumor growth and
development. The presence of these cytokines within malignant tissue can provide key insights
into strategies elicited by the tumor to promote growth. Within each individual patient there is a
unique cytokine profile which determines the microenvironment surrounding the tumor and the
strategies tumors utilize in order to survive and adapt. We have shown that IL-10 is extremely
variable among patients and could provide physicians with additional tools for characterizing
individual patient tumors.
While this study examines IL-10 and TGF-β levels within a small cohort of individuals,
there is need for an analysis within an extrinsic dataset with more patients. Further investigation
will need to be conducted in the future to determine the source of IL-10 and TGF-β within these
tumors. Understanding the composition of cells that secrete these cytokines will provide
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additional insights into ways to potentially reduce their expression within the tumor
microenvironment.
Materials and Methods
Chemicals
DIVA antigen retrieval solution, Background Sniper blocking agent, Universal negative,
Mach 4 HRP antibodies, DAB Peroxidase, and Hematoxylin were all purchased from Biocare
Medical. IL-10 and TGF-β antibodies were purchased from Thermo Fisher Scientific. GAPDH
polyclonal antibody was purchased from cell signaling.
Patients
Colorectal Adenocarcinoma Tissue Microarrays were obtained from Biomax. Each
microarray contains 30 cases of colon adenocarcinoma (grade 1-3), 30 cases of Metastatic
adenocarcinoma from the colon (grade 2-3), 10 cases of tubular adenoma, 20 samples of cancer
adjacent normal tissue, and 10 samples from normal colon tissue. Adenocarcinoma tissue was
assessed for TMN grading and stage. Patient ages ranged from 29 -81 for malignant samples.
Sex was also variable between samples (Table 3-1).
All procedures performed in studies involving human participants were in accordance with the
ethical standards of the institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical standards.
Table 3-1. Distribution of malignant colon tissue and controls

Tissue Type Number of Patients Grade Range Age Range M/F GV: IL-10/TGF-β
30
1-3
31-79
14/16
121.66 / 90.52
Adenocarcinoma
30
2-3
30-79
17/13
112.66 / 89.61
Metastatic Adenocarcinoma from the colon
10
31-69
6/4
117.5 / 85.57
Tubular Adenoma
20
32-81
16/4
120.26 / 89.46
Cancer Adjacent Normal Colon Tissue
10
29-42
10/0
119.88 / 90.15
Normal Colon Tissue
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Immunohistochemistry
Tissues were incubated in Histoclear and rehydrated with a series of ethanol washes.
Tissues were incubated with a DIVA solution for 30 minutes before treatment with a
Background Sniper block. Block was administered for 30 minutes before tissues were washed
and treated with primary antibodies at a 1:100 dilution. Following primary antibody treatment
overnight at 4°C, tissues were washed and treated with Mach 4 HRP antibodies for 20 minutes at
room temperature. After several washes, a DAB Peroxidase solution is added to the tissues.
Areas of antibody binding will convert the colorless substrate to a brown product to highlight
regions of antibody binding. Then, tissues are treated with a hematoxylin solution to show cell
nuclei. Along with IL-10 and TGF-β treatment, GAPDH was utilized as a positive control and a
universal negative was utilized as a negative control for expression.
Tissue Quantification
Following tissue imaging, all tissue was analyzed utilizing ImageJ software. Briefly,
tissue images were each placed under an ‘IHC toolbox’ program with a selected “more DAB”
option to discard areas of the sample without sufficient DAB staining. Following this, tissue
images were converted to a gray scale and then placed under a threshold. In order to avoid
incorporating bias from negative space within the image, a threshold was applied to the image to
measure only areas of staining. The threshold applied for these samples was 50-150 and was
determined utilizing GAPDH and the universal negative samples as guides. Samples with an
average gray intensity of less than 115 were considered positive for cytokine expression
(“High”) and samples with an average gray intensity above 115 were considered negative for
cytokine expression (“Low”). Once the threshold was applied to all images, they were assessed
for average gray intensity. Low gray values are indicative of darkly stained tissue, and high gray
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values are indicative of not staining. Following this evaluation, the images were also analyzed
utilizing plot surfaces to quantify the levels of gray intensity throughout the sample.
Bioinformatic Analysis
We evaluated differences in expression levels of the IL-10 and TGF-β1 genes between
primary tumors (n = 13) and metastases (n = 15) in datqa published by Vignot, et at.[28] These
data had been generated using one-color Agilent microarrays. We preprocessed and normalized
the data using the limma software package (v.3.30.13), using settings recommended in the limma
User’s Guide. To plot the data, we used the ggplot2 package (v.2.2.1). These software packages
are implemented for the R statistical software.
Next we evaluated RNA-Sequencing data from The Cancer Genome Atlas (TCGA) for
metastatic melanoma patients (n = 367). These data had previously been prepared using the
featureCounts algorithm and summarized to transcripts-per-million values. We used the ggplot2
package (v.2.2.1) to plot these data.
Statistical analysis
Comparison between tissue samples was conducted utilizing ANOVA statistical analysis
with the multiple comparison method. In addition, two-way ANOVA tests were performed to
compare the mean expression of each antibody between colon adenocarcinoma and metastatic
carcinoma tissues. Finally, t tests were utilized in conjunction to confirm statistical significance.
All statistical analysis was evaluated using GraphPad Prism 7 software. Differences were
considered significant when the p value was < 0.05.
Funding Details
This work was funded by the Simmons Center for Cancer Research at Brigham Young
University.
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Supplementary Figure 3-1

Isotype negative and GAPDH positive controls for tissue quantification.
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Abstract
Critical thinking and interactive learning, while essential to a student’s success, are
difficult to implement in college lectures of over 200 students. We designed this study to
determine whether Think Pair Share (TPS) was an effective strategy to integrate in college
courses to enhance student collaboration and critical thinking. The implementation of interactive
learning strategies are often costly and require substantial effort by the professor. Thus, there is a
need to find simple strategies to incorporate into college courses to improve student
collaboration, while cultivating positive classroom environments. TPS is a teaching strategy with
the potential to replace standard quizzes. Given a difficult, thought provoking question students
are prompted to answer the question independently, in pairs, and then within groups. The aim of
this study is to determine whether replacing standard quizzes with TPS questions improves
student learning and concept mastery within college classrooms. Our results indicate that
students preferred TPS quizzes over standard quizzes and a majority of students indicated that
they felt more comfortable and challenged when given TPS quizzes over standard quizzes. This
is a teaching technique that can easily be introduced to any higher education environment with
limited cost and time to both administrators and educators.
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Introduction
In college courses it is often difficult to implement standard teaching strategies frequently
utilized to optimize learning in high school classrooms. Instructors are tasked to teach classes of
100-300 students while also covering a significant amount of content within the span of a few
short months. As a result, students often have a difficult time with the transition from high school
to a college lecture format 441.
As of 2013, the average high school classroom size was 15.9 individuals 442. As these
same students enter college they are required to change their method of learning as the classroom
sizes are often over 200 students and the instructor is not easily available. College instructors
estimate 42% of their freshman students were not adequately prepared by their prior education
for the expectations of a college-level course 441. The same frustration experienced by professors
due to this lack of preparation also plagues students as they deal with the frustrations of relearning how to learn.
College classes are often restricted to a lecture-style format. While this form of
instruction is the most efficient way to communicate large amounts of information in the shortest
amount of time, it is not ideal for inducing effective student learning and understanding 443,444. It
has been suggested that college students begin to have difficulty providing their full attention to
lecturers after 15 minutes of instruction 445. This is enhanced by the ever-increasing distractions
that students are exposed to in the current digital society 446. As a result, students start to fall
behind on content and develop a disinterest in the course.
In previous courses we have observed a bimodal curve in which a certain percentage of
the class has significant struggles and a resulting failing score. This curve demonstrates in part
the negative effects of lecturing as some students are ‘lost’ in the process. To combat this,
professors will often try and engage students in order to keep their attention and interest 447–449.
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Frequently this presents as short quizzes during class to ensure students are studying the material
and not falling behind 450,451. We have integrated this strategy in previous courses but have seen
minimal changes in student performance.
Think-Pair-Share (TPS) is an interactive learning strategy that can be easily
implemented in large college classrooms where students can solve problems independently, in
pairs, and in groups. Upon given a difficult question, students first answer with their own
knowledge 452,453. After individual thought, students are given the opportunity to communicate
with another student and compare answers. This is followed by a group discussion and consensus
on an answer to the question. Each of these steps is concluded with students providing their
answers. This method utilizes student’s own knowledge and resources to not only review and
learn the material, but also provides students the opportunity to critically think and teach one
another. By encouraging student communication TPS transforms the classroom from a static
environment of content review to a collaborative classroom that encourages critical thinking and
inspires discussion and debate between classmates452,454. Collaborative learning enables
professors to enter a facilitating role as students engage in conversation while teaching one
another455. Because college classrooms, particularly general education courses, are often
composed of a melting pot of different fields, majors, and backgrounds some students are more
familiar with concepts than others. By collaborating, the gap between student knowledge is
lessened as those who are more competent in the material can instruct and lift those not as
proficient455. This not only helps the student who is teaching master the content, but also helps
the less proficient student view the material through a different perspective as they receive oneon-one training. This type of learning also provides a ‘safe’ environment for less proficient
students to ask questions they may feel uncomfortable voicing to the entire class.
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The use of peer instruction (PI) has been widely used in several classrooms and has
shown merit in improving test performance and critical thinking456–458. Yet, the use of the full PI
technique is often difficult for higher education professors to implement in large class sizes,
especially teaching a subject with a high content load, such as molecular biology459. In
comprehensive survey of PI use, approximately 9% of instructors responded that “the quantity of
material to cover in a semester often made it difficult to devote class time to ConcepTests”460.
TPS is a shorter, modified version of PI that can be easily implemented into a college course
without significant changes to the educator’s time constraints in order to ensure the full content
of the lectures are still covered.
The aim of this study was to investigate the advantages of think pair share questions over
traditional quizzes. We evaluated both the outcome of student performance along with student
opinions of their learning experience and evaluations of student collaboration. Utilizing the same
course including: lectures, tests, assignments, and readings, we compared a course with
traditional quiz questions with a course utilizing the TPS technique. In addition to this
assessment, we also evaluated the demand and difficulty for the professor to implement TPS
within a college setting.
Methods
Experimental Course
We performed this experiment at an internationally recognized and attended university
and utilized a freshman level introductory General Biology course. This class was chosen
because it is designed to be one of the first courses freshman students take for a general
education biology requirement. The course is called MMBio121 and is named “General Biology:
Health and Disease” and covers the basics of biological concepts with a focus on how they
influence human diseases. The course was separated into 10 different units (supplementary Table
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4-1 &4 -2) covering a wide range of biological concepts. An example of the learning outcomes
within every unit is given in supplementary Table 4-2. The book used in this course is called
‘How Life Works’ and is published by MacMillan. The book also includes a subscription to a
Launchpad website with resources for students to utilize. This course was taught in the Fall of
2015, Winter of 2016, and Fall of 2016. The course is 15-weeks long and includes 2 midterm
tests and a comprehensive final. Weekly quizzes were held every Friday, excluding test weeks,
and there were bi-weekly Launchpad online learning assignments. Additionally, three small onepage research reports were assigned to allow students to research controversial topics to increase
their interest in the coursework. The course was taught Monday, Wednesday, and Friday from
10am to 11am. The relative abundance of freshman is displayed in Figure 4-1. These numbers
are not completely accurate as several ‘true’ Freshman students are considered Sophomores due

to AP credit received in high school.
Figure 4-1. Class Age Distribution. Each of the semesters evaluated was assessed for the relative Freshman and
Sophomore abundance.
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TPS questions were developed utilizing the most difficult learning outcomes from the
previous control semesters (Table 14-A). The assigned learning outcome for each quiz is shown
in Table 4-2.
Table 4-1. Student test performance according to learning outcome
Fall 2015
Learning
Outcome
Test 1
1.13
1.18
1.19
1.9
1.8
3.2
3.4
4.3
5.4
3.1
Final
3.2
7.6
8.13
9.9
6.1
Winter 2016
Test 1
1.13
1.14
Test 2

1.15
1.16
1.19
Test 2

3.2
3.4

Final

4.1
3.1
6.1
8.13
3.2
6.9
5.4

Description

Question(s)

Create a mRNA strand from a DNA template.
Create an amino acid chain using codon chart and mRNA
strand
Explore different protein structure and how they contribute to
functionality
Explain the experiments that determined DNA was the
genetic material
Describe the difference between DNA and RNA
Label and describe photosynthesis
Describe cellular respiration and its location
Explain cellular signals
Identify and explain haploid, diploid, and polyploidy
Analyze converting chemical energy to usable energy
Label and describe photosynthesis
Describe X-linked and Y-Linked Traits
Explain mitochondrial DNA inheritance
Create a diagram of primary and secondary infection
Define a genome

9
43

Student
Success (%)
15
20

24
35
17

27
25
37

16
30
30
21
11
19
27
29
53
46
33

45
20
20
39
39
51
22
24
26
30
15

Create a mRNA strand from a DNA template
Understand how mRNA is processed and why it is important
for protein diversity in Eukaryotic organisms
Label and explain the process of translation including where
it takes place, the proteins involved, the organelles involved,
and the final products.
Compare and contrast the differences and similarities
between prokaryotic and eukaryotic translation.
Explore the different protein structures and understand how
those specific structure contributes to the function.
Label and describe photosynthesis and the process by which
light energy is used to convert carbon dioxide to glucose.
Describe the process of cellular respiration and explain its
location within the cell, the organelles and molecules
involved, and the importance of oxidative phosphorylation
Draw an example of a general signaling between cells
Analyze how cells take energy from glucose.
Define a genome.
Explain how mitochondrial DNA is passed on to offspring.
Label and describe photosynthesis
Explain why mitochondria have their own genome
Identify and explain the differences between haploid, diploid,
and polyploidy.

8
9
44
29
48
49
14
39
22
37
30
20
35
40
2
9
19
33
53
27
18
11
52

27
50
57
62
69
44
56
63
19
67
20
41
24
66
65
38
43
21
24
29
7
33
67
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Fall 2016
Learning
Outcome
Test 1
1.19
1.14
1.13
1.2
Test 2

1.8
3.1
3.2

4.1
5.3

Final

10.7/10.8
6.1
6.9
3.2
8.13
5.4

Description
Explore different protein structure and how they contribute
to functionality
Understand how mRNA is processed and why it is important
for protein diversity in Eukaryotic organisms
Create a mRNA strand from a DNA template.
Describe organisms whose determination of life is not yet
decided
Describe the differences between RNA and DNA
Analyze converting chemical energy to usable energy
Label and describe photosynthesis

Draw an example of a general signaling between cells
Explain the difference between chromosomes, homologous
chromosomes, and sister chromatids. Understand which
chromosome doesn’t have a homologous pair.
Describe viral infections and their symptoms
Define a genome
Explain why mitochondria and chloroplasts have their own
genome
Label and describe photosynthesis and the process by which
light energy is used to convert carbon dioxide to glucose
Explain how mitochondrial DNA is passed on to offspring.
Identify and explain the differences between haploid, diploid,
and polyploidy. Give examples of cells with both haploid
and diploid chromosomes.

Question(s)
22

Student
Success (%)
28

9
44
8
34

30
56
33
35

15
19
1
14
20
30
9
49

40
40
66
67
52
22
47
51

4
33
18

56
17
19

27

23

53
11

23
27

Note. Each test for the control semesters with standard quizzes was evaluated for the concepts most difficult for students.
Each question along with the student success rate and the assigned learning outcome is listed for each test. The tests for the
TPS course were also evaluated using the same techniques and the resulting learning outcomes are listed.

Quizzed Course (QC)
Every Friday a five question quiz was given to the students. The quiz was scored for
10pts with each correct question response worth 2 pts. These quizzes were given in complete
silence without student access to materials. Each question had 30-45 seconds of allotted time for
students to provide their answer. iClicker technology was utilized to acquire student answers.
Because students were being graded for correct responses, the quizzes given were less difficult to
maintain adequate student grades.
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Table 4-2. Quiz topic associated learning outcome.
Think Pair Share
Quiz Number

Tested Learning
Outcome

Learning Outcome Description

1
2
3

1.1
1.9
1.13, 1.18

4

3.2

5

3.4

6

4.3, 4.5

7

5.4

8

7.6

9

3.2

Identify and Describe the various qualifications for life
Explain the experiments that determined that DNA was the genetic material
Create a mRNA strand from a DNA template strand; Create a chain of amino acids using
the codon chart and an mRNA strand
Label and describe photosynthesis and the process by which light energy is used to convert
carbon dioxide to glucose.
Describe the process of cellular respiration and explain its location within the cell, the
organelles and molecules involved, and the importance of oxidative phosphorylation
Explain each of the following types of cellular signals:
a.
Paracrine
b.
Endocrine
c.
Juxtacrine
d.
Autocrine
Identify and explain the differences between haploid, diploid, and polyploidy. Give
examples of cells with both haploid and diploid chromosomes.
Describe X-Linked Traits and Y-Linked Traits. Compare and contrast the differences
between the two and explain their expression within individuals.
Label and describe photosynthesis and the process by which light energy is used to convert
carbon dioxide to glucose.

Note. Each quiz number is shown with the learning outcome that was tested. The questions generated for the TPS using the learning
outcomes as the topic were designed to be difficult and test student problem solving.

TPS Course (TPSC)
Every Friday a single TPS question was given to students. These questions were designed
to be very difficult to inspire critical thinking. We prepared the topics for the TPS based on the
lowest scoring learning outcomes from previous courses. Students were given approximately 2
minutes to answer the question on their own without any access to material, and would input
their response. Students were then allowed approximately 2 minutes to discuss with a partner,
and would input their response. Finally, students could discuss within groups the answer to the
question. The final student answers were recorded followed by the true answer reveal. Following
the answer reveal, we would explain the reasoning behind the correct answer. These quizzes
were not graded based on correct responses, however, students were given participation points
for responses.
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Student Feedback
At the end of the TPSC students were given a five-question survey with inquiries about
their experience utilizing the TPS technique in class. Additionally, we also provided an
additional question where students could write their own thoughts, which was the source of the
quotes throughout the paper. This survey was assigned points to ensure that we obtained a
comprehensive overview of students thought on their TPS experience and to reduce sampling
bias. All survey results were anonymous to ensure students shared their true feelings without the
worry of repercussion. This research utilized educational tests and survey procedures along with
general public observations and is exempt from IRB approval as there was no identifying links to
the participating subjects.
Results
Quiz results show the stepwise change in answers as the class discusses the problem
As students answered individually, in pairs, and in groups there was a significant shift in
the responses towards the correct answer in most the quizzes (Figure 4-2). A clear example of
this shift is in Quiz 5 where a third of students had obtained the right answer when responding
individually, but the majority of the class was evenly spread through the other incorrect
responses. As the students thought in pairs the number of individuals with the correct answer
increased, and when those pairs collaborated in groups the number of students with the correct
answer again increased to half of the students. This type of progress was very common
throughout the quizzes, and indicates that students are being influenced by their peers in a
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constructive fashion as many of the students switched from an incorrect answer to the correct
answer.
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Figure 4-2. Quiz results for TPS questions. Quiz responses from the students for the 9 quizzes are listed here to
analyze the success of student cooperation while discussion the question posed. Graphs labelled “individually” show
the results of student responses after answering using their own knowledge. Graphs labeled “in pairs” shows student
responses after collaborating with a partner, and graph “in groups” visualizes student final responses after group
discussion. Each quiz is listed on the right-handed side and the relative abundance of each answer is displayed above
the answer choice.

In addition, these quiz results also demonstrate the influence and importance of having
all three steps in the TPS process. Several quizzes experienced a shift in the classroom responses
towards the correct answer only after the class had collaborated within groups. Quiz 6 is the best
example of this process as the students were still divided almost equally among all the answers
until group discussion where a definitive answer emerged. This shows that all three steps are
crucial in the TPS process as different learning is nurtured within each step. There were also
scenarios such as with Quiz 8, where a clear majority of the students preferred an incorrect
answer, but over the course of the discussion there was a turn in the class and the correct answer
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ended up being the leading majority. These examples show that the collaboration between
students influenced the resulting answers each student provided as students with a clearer
understanding of the concepts are able to explain themselves to other less-confident students.
There was a significant improvement in the overall classroom environment as students felt safe
to answer questions
When students in the TPSC were given the opportunity to interact with one another, there
was a distinguishable change in the overall environment during the course. Students were clearly
more vocal and engaged in the lectures. This was a substantial change in comparison to the QC
where the professor consistently had difficulties engaging the course as students were not
responsive to humor or questioning. The TPSC over the semester became more light-hearted
which enabled better discussion and a safer environment for inquiry.
Over 90% of the students in the TPSC “strongly agreed” or “agreed” that the TPS
questions improved the atmosphere of the class. This overwhelming majority shows that students
believed the TPS questions gave them an important opportunity to interact with their peers.
“This process helps students in the class to get to know each other a little
better and feel more comfortable in asking for help later on”
“I think it made the class become a safer place for questions, discussions,
and mistakes”
“This experience creates a sense of togetherness, or communal effort,
enhancing the classroom connection between students by giving them an
opportunity to work together and apply what they have been taught”
These are some of the comments students said in regarding the improved atmosphere
within the classroom. As one student pointed out, the questions provided an opportunity for
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people to work together that is not often found in college courses of this size. Many people
reported an increase in friendships and several students experienced less caution when asking
other students for help later on in the course. In addition, because there was a collaborative
environment, many students felt the classroom a safer place to ask questions. This safe
environment also fostered the idea that making mistakes increases learning. All of these factors
in conjunction made this class very responsive and interactive within the learning process.
Students felt an increased mastery of the concepts presented in class by learning from their peers
As questions were presented throughout the semester, the students increased their
communication with one another. During quizzes students are actively discussing, turning their
bodies around to interact with groups behind them or pointing to the question making an
argument for their answer. This collaboration aided in expanding students understanding of
difficult concepts. Over 92% of the students in the TPSC “Agreeing” or “Strongly Agreeing”
that student collaboration was important to gain new perspectives of challenging concepts
(Figure 4-3).
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Figure 4-3. The following questions were given to the students to evaluate their opinion of the TPS quiz format. The
question posed to the student is given above the graph displaying the results. The relative number of students with
each answer is displayed.

By learning from their peers, several students were able to obtain a new perspective of
the material by receiving explanations through different viewpoints than the professor. This type
of teaching is especially important for students that have different learning languages from that
of the professor. By sharing the responsibility of teaching, individuals who would have otherwise
had a difficult time understanding the teaching style of the professor are able to grasp the
concepts through the explanations of their fellow classmates.
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“(TPS questions) Helps me to understand the concepts better when I can ask
someone to explain something to me that I don’t get the first time the professor
explains it”
“Provided an opportunity for me to not only apply my knowledge but gain insight
and perspective from my peers. It helped me to understand concepts that would be
otherwise very hard to grasp.”
“It is really helpful seeing different ways to solve the problem and the different
ways people think”
“I found the think pair share quizzes to be extremely helpful because I realized I
was thinking about the problems wrong, so when someone else explained it to me
I understood the concept better and actually kept remembering it as I studied and
listened to lecture”
“Teaching and discussing with a small group of your peers goes a LONG way to
help introduce and retain information”
Additionally, this format of questioning provided students the opportunity to teach. As
one of the most effective ways to retain and master concepts, teaching helped solidify material
and retain knowledge. Since the questions covered a large array of information, every student
had the opportunity to teach as each concept is learned differently by every individual. Students
felt this was extremely helpful during their mastery of the course content.
“I felt way more involved in the concepts and I was enabled to learn more through
either teaching other students or using other students to teach me”
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“They (TPS questions) gave me an opportunity to teach what I know about the
question to my peers quickly, which helps me determine how much I actually
know about the subject and what I need to refine with my studying”
Finally, several students expressed their satisfaction with verbally expressing their
thoughts. Many times, a student may think through a question and come up with logical
conclusions in their mind, but the act of verbalizing those thoughts in an effective way to
communicate their reasoning to other students requires completely different skills and a very
thorough understanding of the question. This articulation and the discussion/argument between
students evoked a deeper investigation into the underlying concepts behind each question as
students had to make logical arguments for their answer.
“By talking through the question with someone else or with a group of people, I
am able to understand the concept more clearly because it forces me to describe
my answers vocally with precision”
“I felt like I understood the material better when I was able to explain it to
someone else and change their opinion”
Students felt less pressure and anxiety during quizzes, which enhanced their ability to critically
think and test their understanding
With the freedom to ask extremely difficult questions, the professor was able to challenge
students. This stimulating environment is usually not possible using traditional quizzes because
students are too concerned with grading, and experience frustration and anxiety when a question
is beyond their understanding. A large majority of the class preferred TPS questions (92%) over
traditional quizzes (Figure 4-3). By providing a question that is designed and known to be very
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challenging, students feel less pressure to get the “right” answer and can instead focus on where
their understanding is lacking.
“I liked the TPS quizzes because they weren’t as stressful as traditional quizzes
and gave me a chance to ask other people questions”
“I liked that it was graded on participation, so there was low pressure and we
could explore more difficult questions”
“My favourite part is that it was okay if we got the quiz questions wrong because
that places more emphasis on learning something new and takes the stress off of
making sure the answer is correct”
“It was a non-stressful way to push our critical thinking and problem-solving
skills”
Because students were not required to have a correct answer for their grade, freedom was
given to ask questions to test student’s ability to critically think about the concepts discussed in
class. As a result, 93% of the students in the TPSC reported the Think Pair Share questions to be
“Helpful” or “Very Helpful” in improving their critical thinking (Figure 4-3). This suggests that
the students knew they experienced an improvement in their critical thinking and problem
solving skills as they applied their knowledge to practical scenarios.
“I feel that collaborative thinking helped broaden my understanding of difficult
topics”
“They (TPS questions) demanded more of an understanding of the material rather than
mere memorization, which can often be more challenging as it differs from the typical
high school mind-set. By letting us work in groups, it makes the transition a lot smoother
and easier”
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There was an increase in student performance on TPS quizzed learning outcomes
Table 4-1 show the differential success of students between the TPSC and QC courses on
tests based on learning outcome. The most difficult learning outcomes for both control QC
semesters were 1.13 for test 1 and 3.2 for test 2. Yet, in the TPSC student performance
significantly increased for these learning outcomes. In addition, several learning outcomes in the
QC that students had poor performance had a significantly better outcome within the TPSC.
There was a decrease in the slight bimodal curve experienced in the QC courses as overall
student performance increased, and less students were ‘lost’ during the semester (Figure 4-4).
Figure 4-4. Listed is the test performance for all the evaluated semesters. The test given is displayed above (there

were a total of 3 tests during the semester) and the semester the test was given is shown on the right. Each histogram
of student performance shows distinguishing differences between the semesters and between overall student
performance.
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An instructor view of the TPSC in comparison to the QC
Often it is difficult to entertain and keep a class of over 200 students engaged within a
50-minute lecture. Yet, when given TPS questions, this challenge was considerably diminished
as students provided the necessary energy and enthusiasm to maintain high levels of class
participation and thought-provoking inquiries. This made teaching easier as the instructor can
gauge student understanding through proposed questions. Meanwhile, students would also aid in
suggestions and provide their own insights into the material, which helped invoke constructive
discussions on applications of the concepts being addressed.
We have also found that TPS questions are as easy to implement within a college
classroom as a standard quiz. Both quiz formats utilize an iClicker system to record grades,
which is often already implanted into the course for other purposes. TPS questions also only
require the creation of one quiz question, which may lighten the work load of the instructor as
they are not required to create multiple questions. Finally, the time requirement for TPS quizzes
is very similar to the time required to take a standard quiz. As such, the transition between the
formats is relatively simple and TPS quizzes are easy to integrate into a standard lecture.
Implications of this technique in a general classroom
The think pair share strategy has shown to be valuable in a college setting to enhance
both student critical thinking and classroom atmosphere. This strategy can easily be implemented
in any college classroom across the world to enhance student learning as it only requires the
instructor to prepare a challenging question on the material taught. In addition, because students
are collaborating with each other, we suggest that this technique is helpful when teaching a
mosaic of students from different ethnic backgrounds. Because students can choose those in
which they sit next to, they can converse with those who they prefer. This provides extra
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opportunities for second language learners, who struggle with content and language barriers, as
they collaborate with other second language learners to explain difficult concepts. We performed
this experiment within a science course because the content is generally difficult for students to
grasp, but this technique can be applied to any subject to provide opportunities for students to
collaborate and solve problems.
Conclusions
The results of this study emphasize the importance of collaborative learning within a
college classroom, especially within a subject that is historically difficult. We found that students
who successfully engaged in conversation and discussion with their fellow classmates were able
to master the concepts being discussed in lecture. By increasing cooperation between students
and encouraging discussion, students increased performance on evaluations compared to students
who were given standard quizzes and were not given the opportunity to engage with one another
in class. When challenged with questions designed to inspire critical thought, students performed
significantly better upon discussion within peer groups 461. This demonstrates the superiority and
effectiveness of Think Pair Share quizzes compared to traditional quizzes within college courses.
While the scope of this study was limited to one course, our findings also report that the
implementation of these quizzes within classrooms does not take substantial effort on the part of
the educator. As such, this technique provides a relatively simple step for educators to bring
collaboration into their large courses. The results of this study highlight the importance of
providing opportunities for collaborative learning in college lecture-style courses for student
concept mastery in addition to providing a strategy that can provide this within courses.
Funding Details
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Supplementary Tables
Supplementary Table 4-1. Course Content Outline.
Unit: Title
Unit One:
Information
Transfers
Necessary for
Life

Concepts
Life: Chemical, Cellular, and
Evolutionary Foundations
The Molecules of Life
Nucleic Acids and Transcription
Translation and Protein Structure

Unit 2: Lipids,
Membranes, and
Energy
Acquisition
Unit 3: Cellular
Respiration and
Photosynthesis
Unit 4: Cell
Communication,
Structure, and
Function
Unit 5: Cell
Division and
Replication
Unit 6: Genomes
and DNA
Techniques
Unit 7: Mutation
and Repair

Unit 8: Evolution
Unit 9:
Immunology
Unit 10: Health
and Disease

Lipids, Membranes, and Cell
Compartments
Making Life Work: Capturing and
Using energy
Cellular Respiration: Harvesting
Energy from Carbohydrates and
Other Fuel Molecules
Photosynthesis: Using Sunlight to
Build Carbohydrates
Cell Signaling
Cell and Tissue Architecture

Description
Life works according to fundamental principles of chemistry and physics.
The fundamental unit of life is the cell.
Carbon is the backbone of organic molecules. Organic molecules include
proteins, nucleic acids, carbohydrates, and lipids, each of which is built
from simpler units.
DNA stores and transmits genetic information. Transcription is the
process by which RNA is synthesized from DNA.
Translation is the process where mRNA specifies the order of amino acids
in a newly synthesized protein
Cell membranes are composed of lipids, proteins, and carbohydrates
Chemical reactions involve the breaking and forming of bonds
Cellular respiration is a series of catabolic reactions that convert the
energy in fuel molecules into ATP
Photosynthesis is the major pathway by which energy and carbon are
incorporated into carbohydrates
Cells communicate primarily by sending and receiving chemical signals
Tissues and organs are communities of cells that perform special functions

Cell Division
DNA Replication and Manipulation

During cell division, a single parental cell divides into two daughter cells
A single parental molecules of DNA produces two daughter molecules

Genomes

A genome is the genetic material of a cell

Mutation and DNA Repair
Genetic Variation

DNA can be damaged but most DNA damage is repaired
Genetic variation describes common genetic differences among
individuals in a population
Genetic inheritance provides the framework for an individual and several
diseases are related to sex-linked traits.
Evolution is the change in the frequency of alleles or genotypes over time

Mendelian Inheritance, Inheritance of
Sex
Evolution: How Genotypes and
Phenotypes Change Over Time
Natural Defense Against Pathogens
Epidemiology
Bacterial and Viral Diseases
Soil Borne Bacterial Diseases
Water Borne Bacterial Diseases
Eukaryotic Pathogens

Study of the body’s natural defense against disease
Study of the occurrence of disease within populations and the variables
affecting that.
Diseases associated to bacterial or viral infections
Diseases from soil residing bacteria that affect human health
Diseases from water residing bacteria that affect human health
Eukaryotic organisms that have an influence on human health

Note. Displayed is the content covered throughout the course. Each unit is separated according key concepts.
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Supplementary Table 4-2. Course Content Outline.

Objective Description
1.1
Identify and describe the various qualifications for life
1.2
Describe organisms whose determination of life is not yet decided and give evidence
1.3
1.4
1,5
1.6
1.7
1.8
1.9
1.10
1.11
1.12
1.13
1.14
1.15
1.16
1.17
1.18
1.19
1.20

for and against those organisms being classified as living or nonliving
Draw the structure of an element including: protons, neutrons, and electrons
Describe the various chemical bonds and how they are important in molecular stability
Describe lipids, proteins, nucleic acids, and carbohydrates and explain how they are
important in maintaining organism life and functionality
Identify various amino acids by their structure.
Label and explain the individual components of DNA including the nitrogenous bases
(Adenine, Thymine, Guanine, and Cytosine), the sugar-phosphate backbone, the sugar,
and the antiparallel nature of DNA
Describe the differences between RNA and DNA
Explain the experiments that determined that DNA was the genetic material
Identify and provide the function of the proteins associated with DNA replication:
Compare and Contrast the differences and similarities between Prokaryotic
Transcription and Eukaryotic Transcription
Describe various proteins associated with Transcription
Create a mRNA strand from a DNA template strand
Understand how mRNA is processed and why it is important for protein diversity in
Eukaryotic organisms
Label and explain the process of translation including where it takes place, the proteins
involved, the organelles involved, and the final products.
Compare and contrast the differences and similarities between prokaryotic and
eukaryotic translation and the resulting consequences of their differences.
Relate how mistakes in translation can lead to serious problems in the cell in regards to
the protein product.
Create a chain of amino acids using the codon chart and an mRNA strand
Explore the different protein structures and understand how those specific structure
contributes to the protein’s functionality and purpose in the cell.
Explain the scientific method and how it has contributed to our understanding of
scientific principles.

Note. The following is a table of the learning outcomes that were evaluated for Unit 1 to provide an
example of the expectations for the remainder of the units. Each unit had similar learning outcomes that
were used to evaluate the concepts that were most difficult for students to comprehend. These learning
outcomes became the focus of the TPS questions created.

99

CHAPTER 5
Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine
phosphoribosyltransferase on the plasma membrane
Michelle H Townsend, Michael D Anderson, Evita G Weagel, Edwin J Velazquez, K Scott
Weber, Richard A Robison, and Kim L O’Neill
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The following chapter is taken from an article published in OncoTargets and Therapy. All
content and figures have been formatted for this dissertation.
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Abstract
In both males and females, lung cancer is one of the most lethal cancers worldwide and
accounts for .30% of cancer-related deaths. Despite advances in biomarker analysis and tumor
characterization, there remains a need to find suitable biomarker antigen targets for treatment in
late-stage lung cancer. Previous research on the salvage pathway enzyme TK1 shows a unique
relationship with cancer patients as serum levels are raised according to cancer grade. To expand
this analysis, the other salvage pathway enzymes were evaluated for possible upregulation within
lung cancer. Adenine phosphoribosyltransferase, deoxycytidine kinase, and hypoxanthine
guanine phosphoribosyltransferase (HPRT) were assessed for their presentation on two nonsmall-cell lung cancer cell lines NCI-H460 and A549. In the present study, we show that
deoxycytidine kinase and adenine phosphoribosyltransferase have no significant relationship
with the membrane of NCI-H460 cells. However, we found significant localization of HPRT to
the membrane of NCI-H460 and A549 cells. When treated with anti-HPRT antibodies, the
average fluorescence of the cell population increased by 24.3% and 12.9% in NCI-H460 and
A549 cells, respectively, in comparison with controls. To ensure that expression was not
attributed to cytoplasmic HPRT, confocal microscopy was performed to visualize HPRT binding
on the plasma membrane. After staining NCI-H460 cells treated with both fluorescent antibodies
and a membrane-specific dye, we observed direct overlap between HPRT and the membrane of
the cancer cells. Additionally, gold-conjugated antibodies were used to label and quantify the
amount of HPRT on the cell surface using scanning electron microscopy and energy-dispersive
analysis X-ray. Further confirming HPRT presence, the gold weight percentage of the sample
increased significantly when NCI-H460 cells were exposed to HPRT antibody (P=0.012) in
comparison with isotype controls. Our results show that HPRT is localized on the surface of
these non-small-cell lung cancer cell lines.
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Introduction
Lung cancer is one of the leading causes of cancer-related deaths in both males and
females worldwide. In 2015, 221,200 individuals in the US were diagnosed with lung cancer,
while another 158,040 individuals were killed by the disease 462. Approximately 85% of lung
cancer cases are diagnosed as non-small-cell lung cancer, which encompasses squamous cell
carcinoma, adenocarcinoma, and large cell carcinoma 463. Despite advances in combinatorial
therapy using both chemotherapy and radiotherapy, patient outcome has not improved at a
satisfactory rate 464. Currently, the 1-year survival rate for lung cancer patients is 44%, and the 5year survival is only 17%. Low survival is largely attributed to late-stage diagnoses.
Approximately 57% of patients are diagnosed at a late stage, leading to reduced treatment
options and increased mortality. When diagnosed at a late stage, the survival rates are reduced to
26% and 6% for 1-year and 5-year survival, respectively 462.
Because early detection of lung cancer is integral to patient survival and outcome,
substantial efforts have been made to develop noninvasive tests that identify non-small-cell lung
cancers, allowing physicians to diagnose the disease at an earlier stage 465,466. Although profiling
cancer tissues to find circulating biomarkers can aid in identifying tumor-derived proteins, these
methods are extremely invasive. As a result, researchers have developed techniques to identify
cancer biomarkers in the sputum of patients. These tests utilize DNA-based assays to detect
methylated gene promoter regions that are commonly found in tumors and lead to the loss of
tumor suppressor function 467,468. RARβ is a chief candidate for this type of analysis because it is
involved in cellular signaling during embryonic morphogenesis, cell growth, and differentiation
469

. Studies show that 95% of the cancer tissue has upregulated methylation of the RARβ

promoter compared to controls, demonstrating its use as an effective biomarker for lung cancer
detection 469. The p16 tumor suppressor gene has also been used in early detection through
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evaluation of hypermethylation at its locus 470–472. This methylation change is often detected in
precursor lesions of tumors and serves as an early event in cancer development and progression
473

. In addition, recent advancements have allowed physicians to detect cancer using breath

samples from patients by analyzing volatile organic compounds. By evaluating panels of
patients, cancer profiles are established that can later be used as references to aid physicians in
early lung cancer detection 474,475.While these methods are promising for the early recognition of
lung cancer, they are not suitable for the treatment of patients.
Once lung cancer is detected and diagnosed, a majority of patients are treated with
surgery, chemotherapy, radiation therapy, and targeted therapy. For patients suffering with nonsmall-cell lung cancer, the most common treatment is chemotherapy combined with targeted
drugs. Although many patients go into remission after initial treatment, a large percentage
eventually relapse, and chemotherapy regimens offer little advantage over other treatments for
advanced non-small-cell lung cancer 476. New therapies utilize cancer antigens to target tumors,
which enables physicians to personalize treatments. Treatment efficacy is enhanced with tumor
biopsies, which classify the individual mutations in a tumor to help determine the best course of
treatment 477. Because of these biopsies, multiple genes have been assessed and shown as
biomarkers for lung cancer due to their upregulation in comparison with normal tissue. CBLC,
CYP24A1, S100P, and ALDH3A1 all have 5- to 10-fold increases in the level of expression in
both adenocarcinoma and squamous cell carcinoma samples in comparison with normal tissue
478

. This information leads to personalized treatment and aids physicians in determining effective

drug regimens. For example, ∼10% of patients with non-small-cell lung cancer have a mutation
in the epidermal growth factor receptor (EGFR) that renders them sensitive to tyrosine kinase

inhibitor drugs 479–482. Although personalizing treatment based on tumor characteristics can be
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effective and lead to increased survival rates for small subsets of patients, the current targeted
treatments lack specificity and can often lead to unwanted off-target effects 483.
The purpose of this study was to find a lung cancer biomarker on the surface of nonsmall-cell lung cancer cells. Due to the proliferative capacity of cancer cells and the need for
necessary nucleotide production to support rapid division, the salvage pathway enzymes
deoxycytidine kinase (DCK), adenine phosphoribosyltransferase (APRT), and hypoxanthine
guanine phosphoribosyltransferase (HPRT) were evaluated for potential expression on nonsmall-cell lung cancer cell lines. DCK functions by transferring a phosphate group to
deoxycytidine in the production of cytosine bases. APRT catalyzes the transfer of a
phosphoribosyl group from phosphoribosyl pyrophosphate (PRPP) to adenine, forming adenine
monophosphate in the production of adenine bases. HPRT is a crucial enzyme for the large-scale
production of guanine and inosine bases. HPRT functions by transferring phosphoribose from
PRPP to hypoxanthine or guanine bases to form inosine monophosphate (IMP) and Guanine
monophosphate (GMP), respectively 10,12. We designed this study to evaluate the potential of
these salvage pathway enzymes as possible biomarker targets for the treatment of non-small-cell
lung cancer.
We utilized a variety of methods, including flow cytometry, confocal microscopy, and
scanning electron microscopy, to determine whether DCK, APRT, or HPRT had any significant
relationship with the surface of H460 and A549 cells. In addition, we also evaluated HPRT
expression within patient tissue to determine whether there was a unique elevation in patients
with lung carcinoma. Although we found no significant relationship between DCK and APRT
with H460 non-small-cell lung cancer cells, HPRT had a significant colocalization with the
membrane of both A549 and H460 cancer cells.

104

Materials and Methods
Chemicals
Mouse-antihuman HPRT monoclonal antibody clone 1F8D11 (Thermo Fischer
Scientific, Waltham, MA, USA) was aliquoted and stored at −20°C. DCK antibody clone
2243C2 (Santa Cruz Biotechnology Inc., Dallas, TX, USA) and APRT antibody lot 10196
(Abnova, Taipei City, Taiwan) were stored at −20°C. Mouse-FITC and rabbit-FITC antibody
(Sigma Aldrich, St Louis, MO, USA) were stored at 4°C and were used in minimal light
conditions. Bovine serum albumin (BSA, Sigma Aldrich) and sodium thiolsulfate (Macron Fine
Chemicals, Center Valley, PA, USA) were dissolved in phosphate-buffered saline (PBS) at a 1%
concentration and stored at 4°C. A 50% glutaraldehyde stock solution (Electron Microscopy
Sciences, Hatfield, PA, USA) was stored at −20°C, and workable solutions were diluted to
0.25% in PBS and stored at 4°C. Glycine (Thermo Fischer Scientific) was diluted to 0.2 mM in
PBS and stored at 4°C. NF-κB polyclonal antibody (Bioss Antibodies, Woodburn, MA, USA)
was stored at −20°C. CD44 monoclonal antibody (One World Lab, San Diego, CA, USA) was
stored at −20°C.
Cell culture conditions
The human non-small-cell lung cancer cell lines H460 and A549 were obtained from the
American Type Culture Collection (Rockville, MD, USA). H460 cells were grown in RPMI
1640 medium supplemented with 10% fetal bovine serum and 2 mM L-glutamine (all from
Hyclone, Logan, UT, USA). A549 cells were grown in DMEM/F12 medium supplemented with
10% fetal bovine serum and 4 mM L-glutamine (all from Hyclone). The cell media were
replaced every 48 hours, and cells were trypsinized and reduced once 90% confluence was
obtained. Cells were treated with Accutase (Stemcell Technologies, Vancouver, Canada) when
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utilized for flow cytometry, and when plated for all other applications. All cells were grown at
37°C and 5% CO2. Cell lines were authenticated in May 2016 by the University of Arizona
Genetics Core.
Flow cytometry
The expressions of HPRT, DCK, and APRT in cultured cells were evaluated by
measuring the levels of fluorescence in cells treated with each salvage pathway enzyme
antibody. All samples were analyzed on a Blue/Red Attune (Applied Biosystems, Foster City,
CA, USA), which recorded 25,000–50,000 events per sample. Briefly, 250,000 cells were
incubated with 200 μL of PBS containing 1 μg of antibody to DCK, APRT, and HPRT for 15
minutes on ice. Cells were then labeled with FITC-conjugated secondary (mouse or rabbit)
antibody for 15 minutes on ice. Isotypic IgG and unstained cells served as negative controls. The
forward/side-scatter plots were used to gate out cell doublets and dead cells. Resulting data were
analyzed and plotted using FlowJo Software (FlowJo Enterprise, Ashland, OR, USA). CD44 was
utilized as a positive control (Figures 5-S1 and 5-S2), and NF-κB was utilized as a negative
control.
Confocal microscopy
Fluorescently stained cells were examined under an epifluorescence microscope
(Olympus, Tokyo, Japan) equipped with a laser confocal system (Bio-Rad Laboratories,
Hercules, CA, USA) using a 15 mW Krypton/argon laser. Image processing was carried out with
Laser Sharp Computer Software (Bio-Rad Laboratories). After accutase treatment, cells were
plated at a concentration of 4×105 cells/mL on glass coverslips. Following 1 day of growth, cells
were incubated in 500 μL of PBS containing 2.5 μg of anti-HPRT antibody for 15 minutes on a
shaker at 4°C. Cells were then labeled with 2.5 μg of FITC-conjugated secondary antibody for
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15 minutes on a shaker at 4°C. Then, cells were incubated at 37°C for 10 minutes with a 1:1,000
dilution of a Cell Mask Deep Red plasma membrane dye (Fisher Scientific, Waltham, MA,
USA).
Scanning electron microscopy
After acutase treatment, cells were plated at a concentration of 400,000 cells/mL on glass
coverslips. After 1 day of growth, cells were placed in 6-well plates and washed three times with
PBS followed by a 1% BSA in PBS wash, a 1% sodium thiolsulfate in PBS wash, and a 1%
sodium azide wash for 5 minutes each at 4°C. Cells were then incubated with 5 μg of primary
antibody conjugated to Biotin for 15 minutes on a shaker at 4°C. After primary incubation, cells
were washed with 1% BSA followed by two washes with PBS. Then, cells were washed with 1%
PBS–BSA and 1% sodium thiolsulfate for 5 minutes on a shaker at 4°C. Cells were then
incubated with 2.5 μg of a streptavidin–gold conjugate (Nanoprobes, Yaphank, NY, USA) for 15
minutes on a shaker at 4°C. This was followed by a 1% BSA wash and three PBS washes. Cells
were then fixed via incubation in a 0.25% glutaraldehyde solution diluted in PBS for 5 minutes.
The reaction was extinguished by adding a 0.2 mM glycine diluted in PBS solution and
incubating for 10 minutes until the solution turned to a slight yellow color. Cells were then
washed three times with ddH2O. Solutions A and B from the Nanoprobes gold enhancement kit
were incubated together for 5 minutes. Solutions C and D were then added, vortexed, and 40 μL
of the gold enhancement solution was added to each sample and incubated for 5 minutes. Each
sample treated with gold enhancement is coated in a solution of 2 nm gold particles, but only
gold already present via secondary antibody binding will be enhanced to form a definitive
particle. Each sample was subsequently put through a series of dehydrations with 70%, 80%,
90%, and 100% EtOH before analysis. Gold-labeled samples were examined under a Phillips
XL-30 ESEM using a 15 kV electron stream under low vacuum conditions at 0.8 Torr. A
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gaseous side electron (GSE) detector was utilized to image the cell morphology and topography.
A back scatter electron (BSE) detector was utilized to visualize gold particles on the cell surface.
Once images for the cells were obtained, the elemental composition was evaluated using energydispersive analysis X-ray (EDAX). Because of gold enhancement, the elemental gold percentage
of the background levels of gold was ∼8%.
Immunohistochemistry
Lung carcinoma tissue arrays were obtained from Cybrdi (Frederick, MD, USA). These
tissues contain various stages of cancer along with corresponding benign and normal tissues
from 35 different patients. HPRT levels were assessed utilizing standard immunohistochemistry
staining. Tissues were rehydrated in a series of ethanol washes before treatment with a DIVA
decloaker solution to retrieve antigen. Tissues were then incubated with a background sniper
solution to reduce nonspecific antibody binding. Following blocking, a primary antibody is
added to the tissue at a concentration of 1:100 to 1:200 and incubated overnight at 4°C.
Following primary staining, tissues were washed and then treated with secondary antibody
conjugated to a horse radish perioxidase polymer and incubated for an hour. Following washing,
a DAB (3,3′ diaminobenzidine) peroxidase solution is incubated with the tissues. Areas of
antibody binding will convert the colorless substrate to a brown product, effectively highlighting
the target protein. Tissues were treated with hematoxylin to stain the nucleus of the cells. Along
with HPRT treatment, a universal negative antibody was used as a negative control.
Tissues were quantified utilizing ImageJ software. All images were evaluated using the
IHC toolbox ImageJ plugin. The DAB option is chosen, and the tissue image is then removed of
all other staining except for DAB. Following this analysis, the image is then converted to a gray
scale and a threshold is applied in order to eliminate areas of white inherit in the tissue. Once the
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threshold is applied, the average gray value of the tissue is collected. The same threshold is
applied to all tissue samples in order to ensure consistency.
Statistical analysis
Analysis of variance (ANOVA) statistical analysis with the multiple comparison method
was used to determine the differential surface expression of various treatments for flow
cytometry data on both A549 and H460 cells. In addition, two-way ANOVA tests were
performed to compare the mean values of HPRT expression between A549 and H460 cells.
EDAX data were analyzed using ANOVA with the multiple comparison method in addition to
unpaired t-tests to determine significance between samples. All statistical analyses were
performed using GraphPad Prism
7 software. Differences were considered significant when the P-value was ,0.05.
Results
DCK and APRT are not found on the surface of non-small-cell lung cancer H460 cells
Flow cytometry utilizing FITC fluorescent antibodies was used to quantify the DCK and
APRT surface antigens. Figure 5-1A and B shows the relative binding of DCK and APRT
protein on the surface of H460 cells, while Figure 5-1C shows the binding of HPRT. In the
presence of anti-DCK and anti-APRT antibody, there was no significant increase in the
fluorescent intensity of treated samples and no resulting shift in the cell population. Further
statistical analysis revealed that DCK and APRT were not significantly different than the
secondary IgG antibody controls. These data show no relevant binding of specific antibodies to
the cell surface and suggest that the therapeutic potential of DCK and APRT is minimal for nonsmall-cell lung cancers.
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Figure 5-1. Flow cytometry analysis of the salvage pathway enzymes in H460 cells. Notes: The following samples
were utilized in order to evaluate the expression of APRT, DCK, and HPRT on the surface of H460 cells: unstained
(autofluorescence control), mouse IgG (nonspecific binding control), rabbit IgG (isotype control), NF-κB (cytosolic
protein control), and CD44 (positive surface antigen). (A) When anti-APRT antibody (green) was used to treat cells,
a resulting insignificant shift in the population was observed upon comparing the histogram diagrams to controls.
This insignificant shift is also shown in the lack of movement from Q3 in isotype controls to Q3 in APRT-treated
cells (equaling only 4%). Cells treated with APRT have an insignificant level of binding compared to isotype
controls (P=0.224). (B) Cells treated with anti-DCK antibody (purple) had an even smaller shift in the fluorescent
population compared to APRT. No cells from Q3 in the mouse IgG control moved to Q3 in the DCK-treated cells,
indicating a complete lack of the DCK antigen on the surface of H460 cells. Statistical analysis reveals no presence
of DCK on the surface of H460 cells (P=0.106). (C) When treated with anti-HPRT antibody (pink), the histogram
representation of the cell population showed a definitive shift in the population toward a higher fluorescence. This
was confirmed when .20% of the population from Q3 in the mouse IgG control shifted to Q4 upon HPRT treatment.
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Of the three salvage pathway enzymes evaluated, only HPRT had a significant movement of the cell population
toward a higher fluorescence, indicating the presence of HPRT on the surface of H460 cells. Statistical analysis
shows significant HPRT binding on the surface of H460 cells (P=0.0036).
Abbreviations: APRT, adenine phosphoribosyltransferase; DCK, deoxycytidine kinase; HPRT, hypoxanthine
guanine phosphoribosyltransferase.

Flow cytometry shows significant HPRT expression on the surface of A549 and H460 cells
When treated with anti-HPRT fluorescent antibodies, both A549 and H460 cancer cells
had an increase in the fluorescent population (Figures 5-1C and 5-2). A 28% shift in the
population is observed in H460 cells (Figure 5-1C), while a 12% shift is observed in A549 cells
(Figure 5-3). Statistical analysis comparing anti-HPRT-treated cells with isotype IgG controls
showed a statistically significant difference in H460 and A549 cells (Figures 5-1C and 5-2C).
Thus, these data show a significant association between HPRT and the surface of non-small-cell
lung cancer cells. This analysis also revealed a significantly higher HPRT surface expression in
H460 cells when compared to A549 (Figure 5-3).
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Figure 5-2. HPRT surface expression on A549 non-small-cell lung cancer cells. Notes: The following samples were
utilized in order to evaluate the expression of APRT, DCK, and HPRT on the surface of H460 cells: unstained
(autofluorescence), mouse IgG (nonspecific binding), rabbit IgG (isotype control), NF-κB (cytosolic protein
control), and CD44 (positive surface antigen). (A) Although not as prominent as the population shift in H460 cells
(Figure 5-1C), A549 cells treated with anti-HPRT antibody (pink) have a clear shift in the population toward a
higher fluorescent value, indicating the presence of HPRT antigen on the surface of A549 cells. (B) When treated
with anti-HPRT antibody there is a shift in the cell population from Q4 to Q3 of an average of 8% when populations
are compared to unstained and mouse IgG Q3 populations. (C) Statistical analysis reveals significant HPRT binding
on the surface of A549 cells (P=0.0245) when compared to controls. ***P<0.001.
Abbreviations: APRT, adenine phosphoribosyltransferase; DCK, deoxycytidine kinase; HPRT, hypoxanthine
guanine phosphoribosyltransferase.
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Figure 5-3. Levels of HPRT expression compared between A549 and H460 cells. Notes: While both A549 and H460
cells show a statistically significant increase in the surface expression of HPRT, H460 cells had a significantly
higher expression (P,0.0001). H460 cells are a faster growing cell line, with a growth rate almost double that of
A549 cells. As a result, HPRT expression on the surface of non-small-cell lung cancer cells may directly correspond
to cell proliferation. ****P<0.0001.
Abbreviation: HPRT, hypoxanthine guanine phosphoribosyltransferase.

Confocal microscopy confirms that HPRT is bound to the surface of the cell
In order to confirm that HPRT was not bound to cytoplasmic protein, the surface
expression of HPRT was further evaluated with confocal microscopy (Figure 5-4). Images
obtained from cells treated with membrane dye and FITC antibody stain were overlapped to
show colocalization of treated antigen on the plasma membrane of the cancer cell. When cells
are treated with anti-HPRT antibody, a yellow pigment appears in the merged image, which
indicates a direct relationship between the plasma membrane dye and the FITC dye. No other
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treatment experienced this same overlapped pigmentation, which confirms the relationship
between HPRT and the plasma membrane of H460 cells.

Figure 5-4. Plasma membrane colocalization with HPRT in H460 cells. Notes: H460 cells were dyed with both a
FITC dye and a Rhodamine Red membrane dye to label antibody treatments and the plasma membrane,
respectively. Utilizing unstained cells, IgG-treated cells, and NF-κB-treated cells as controls, plasma membrane
associations were evaluated to determine whether any of the treatments significantly bound to the membrane of
H460 cells. (A) Each sample was analyzed and imaged by a 488 nm laser to illuminate FITC-positive cells. These
images show the binding of the respective antigen treatment. (B) Samples were also imaged in a 594 nm laser to
show rhodamine-positive cells. This dye binds to the plasma membrane of all cells. (C) The two images obtained
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from columns A and B were merged to show associations between treated antibodies and the plasma membrane of
cells. These results show a clear overlap between cells treated with anti-HPRT antibody and those treated with the
membrane dye. This demonstrates a clear association between HPRT and the plasma membrane of H460 cells.
Abbreviation: HPRT, hypoxanthine guanine phosphoribosyltransferase.

HPRT antigen is scattered randomly across the surface of H460 cells
The location of the HPRT protein on the surface of H460 cells was also analyzed with
scanning electron microscopy (Figure 5-5). The gold elemental peak along with the elemental
composition of each sample reveals the changes in the surface gold percentages when cells are
exposed to primary antibodies. Images obtained from this analysis show HPRT on the cell
surface, but there is no apparent clustering of the antigen as gold particles are scattered across the
cell randomly. EDAX analysis showed that cells treated with anti-HPRT antibody had an
increase in the average gold weight percentage of 10.39% in comparison with only 8.75% for
IgG controls. With a P-value of 0.012 (Figure 5-6), these data indicate a statistically significant
presence of HPRT on the surface of H460 cells while also demonstrating that the antigen shows
no patterns of expression.
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Figure 5-5. Scanning electron microscopy images and resulting EDAX in H460 cells. Notes: Cells were labeled with
gold toward their respective antibody treatment. (A) Images were obtained using a BSE . This detector is specialized
to image heavy metals within samples and highlights enhanced gold within the sample. Any distinguishable large
particles of gold represent a bound antibody enhanced with gold. (B) Images were also obtained with a GSE , which
showed cell morphology to ensure correct cell structure and integrity. (C) EDAX analysis of each sample showed
the gold elemental peaks for all the elements present within the sample. Silicon is the highest represented element
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because cells were mounted on silicon cover slips for analysis. The gold elemental peak is indicated with a gold
error. Images obtained from this analysis show the exact location of the HPRT bound to the surface of the cell and
show no clear pattern indicating a random distribution of the antigen across the surface of the cell.
Abbreviations: BSE , back scatter electron; EDAX, energy-dispersive analysis X-ray; GSE , gaseous side electron;
HPRT, hypoxanthine guanine phosphoribosyltransferase.

HPRT expression in H460 cells is higher than expression within A549 cells
While HPRT is present on both H460 and A549 cells, there is a statistically significant
difference between the amount of the protein expressed between the two cell lines (Figure 5-3).

Figure 5-6. Gold percentage of H460 cells. Notes: The gold elemental composition of each sample is denoted on the
Y-axis. The increase in the gold percentage when cells were exposed to HPRT and CD44 shows a quantifiable
increase in the gold present on the outside of the cell. Cells exposed to HPRT antibody had a gold weight of
∼10.4%, which is statistically significant to the IgG controls used for background binding (P=0.0159). These data
indicate a statistically significant presence of HPRT on the surface of H460 cells. *P<0.05; **P<0.01.
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Figure 5-7. Evaluation of HPRT expression within patient tissue. Notes: All tissues were stained with a monoclonal
anti-HPRT antibody. The gray plots for each of the tissues are imaged below. (A) Tissue from a 69-year-old female
patient with stage III basaloid carcinoma and (B) normal tissue from a 59-year-old female patient. The malignant
tissue is significantly darker than the corresponding normal tissue. These tissues show an upregulation of HPRT
within malignant cells.
Abbreviation: HPRT, hypoxanthine guanine phosphoribosyltransferase.

H460 cells have ∼50% more protein on the surface when compared to A549 cells. This

altered expression may directly correspond to tumor proliferation as H460 cells grow at a much
faster rate, approximately double that of A549 cells. These results suggest that HPRT surface
expression may be more prevalent in rapidly proliferating cells as the need for protein is
increased.
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HPRT is elevated in half of the patients with lung carcinoma
In ∼50% of patients evaluated, there was a significant increase in HPRT expression

(Figure 5-7). This increase in protein was significant when compared to normal lung tissue,
whose expression was minimal. This different expression demonstrates HPRT variability
between patients as only half of the patients experienced this increase in protein levels. In
addition, the presence of HPRT also appears to be dependent on cell proliferation. On average,
there was an increased expression of HPRT in stage III tissues in comparison with other tissue
types (P=0.049). This indicates that HPRT overexpression may depend on cell proliferation as
stage III tissue is more aggressive and has a higher proliferative capacity than stage II or stage I
tissue (Figure 5-8).
Discussion
HPRT is a salvage pathway enzyme involved in the production of both guanine and
inosine bases. The enzyme functions by transferring phosphoribose from PRPP to hypoxanthine
or guanine bases to form IMP and GMP, respectively 10,12. Because of the proliferative
capabilities of cancer cells and the large demand for nucleotide production, an upregulated
expression at the HPRT locus is hypothesized in these environments 484. We have found that
there is significant HPRT colocalization with the plasma membrane in H460 and A549 cancer
cells. This same expression is not observed for the salvage pathway enzymes DCK and APRT,
indicating that HPRT may possess a role in cancer that is not shared by other salvage pathway
enzymes and could be a useful biomarker target for non-small-cell lung cancer.
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Figure 5-8. Statistical analysis of HPRT expression within patient tissue. Notes: Quantification of tissue was
conducted utilizing a gray scale. The lower the gray value, the darker the tissue is stained. (A) There is a statistically
significant presence of HPRT in approximately half of the tissues obtained from patients. This increased expression
shows that in some patients there is an upregulation of the protein. As HPRT is a housekeeping gene, there is a basal
level of expression present within the tissue. An isotype control was run to establish the gray value of unstained
tissue and to account for nonspecific antibody binding. (B) Of the tissues evaluated there was a significant
difference in HPRT presence in stage III tissue, indicating an increase in HPRT presence as cancer progressed and
proliferated. *P<0.05; ***P<0.001; ****P<0.0001.
Abbreviation: HPRT, hypoxanthine guanine phosphoribosyltransferase.

The reason for the surface expression of HPRT is currently unknown, and the purpose of
its external presentation in lung cancer cells can only be speculated 485. We hypothesize that this
unique surface expression may point to a secondary function of HPRT that goes beyond its
primary role as a purine synthesis enzyme. HPRT is already known to have a secondary
regulatory role in neural development and purine synthesis as patients who have a deficiency of
the enzyme develop a disease known as Lesch–Nyhan syndrome. This disease is characterized
by severe neurological illness, hyperuricemia, and purine overproduction. Purine overproduction
is directly related to the loss of HPRT function and demonstrates the enzyme’s necessary
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responsibility in cells to regulate and control certain pathways. The regulatory role of HPRT may
be important for its unique role within cancer. Loss of strict HPRT regulation may enhance
cellular proliferation and may contribute to tumor development as cells no longer have regulation
of processes normally controlled or limited by HPRT. Further defining these secondary functions
may provide additional information about the unique cellular interactions present in the tumor
microenvironment 22,486.
Although there is significant HPRT expression on A549 and H460 cells, the relative protein level
is not equal between the cell lines. The differential expression of HPRT between these two
cancer cell lines may be attributed to the growing capacity of the cells, as H460 cells grow at a
rate that is nearly double the rate of A549 cells. In addition, H460 cells are known to be highly
aggressive due to their increased vascularity and ability to metastasize 487,488 It is likely that the
surface expression of HPRT may correspond with proliferation and tumor aggressiveness. This is
further explored as stage III tissue stained with HPRT appears to be more prevalent in patient
tissue.
We have shown this phenomenon in vitro, but further research into the in vivo expression
is required to confirm whether HPRT could be utilized as a biomarker within patients, although
we report a significant increase in HPRT within some patients. If found expressed in vivo, HPRT
could be utilized in therapies to effectively treat non-small-cell lung cancer.
Conclusion
HPRT is expressed on the surface of NCI-H460 and A549 non-small-cell lung cancer
cells and may be used as a biomarker target.
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Abstract
The aim of this study is to investigate these enzymes as possible biomarkers in two
colorectal cancer cell lines: HT29, SW480, SW620, and Colo205. With 1,168,929 individuals
currently diagnosed with colorectal cancer in the United States, there remains a need to find
biomarkers to improve diagnosis and expand treatment options for patients. Due to their role in
proliferation and cell cycle regulation, we hypothesized an increase in salvage pathway enzyme
(APRT, DCK, and HPRT) expression and possible presentation within colon cancer cells.
Enzyme surface localization was assessed utilizing confocal microscopy, flow cytometry, and
scanning electron microscopy. General protein expression was evaluated utilizing
immunohistochemistry and Western blot analysis. While we found no statistically significant
presence of either APRT or DCK on the membranes of SW620, Colo205, and HT29 cells, we
found significant expression of HPRT on the surface of HT29, SW480, and SW620 cells. The
average population fluorescence increased by 28%, 58%, and 40% in HT29, SW620, and SW480
cells, respectively, when compared to isotype controls. Confocal microscopy images revealed
direct overlap between SW620 cells stained with a membrane dye and anti-HPRT antibody,
indicating co-localization on the plasma membrane. In addition, cells treated with gold labelled
HPRT antibody experienced significant changes in gold weight percentage on both SW620 and
HT29 cells when compared to isotype controls. When evaluating expression within normal
tissue, there was insignificant levels of HPRT binding. These data collectively suggest that
HPRT may be a possible biomarker target for the identification and treatment of colorectal
cancer.
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Introduction
Colorectal Cancer (CRC) is one of the leading causes of death in the United States. Every
year 49,700 individuals die as a result of CRC while an estimated 1,168,929 are currently
diagnosed with the disease 462. CRC is one of the most common cancers in the western world as
1 in 21 men and 1 in 23 women are predicted to develop the disease489–491.
In order to combat disease progression, a variety of markers have been identified that act
as useful tools for predicting tumor aggressiveness, mucin content, and aneuploidy in cancer
DNA 492–494. These markers are valuable when determining treatment options for individuals
with a unique blend of cancer characteristics. Recent research using cultured cancer cells have
identified cancer biomarkers such as the 1,25-Dihydroxyvitamin D3 receptor that may act as a
marker for colon carcinoma cell differentiation and growth. Receptors such as Vitamin D
receptor are upregulated on colon cancer cell surfaces and can serve as a target for tumour
reduction and elimination. Additionally, markers such as CD133 and CD44 have also been
identified for the elimination of cancer stem cells 489,495. While a number of tumor antigens have
been identified, additional markers will aid in better understanding colorectal cancer disease
progression and could lead to additional treatment options.
In the search to further characterize colorectal cancer cells, we decided to evaluate the
salvage pathway enzymes Hypoxanthine Guanine Phosphoribosyltransferase (HPRT), Adenine
Phosphoribosyltransferase (APRT) and Deoxycytidine Kinase (DCK) as a possible upregulated
targets. Salvage pathway enzymes act as recycling agents, reusing the components of old
nucleotides to skip energetically expensive steps in the formation of nucleotide bases 9. The
salvage pathway is the chosen method of nucleotide synthesis for a majority of the cell cycle in
humans as 90% of free purines are recycled 10. Responsible for the salvage of adenine in the cell
cycle, APRT is found constitutively expressed in a majority of mammalian cells 496. DCK is
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primarily involved in the phosphorylation of deoxycytidine in the production of cytosine 497.
HPRT functions by transferring phosphoribose from phosphoribosyl pyrophosphate (PRPP) to
hypoxanthine or guanine bases in the purine biosynthesis of inosine and guanine 10,12.
A deficiency of HPRT results in a spectrum of diseases that directly correspond with the
availability of the protein. Individuals with a complete lack of functional HPRT will develop
Lesh-Nyhan syndrome, while individuals with a partial deficiency will develop gout-like
symptoms characteristic of Kelley-Seegmiller syndrome 21,22,498. Because the gene is located on
the X chromosome, it is an X-linked recessive condition that predominantly affects males of
diseased families. Evaluation of the HPRT gene has become a common biomarker for
mutational assessment, and over 500 mutations in the gene have been described 23.
Having functional salvage pathway enzymes is important in the survival and functionality
of mammalian cells. Salvage enzymes, such as HPRT, are known as common housekeeping
genes, and are integral in several daily cellular functions regulating cell proliferation and cell
cycle progression 10,499. We evaluated these enzymes because of their intimate role in the
production of nucleotides necessary to maintain rapid cell proliferation. Additionally, these
enzymes maintain responsibility for synthesizing GTP and ATP which provide the critical
energy source for several cellular processes that are found upregulated within malignant cells
2,500,501

.
The aim of this study was to evaluate HPRT, APRT, and DCK as potential biomarkers

for CRC. We assessed the expression of the proteins on the surface of four CRC cell lines in
addition to evaluation within tumor tissue and normal tissue to determine the clinical relevance
of the protein expression. Results from these experiments could provide an additional marker for
the characterization of colorectal cancer.
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Figure 6-1. Analysis of APRT and DCK expression on SW620 and HT29 colon cancer cells. A, Cells treated with
APRT antibodies experienced no shift in the fluorescent population and had similar fluorescent signatures to isotype
controls. B, Cells treated with DCK antibodies experienced an insignificant change in the population when
compared to isotype controls, indicating no surface presence. Statistical analysis of APRT and DCK binding reveal
insignificant levels of either protein on the surface of SW620 cells. APRT antibodies were mouse and were
compared against mouse isotype controls, and DCK antibodies were rabbit and were compared against rabbit
isotype controls for statistical analysis. Insignificant shifts in the fluorescent intensity of the cells was observed
when treated with both B, APRT and DCK antibodies. Statistical analysis of APRT and DCK binding in HT29 cells
showed insignificant levels of the proteins on the surface. C, Insignificant surface binding was also observed in
Colo205 cells as well with no shifts in the fluorescent population upon treatment with either APRT or DCK
antibodies.

Results
Flow cytometry reveals an overall increase in fluorescence when colon cancer cells were
exposed to HPRT antibody, but not when treated with DCK or APRT antibodies.
Flow cytometry revealed no significant presence of APRT (p-value = 0.93) or DCK (pvalue = .243) on the surface of SW620 cells (Figure 6-1). There was also no statistically
significant presence of both enzymes (APRT, p-value = 0.39; DCK, p-value = 0.57) on the
surface of HT29 cells or Colo205 cells (APRT, p-value = 0.75; DCK, p-value = 0.96). We did
find that SW480, SW620, and HT29 cells had statistically significant HPRT expression on the
surface of the cells. The average fluorescence of the cell population increased by 27.73% in
HT29 (p-value = 0.013), 39.6% in SW480 (p-value = 0.0095), and 58.85% in SW620 cells (pvalue = 0.0079) when compared to isotype controls (Figure 6-2). This indicates a strong presence
of HPRT on the surface of the cells. Figure 6-2 shows insignificant isotypic binding, lower than
3% average of the total population (p-value = 0.374) in SW620 cells, 7% (p-value = 0.11) in
HT29 cells, and 3.94% (p-value = 0.058) in SW480 cells. While these cell lines showed positive
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HPRT surface localization, Colo205 cells showed no significant increase in the surface presence
of HPRT (p-value = 099). All cells were gated to exclude dead cells and cell doublet populations.

Figure 6-2. Flow cytometry analysis of HPRT expression on HT29, SW480, and SW620 cells. The following samples
were utilized in order to evaluate the expression of HPRT on the surface of CRC cells: Unstained (auto-fluorescence
control), Mouse IgG (Non-specific binding control), Rabbit IgG (Isotype control), NF-κB (cytosolic protein control),
and CD44 (positive surface antigen). A, When treated with anti-HPRT antibody (pink), the histogram
representation of the cell population showed a definitive shift in the population towards a higher fluorescence.
Statistical analysis shows significant HPRT binding on the surface of SW620 cells (p value < 0.0001). B, SW480
cells treated with anti-HPRT antibody experienced a shift in fluorescent intensity, indicating HPRT surface
localization. Upon statistical evaluation anti-HPRT treated cells show a significant difference when compared to
isotype antibody controls (p-value = 0.0095). C, The same fluorescent shift in the population is seen when HT29
cells are exposed to anti-HPRT antibody. There was a shift in the population equivalent to 20%, which is
statistically significant from the IgG controls (p value = 0.0016). While HPRT is statistically significant in both cell
lines, the difference between the cell line expression is also statistically significant as SW620 cells have over 25%
higher expression (p value = 0.0002). D, There was no significant change in the fluorescent population upon HPRT
antibody treatment on the surface of Colo205 cells (p-value = 0.99).
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Figure 6-3. Plasma membrane co-localization of HPRT in SW620 cells. SW620 cells were dyed with both a FITC
dye and a Rhodamine Red membrane dye to label antibody treatments and the plasma membrane respectively. A,
Each sample was analyzed and imaged by a 488nm laser to illuminate FITC positive cells. These images show the
binding of the respective antigen treatment. B, Samples were also imaged in a 594nm laser to show rhodamine
positive cells. This dye binds to the plasma membrane of all cells. C, The two images obtained from column A and
B were merged to show associations between treated antibodies and the plasma membrane of cells. These results
show a clear overlap between cells treated with anti-HPRT antibody and those treated with the membrane dye.
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HPRT is strongly associated with the plasma membrane of SW620 cells.
To ensure antibody binding was towards surface HPRT and not cytoplasmic HPRT,
confocal microscopy was performed to visualize protein localization on SW620 cells (Figure 63). In all controls we observed a minimal FITC signal, indicating insignificant antibody binding,
with the exception of samples treated with anti-HPRT. SW620 cells treated with anti-HPRT
FITC antibody had a noteworthy association with the plasma membrane. These images reveal a
direct overlap between the plasma membrane and antibodies targeting HPRT. In addition, the
FITC channel reveals a distinguishable external presence of HPRT as fluorescent antibody
binding is only seen on the periphery of the cells.

Figure 6-4. Western analysis of HPRT expression in both cytosolic and membrane fractions. Surface proteins were
biotinylated and isolated for analysis. SW620 cell extract, membrane fractions, and cytosolic fractions were probed
for HPRT along with a non-biotinylated control. This data shows that there is a very significant presence of HPRT
within SW620 cytosol in addition to a clear presence on the surface of the cells.

Western Blot analysis shows there is a significant presence of HPRT within SW620
cancer cells. Along with a clear presence of the protein, this analysis also confirmed HPRT as a
membrane associated protein, as it is found in the biotinylated fraction of the cells (Figure 6-4).
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Figure 6-5. Scanning Electron Microscopy Images and resulting EDAX in HT29 and SW620 cells. Cells were
labelled with gold towards their respective antibody treatment. The size scale is shown in each image and represents
a 2µm distance. 5a-A & 5b-A, Images were obtained using a Back Scatter Electron (BSE) detector. This detector is
specialized to image heavy metals within samples, and highlights enhanced gold within the sample. Any
distinguishable large particles of gold represent a bound antibody. 5a-B & 5b-B, Images were also obtained with a
Gaseous Side Electron (GSE) detector, which showed cell morphology to ensure correct cell structure and integrity.
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5a-C & 5b-C, EDAX analysis of each sample showed the gold elemental peaks for all the elements present within
the sample. Silicon is the highest represented element because cells were mounted on silicon cover slips for analysis.
The gold elemental peak is indicated with a gold arrow. Images obtained from this analysis show the exact location
of the HPRT bound to the surface of the cell, and show no patterns indicating a random distribution of the protein
across the surface of the cell.

Figure 6-6. Gold percentage of SW620 and HT29 cells. The gold elemental composition of each sample is denoted
on the Y-axis. The increase in the gold percentage when cells were exposed to HPRT and CD44 shows a
quantifiable increase in the gold present on the outside of the cell. A, Gold elemental percentages in SW620 cells
exposed to HPRT antibody had a gold weight of approximately 11.2%, which is statistically significant to the IgG
controls used for background binding (p value < 0.0001). These data indicate a statistically significant presence of
HPRT on the surface of SW620 cells. B, Gold elemental percentages in HT29 cells. Gold weight was approximately
10.4% with a p value < 0.0001.

Scanning Electron Microscopy reveals a random distribution of the protein across the surface of
HT29 and SW620 cells.
To evaluate whether surface HPRT binding was distributed across the membrane
randomly, we utilized scanning electron microscopy to physically visualize the position of the
enzyme on the surface of the cells. As pictured in Figures 6-5 and 6-6, both cell lines show an
increase in gold particle binding when exposed to anti-HPRT antibodies. This same increase in
expression is not seen with isotype controls and further implicates HPRT on the surface of the
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cells. The protein appears to be randomly presented across the plasma membrane with no clear
pattern of expression. EDAX analysis (Figure 6-6) for each sample shows an increase in the gold
percentage when cells were treated with anti-HPRT antibodies. A significant increase in sample
elemental gold percentages is seen as SW620 cells (p-value of 8.14x10-6) and HT29 cells (pvalue of 1.74x10-4) were treated with gold labelled HPRT antibodies. This analysis provides a
further confirmation that HPRT is present on the surface of SW620 and HT29 colon cancer cells.
Within normal colon samples from patients, there is insignificant levels of HPRT binding.
To evaluate whether HPRT would be useful as a biomarker target for CRC patients, we
measured the proteins levels on the surface of normal tissue. Flow cytometry revealed
insignificant HPRT presence within normal colon tissue from healthy patients when compared to
isotype controls (p value = 0.998) and unstained controls (p value = 0.996). When compared to a
CD44 control, HPRT levels were minimal and shared similar binding to that of the isotype
control, indicating its presence to be negligible in normal tissue (Figure 6-7).
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Figure 6-7. Normal colon tissue stained with HPRT antibodies shows no significant increase in fluorescence. A,
Normal colon cells were treated with a variety of antibodies in order to select the correct cell population. Once this
population was established, the fluorescent profile of each sample was obtained and graphed. Shown is the unstained
control, CD44 positive control, and HPRT. There is a significant shift in the population when cells were exposed to
anti-CD44 fluorescent antibodies, but a minimal shift is seen for anti-HPRT treated cells. B, Statistical analysis
shows that HPRT had insignificant fluorescent increases when compared to isotype controls. C, These images
portray the cell population of interest in quadrant Q3, which are CD45- and PI-, ensuring that cells analysed were
not inherit lymphocytes within the tissue or dead cells.
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HPRT expression within malignant cells and tissue demonstrates the variable nature of HPRT
upregulation.
In order to evaluate HPRT expression levels within malignant tissue, 94 patient samples
were stained (Table 6-1). While the overall average staining intensity of all malignant samples
(p-value = 0.545) was insignificant when compared to normal patients, in 59% of the malignant
tissue stained for HRPT, there was a substantial increase in the protein expression, while 41% of
the patient samples showed insignificant increases in HPRT expression (Figure 6-8). This
elevation was statistically significant from normal tissue (p < 0.001) and demonstrates unique
HPRT production within a cohort of the patients (Figure 6-9). This expression was also
significant when compared to the GAPDH control, which was utilized to assess housekeeping
levels of protein expression. As the presence of HPRT is variable among cancer cell lines, this
variation between patients would be expected as the mutational load of each patient is unique.

Table 6-1. HPRT levels within malignant and normal colon tissue.
Tissue Type Number of Patients
Adenocarcinoma (+)
16
Adenocarcinoma (-)

11

Metastatic Adenocarcinoma (+)

11

Metastatic Adenocarcinoma (-)

16

Grade Range
1-3

Age Range
31-79

M/F
12/15

2-3

30-79

15/12

Overall Gray Intensity
97.85
114.92
92.01
106.12

Tubular Adenoma

10

-

31-69

6/4

99.09

Cancer Adjacent Normal Colon Tissue

20

-

32-81

16/4

103.01

Normal Colon Tissue

10

-

29-42

10/0

105.00

M/F; Male/Female patients.
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Figure 6-8. Evaluation of HPRT expression within patient tissue. All tissues were stained with a monoclonal antiHPRT antibody. The resulting converted grayscale image is pictured in the top left corner of each image while the
grayscale plot is below. A, Tissue from a 79-year-old female patient with stage IIB colon adenocarcinoma and B,
tissue from a 48-year-old female patient with stage IV colon adenocarcinoma. These malignant tissues are
significantly darker stained than normal colon tissue. C, Normal colon tissue from a 36-year-old male patient and D,
tissue from a 31-year-old male patient. These tissues show an upregulation of HPRT within malignant cells.
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Figure 6-9. Statistical Analysis of HPRT expression within patient tissue. Quantification of tissue was conducted
utilizing a grayscale. The lower the gray value, the darker the tissue is stained. An isotype control was run to
establish the gray value of unstained tissue and to account for non-specific antibody binding. There is a statistically
significant presence of HPRT in approximately half of the tissues obtained from patients which are labelled as
HPRT Cancer Tissue (+). Patient tissue that did not show significant staining are labelled as HPRT Cancer Tissue (). This increased expression shows that in some patients there is an increased expression of the protein when
compared to normal tissue. GAPDH served as a positive control to establish housekeeping levels of staining and
showed no statistical difference in expression between normal tissue and cancer tissue. This data indicates that
HPRT may be upregulated within some patients and provides insight into how the protein may present on the
surface of the cell.

Analysis within malignant colon samples confirms the variable nature of HPRT surface
localization within patients.
Three malignant samples were obtained from patients with colorectal cancer. Of the three
samples obtained, two of them had no HPRT surface localization, while one of the samples had
elevated surface HPRT (Figure 6-10). This confirms the variation found within the tissues and
the cell lines evaluated as the observed HPRT over-expression and subsequent surface
presentation was not found within all the patients. Patients without surface localization had
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expression similar to the Colo205 cell line, while patients with surface localization had HPRT
expression similar to SW620, HT29, and SW480 cell lines. As one of the patients had a
significant level of HPRT on the surface of their tumor cells, it demonstrates there is potential for
the protein to be targeted within those individuals who experience an up-regulation of the
enzyme within their tumors.

Figure 6-10. Evaluation of HPRT surface expression in malignant HPRT tissue. Malignant tissue was treated with PI
and anti-CD45 antibodies in order to isolate the correct cell population. Upon analzying three separate patients with
colon cancer, there were two patients with “HPRT low” tumors and one patient with an “HPRT High” tumor.

Discussion
HPRT is a common housekeeping gene critical to the successful production and regulation of
nucleotides within the cell cycle 10. Our results show a significant presence of HPRT on the
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surface of HT29, SW620, and SW480 colorectal cancer cell lines. These results show a different
role of HPRT within a malignant environment that has not been reported. Currently, HPRT is
understood to be expressed at a relatively constant level within tumor cells as it is commonly
used as an endogenous control for several molecular techniques 502–507. Our results question the
current view of HPRT within colon cancer tissue as it has shown to possess unique
characteristics within cancer cell lines in addition to within malignant colon tissue. HPRT
expression appears to be very similar to the expression of other biomarkers for colorectal cancer,
such as the Vitamin D3 receptor which also shows presence on the surface of colon cancer cells
and serves as a marker for cell differentiation and growth 508. This marker is currently used to
reduce tumors and it is likely that HPRT could serve this same purpose within colon cancer
tissue as it seems to be related to cell proliferation and appears to be absent on the surface of
healthy tissue.
There is other evidence of salvage enzymes serving as diagnostic and prognostic
biomarkers to diagnose and monitor cancer development in patients 509. Thymidine Kinase 1
(TK1), another salvage pathway enzyme, serves as a serum biomarker for cancer recurrence and
has shown to have potential as a therapeutic biomarker as well 32,38,40,510. HPRT may also be
used in a similar setting to aid in diagnosing cancers as it appears to only be upregulated in
cancer tissue. Unlike TK1, it does not appear to be stage dependent, which would be useful as an
early diagnostic companion tool to detect early stage cancers 61. While pathologists analyze
patient biopsy tissue, HPRT could also be evaluated to help in the initial diagnosis.
While HPRT is present on SW620, SW480 and HT29 cells, the relative abundance of the
protein is not equal between the cell lines. SW620, the highest expressing cell line, has upwards
of 25% more protein on the surface when compared to the lowest expressing HT29 cells. SW620
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cells are derived from a metastatic lymph node and are aggressive, fast growing cancer cells. In
contrast, HT29 cells are derived from a colorectal adenocarcinoma originating in the mucus
glands in the colon and rectum and are consequently less aggressive. Our results potentially
indicate that HPRT surface expression may be more abundant in aggressive, rapidly proliferating
cells, but this needs to be further explored.
We hypothesize the observed surface expression of HPRT in these cell lines may point to
a regulatory element of HPRT expression that has lost function in cancer cells within certain
patients 61. The HPRT gene has several regulatory transcription factors that control its expression
(P53, NF-κB, FOXL1, etc…) which may be altered in SW620, SW480 and HT29 cells due to
mutation. Loss of HPRT gene control may increase levels of the protein in the cell and
subsequently result in the export of the protein to the extracellular matrix where it may
transiently reside on the surface of the cell. Further investigation into the mechanism by which
this cytosolic protein is transported to the plasma membrane of these cancer cells needs to be
evaluated to elucidate how HPRT is able to localize to the surface, and if it provides any
functional advantage to the cancer cell. Furthermore, HPRT has shown to have a unique
expression profile within a cohort of patients as determined by IHC staining. The overexpression of HPRT within these patients also points to a loss of HPRT regulation and may aid
in determining which patients may experience this unique surface expression HPRT. While we
were able to evaluate a few malignant cell lines and tumors for HPRT surface presentation,
further testing with more patient samples will need to be done to determine how prevalent HPRT
surface expression is and which patients could benefit from potentially targeting the protein. As
colo205 cells do not show significant HPRT surface localization, further investigation into the
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mechanism of surface presentation needs to be conducted to determine the reason some cells
express HPRT on the surface while others do not.
HPRT could be used as a valuable marker for studies evaluating biomarker targeting 62.
Testing against this antigen could provide researchers with significant advantages when
evaluating therapy efficiency and may lead to a new biomarker target for the treatment of a
subset of colorectal cancer patients who experience an upregulation and surface presentation of
the protein.
Conclusion
As a surface biomarker that is not present in normal cells, HPRT could be used as a
valuable target for immunotherapies. Patients who experience an elevation in HPRT within their
tumors may use the protein as a means to reduce tumor burden by targeting HPRT+ cells.
Materials and Methods
Chemicals
Anti-HPRT monoclonal antibody (Thermo Fischer Scientific) was aliquoted and stored at
-20°C. Mouse-FITC and Rabbit-FITC antibodies (Sigma Aldrich) were stored at 4°C and were
used in dark conditions. Bovine Serum Albumin (Sigma Aldrich) and Sodium thiosulfate
(Macron Fine Chemicals) were dissolved in PBS at a 1% concentration and stored at 4°C. 50%
Glutaraldehyde stock (Electron Microscopy Sciences) was stored at -20°C and workable
solutions were diluted to 0.25% in PBS and stored at 4°C. Glycine (Thermo Fischer Scientific)
was diluted to 0.2mM in PBS and stored at 4°C. NF-kB polyclonal antibody (Bioss Antibodies),
DCK polyclonal antibody (rabbit: Abnova) and monoclonal antibody (mouse: Santa Cruz, Dallas
TX) and APRT polyclonal antibodies (mouse: One World Labs, San Diego, Cal; rabbit: Abnova)
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were stored at -20°C. CD44 monoclonal antibody (One World Lab) was stored at -20°C.
Propidium Iodide (Sigma Aldrich Inc.) was stored at 4°C and aliquoted for use. Fc Block was
purchased from Biolegend and stored at 4°C. An APC-Conjugation Kit (Abcam) was stored at 20°C.
Cell Culture Conditions
The human colon carcinoma cell lines SW620, SW480, Colo205 and HT29 were
obtained from the American Type Culture Collection. HT29 and Colo205 cells were grown in
RPMI 1640 medium supplemented with 10% fetal bovine serum and 2mM L-Glutamine (all
from Hyclone). SW620 and SW480 cells were grown in DMEM medium supplemented with
10% fetal bovine serum and 4mM L-Glutamine (all from Hyclone). The cell media was replaced
every 48 hours and cells were trypsinized and the cell population was reduced by half once 90%
confluence was obtained. Cells were treated with Acutase (Stem Cell Technology) when utilized
for flow cytometry and when plated for all other applications. Cell viability was evaluated using
a trypan blue staining, and cells were utilized for all applications when the viability was greater
than 98%. All cells were grown at 37°C and 5% CO2. Cell lines were authenticated in May of
2016 by the University of Arizona Genetics Core.
Flow Cytometry
The surface presence of HPRT, APRT, and DCK in cultured cells was evaluated
measuring the fluorescence intensity of antibodies against each of the salvage pathway enzymes.
All samples were analyzed on a Blue/Red Attune (Applied Biosystems), and 25,000-50,000
events were recorded per sample. Briefly, 3-5x105 cells were incubated with 200µL of PBS
containing 1µg of primary antibody treatment for 15 minutes on ice. Cells were then labelled
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with FITC-conjugated secondary (mouse or rabbit) antibody for 15 minutes on ice. Isotypic IgG
and unstained cells served as negative controls to ensure correct cell gating. The forward/sidescatter plots were used to gate out cell doublets, dead cells, and cell debris. Using unstained and
isotype controls as guides, the positive population was determined by the overall shift in the
fluorescent intensity. Each cell line was independently analyzed four times and the data was
plotted using FlowJo Software (FlowJo Enterprise). Cells were washed appropriately after each
step of the protocol.
Patient Tissue Dissociation and analysis
Healthy and malignant colon tissue samples were obtained from the Utah Valley
Regional Medical Center. Tissue samples were minced using sterile scalpels into pieces ranging
from 2-3mm in length and were suspended in Hanks media (5% FBS). Minced tissue was then
placed in a solution of Collagenase IV on a shaker for 1-4 hours depending on the fat percentage
of the tissue. Once dissociated the solution was washed through a 100 micron filter, to produce a
single cell suspension. These cells were then washed and treated with an Fc block to minimize
non-specific antibody binding. Following blocking, cells were treated with anti-CD45 FITC,
anti-HPRT APC and PI to aid in the selection of correct cell populations for analysis. Cells were
gated on CD45- and PI- populations to avoid analysis of lymphocytes resident in the tissue and
dead cells.
Biotinylation and Western Blot Analysis
Cells were analysed for surface presence along with general expression within the cell
utilizing the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific). Briefly, 3 flasks of
SW620 cells were grown to 95% confluency, washed, and treated with a kit-provided biotin
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solution. Following rocking on a shaker for 30 minutes at 4°C, the cells were treated with a
quenching solution. Cells were detached from the flask via cell scraping and transferred to a
50mL conical vial for washing. Then, cells were treated with a lysis solution and incubated for
30 minutes at 4°C. Cell lysis was added to a neutravidin gel and incubated for 60 minutes at
room temperature. This solution was then passed through a filter and proteins bound to biotin are
trapped within the column. The neutravidin gel was washed 4 times and the flow through was
collected and labelled “cytosolic fraction”. The biotin labelled protein was then eluted from the
column utilizing a 50mM DTT solution and labelled “membrane fraction”.
Both membrane fractions and cytosolic fractions along with cell extract from SW620s
were evaluated for protein expression utilizing standard Western Blotting techniques described
in Sewda et al. with slight modifications [22]. Briefly, each sample was boiled for 5 minutes
prior to running on a 12% polyacrylamide gel under reducing conditions. Gels were then
transferred to a nitrocellulose membrane (Biorad Laboratories), blocked, and treated with an
anti-HPRT monoclonal antibody overnight at 4°C. Following primary antibody treatment,
membranes were washed and treated with a rabbit fluorescent secondary antibody (Licor) for 1
hour. Membranes were then imaged on a Licor Odyssey CLx. SW620 cells were utilized for this
analysis because their expression of HPRT on the membrane is significantly higher than that of
HT29 cells.
Confocal Microscopy
Flourescently-stained cells were examined under an epiflouresence microscope
(Olympus, Tokyo, Japan) equipped with a laser confocal system (Bio-Rad Laboratories,
Hercules, CA) containing a 15mW Krypton/Argon laser. Image processing was carried out with
Laser Sharp Computer Software (Bio Rad Laboratories). After treatment with acutase, cells were
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plated at a concentration of 400,000 cells/mL on glass coverslips. Following one to two days of
growth, cells were incubated in 500uL of PBS containing 2.5µg of anti-HPRT antibody for 15
minutes on a shaker at 4°C. Cells were then labelled with 2.5µg of FITC-conjugated secondary
antibody for 15 minutes on a shaker at 4°C. Then, cells were incubated at 37°C for 10 minutes
with a 1:1000 dilution of a Cell Mask Deep Red plasma membrane dye (Fisher Scientific).
Electron Microscopy
Following acutase treatment, cells were plated at a concentration of 400,000 cells/mL on
glass coverslips. After one to two days of growth, cells were placed in 6 well plates and washed
with PBS three times and with 1% PBS-BSA for 5 minutes at 4°C followed by a sodium azide
wash. Cells were then incubated with 2.5µg or 5µg of primary antibody conjugated to Biotin for
15 minutes on a shaker at 4°C. After primary incubation, cells were washed with 1% PBS-BSA
followed by two washes with PBS. Then, cells were washed with 1% PBS-BSA and 1% PBSsodium thiosulfate for 5 minutes on a shaker at 4°C. Cells were incubated with 2.5µg of
Streptavidin-gold conjugate (Nanoprobes, Yaphank, NY) for 15 minutes on a shaker at 4°C. This
is followed by a 1% PBS-BSA wash and three PBS washes. Cells were then fixed with a 0.25%
Glutaraldehyde solution diluted in PBS for 5 minutes. The reaction was then extinguished by
adding a 0.2mM PBS-Glycine Solution and incubating for 10 minutes until the solution turned a
slight yellow color. Cells were then washed three times with ddH2O. Solutions A and B from the
Nanoprobes gold enhancement kit (Nanoprobes Inc.) were incubated together for 5 minutes.
Solutions C and D were then added, vortexed, and 40µL of the gold enhancement were added to
each sample and incubated for 5 minutes. Each sample was put through a series of dehydrations
with 70%, 80%, 90%, and 100% ethanol. Gold labelled samples were examined under a Phillips
XL-30 ESEM using a 15kV electron stream under low vacuum conditions at 1 Torr. A Gaseous
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Side Electron (GSE) detector was utilized to image the cell morphology and topography. A Back
Scatter Electron (BSE) detector was utilized to visualize gold particles on the cell surface. Once
images for the cells were obtained, the elemental composition of the cells was evaluated using
energy dispersive spectroscopy (EDAX) and X-rays. EDAX analysis will provide a k-ratio, a Z
value, an A value, and an F value. The k-ratio represents the element’s peak height compared to
a sample of the pure element collected under the same conditions. The Z value represents a
correction in the atomic number taking backscattered election yield of the pure element and the
sample. The A value represents a compensation for X-rays generated in the sample that are
cannot emit energy. The F value represents a correction for the generation of X-rays. We used
these EDAX output values to normalize our samples gold weight percentages using the
following equation:
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =
Immunohistochemistry

𝑘𝑘 − 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 ∗ 100
𝑍𝑍 ∗ 𝐴𝐴 ∗ 𝐹𝐹

Colorectal Adenocarcinoma tissue arrays were obtained from BioMax. These tissues
contain various stages of cancer along with corresponding benign and normal tissue from 100
different patients. HPRT levels were assessed utilizing standard immunohistochemistry staining.
Tissues were rehydrated in a series of ethanol washes before treatment with a DIVA (Biocare
Medical) solution to retrieve antigen. Tissues were then incubated with a Background Sniper
(Biocare Medical) solution to reduce non-specific antibody binding. Following blocking, a
primary antibody is added to the tissue at a concentration of 1:100 to 1:200 and incubated
overnight at 4°C. Following primary staining, tissues were washed and then treated with
secondary antibody conjugated to a HRP polymer (Biocare Medical) and incubated for an hour.
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Following washing, a DAB Peroxidase solution was incubated with the tissues. Areas of
antibody binding converted the colorless substrate to a brown product, effectively highlighting
the target protein. Tissues were treated with hematoxylin (Biocare Medical) to stain the nucleus
of the cells. Along with HPRT treatment, a universal negative antibody (Biocare Medical) was
used as a negative control, and a GAPDH antibody was used as a positive control.
Tissues were quantified utilizing ImageJ software. All images were evaluated using the
IHC toolbox ImageJ plugin. The DAB option is chosen and the tissue image is then removed of
all other staining except for DAB. Following this analysis, the image is then converted to a
grayscale and a threshold is applied in order to eliminate areas of no staining inherit within the
tissue image. Once the threshold is applied the average gray value of the tissue is collected. The
same threshold is applied to all tissue samples in order to ensure consistency.
Statistical Analysis
ANOVA statistical analysis with the multiple comparison method were used to determine
the differential surface expression of the various treatments for flow cytometry data on all cell
lines. In addition, two-way ANOVA tests were performed to compare the mean expression of
HPRT between SW620 and HT29 cells. EDAX data was analyzed using an ANOVA with the
multiple comparison method in addition to unapired t tests to determine significance between
samples. All statistical analysis was evaluated using GraphPad Prism 7 software. Differences
were considered significant when the p value was <0.05.
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Abstract
Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) is a housekeeping enzyme
involved in the purine synthesis of guanine and inosine in the salvage pathway. While other
salvage pathway enzymes, such as TK1, have been established as biomarkers for both cancer cell
proliferation and cancer development, little has been done to evaluate whether HPRT has the
same potential as a cancer biomarker. We designed this study to determine if HPRT has value as
an identifier of malignancy within the most common types of cancer. We utilized histological
samples from lung, colon, prostate, and breast cancer with additional normal tissue to evaluate
whether there was any elevation within malignant samples. In addition, we also assessed general
HPRT expression within patient’s samples from The Cancer Genome Atlas (TCGA) to confirm
clinical relevance. We found that within a subset of patients there was significant elevation of
HPRT when compared to normal tissue controls. This elevation was seen in 33-55% of the
malignant samples and appears to have no dependence on stage. There were slight differences in
staining patterns among all the organ types, but overall each organ displayed the same pattern of
‘HPRT high’ and ‘HPRT low’ populations within malignant samples. We found that in our
TCGA samples there was a similar elevation of HPRT that was significant when compared to
normal controls. Overall, as an upregulated enzyme that does not directly correlate with stage,
HPRT could become a valuable marker in the early diagnosis of a variety of solid tumors.
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Introduction
With 14 million new cases diagnosed and 8.2 million deaths reported worldwide in 2012,
cancer is a leading global health concern511. In 2016, the most common malignancies reported
are lung, breast, prostate, and colon which comprised approximately 44.5% (Lung - 224,390;
Breast - 249,260; Prostate - 180,890; Colon - 95,270) of all new cancer cases in the United
States417,512,513. As the most common cancers throughout the world, new biomarkers are
constantly needed to identify cancer in early stages to decrease mortality rates. While several
cancer markers have been identified for each of these diseases, Hypoxanthine Guanine
Phosphoribosyltransferase (HPRT) has the potential to provide an additional diagnostic tool for
several cancer types.
HPRT is a transferase responsible for the salvage of both guanine and inosine nucleotides
throughout the cell cycle10,12,514. As an established human reporter gene, HPRT is currently
utilized to provide understanding of somatic mutations and mutagenesis in both in vitro and in
vivo systems43,44,515. Mutation events in this locus are extensively monitored in population
studies to evaluate the effects of continuing exposure to mutagens and detect carcinogenic agents
that lead to increased cancer risk49,51,516. In at-risk populations including smokers, patients with
DNA repair deficiency syndromes, and atom bomb survivors, there are significant mutations in
the HPRT locus, which directly correspond with higher cancer incidence45,52,54,55,57,58,516,517.
While its role as a standard mutational biomarker for cancer development has been well
established, the relevance of HPRT to the proliferative capacity and tumorigenesis of cancer has
not been evaluated. It has established that other salvage enzymes, such as TK1, have a direct
relevance to cancer stage and aggressiveness as serum detection of the enzyme is correlated to
cancer stage and recurrence29,38,509,518,519. To address whether this same stage-dependent protein
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elevation pattern existed for HPRT, we have evaluated the expression of the enzyme in hundreds
of patient samples to determine if HPRT could also serve as a cancer biomarker for early cancer
detection. We compare HPRT expression in the most commonly diagnosed cancers throughout
the world (lung, breast, prostate, and colon).
Methods
Chemicals/Reagents
DIVA Decloaker 10x, Background Sniper, Mach 4 HRP polymer, DAB Peroxidase,
Hematoxylin, Hydrophobic pen, and Universal Negative antibodies were all obtained from
Biocare Medical, Concord, CA. Anti-HPRT monoclonal antibody (Abcam, Cambridge, UK) was
aliquoted and stored at -20°C. GAPDH polyclonal antibody (One World Labs, San Diego CA)
was aliquoted and stored at -20°C. Tween20 (Fisher Reagents, Waltham MA) was stored at room
temperature. 30% Hydrogen Peroxide (Fisher Reagents, Waltham MA) was stored at 4°C.
Patient Samples
All tissue microarrays were obtained from Biomax and stained for HPRT, GAPDH, and
an isotype antibody to evaluate protein expression and upregulation. Lung samples were
evaluated from 54 patients ranging in age from 39-77 containing malignant (n=17), normal
(n=18), and marginal tissue (n=17) samples. Malignant tissue ranged from grade 1-3 and
included female (n=4) and male (n=13) patients with either large cell carcinoma (n=3),
adenocarcinoma (n=5), or squamous carcinoma (n=6). Colon samples were evaluated from 100
patients ranging in age from 30-79 with colon adenocarcinoma (n=30), metastatic
adenocarcinoma from the colon (n=30), tubular adenoma (n=10), cancer adjacent normal tissue
(n=20), and normal colon tissue (n=10). Sex (male, n=63; female, n=37) and grade (1-3) were
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variable between samples. Breast samples were analyzed from 63 patients ranging in age from
29-68 containing malignant (n=18), normal (n=24), and margin of carcinoma samples (n=21).
Prostate samples were analyzed from 63 patients ranging in age from 60-87 containing
adenocarcinoma (n=60) and hyperplasia (n=3) samples.
Immunohistochemistry
HPRT levels were assessed using standard immunohistochemistry staining. Tissues were
treated with Histoclear (National Diagnostics, Charlotte, North Carolina) and subsequently
rehydrated in a series of ethanol washes before treatment with a DIVA Decloaker solution to
retrieve antigens. Tissues were washed with a diluted hydrogen peroxide solution followed by a
Tris Buffered Saline-Tween20 (TBST) wash. Following washing, tissues were incubated with a
blocking Background Sniper solution to reduce non-specific antibody binding. Following
blocking, a primary antibody was added to the tissue at a concentration of 1:100 and incubated
overnight at 4°C. Following primary staining, tissues were then washed and then treated with
secondary antibody conjugated to a HRP polymer and incubated for an hour. Following washing,
a DAB Peroxidase solution was incubated with the tissues. Areas of antibody binding converted
the colorless substrate to a brown product, effectively highlighting the target protein. Tissues
were treated with hematoxylin to stain the nucleus of the cells. Along with HPRT treatment, a
universal negative antibody was used as a negative control, and a GAPDH antibody was used as
a positive control.
Tissue Quantification
Tissues were quantified utilizing ImageJ software. All images were evaluated using the
IHC toolbox ImageJ plugin. The DAB option is chosen and the tissue image is removed of all
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other staining. Following this modification, the image is then converted to a grayscale and a
threshold is applied in order to eliminate areas of negative space inherit within the tissue image.
Once a universal threshold was applied, the average gray value of the tissue was collected. The
same threshold was applied to all tissue samples within the same organ in order to ensure
consistency and reduce bias.
Bioinformatic analysis
We evaluated differences in expression levels of the HPRT gene in 3,147 tumor and 316
normal samples from The Cancer Genome Atlas (TCGA). RNA-sequencing data that had been
processed using the featureCounts algorithm to transcripts-per-million values was utilized. The
normal expression data were from adjacent normal tissue or blood samples and were not
necessarily matched to the tumor data on a per-sample basis. We parsed and prepared the data
using the Python520 (v3.6.1) programming language. In making graphs, we used the R (v3.2.2)
statistical software and the ggplot2 package (v.2.2.1).
Statistical analysis
Comparison between tissue samples was conducted utilizing ANOVA statistical analysis
with the multiple comparison method. Unpaired t tests were utilized in conjunction to confirm
statistical significance. All statistical analysis were evaluated using GraphPad Prism 7 software.
Differences were considered significant when the p value was < 0.05.
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Results

Figure 7-1. HPRT staining within malignant and normal breast, colon, lung, and prostate. A) All organs observed
contained a population of patients who had a significant increase in HPRT staining, which are labeled “HPRT
High”. These tissues were significant when compared to normal controls. B) Organs also contained a population of
patients who did not experience an increase in HPRT when compared to normal controls and are labeled “HPRT
Low”. C) Normal tissue was stained within all organs to provide a standard to compare expression. Normal tissue is
labeled with identifying features.
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HPRT has variable expression in several cancers and shows an upregulation in malignancy.
Within all malignant tissue there were populations of patients with high HPRT expression
and populations with relatively low HPRT expression. We have labeled these patients as “HPRT
high” and “HPRT low” (Figure 7-1). Patients with high levels (Figure 7-1A) were significantly
separated from patients with low levels (Figure 7-1B), which had staining characteristics similar
to normal tissue (Figure 7-1C). The variability of HPRT within malignant tissue was also
variable between cancer types as each organ had a different percentage of patients who
experienced an upregulation (Lung- 33%, Breast-55%, Colon-33%, Prostate-47%).These data
indicate that HPRT is only elevated within some patients, and may serve as a diagnostic marker
for characterizing tumors.
Table 7-1. HPRT staining in malignant and normal tissue.

Organ
Lung

Normal
Malignant

Mean Gray
Intensity
101.08
100.24

High
Expression
4
6

Low
Expression
11
12

Breast

Normal
Malignant

91.91
81.86

2
10

9
8

Colon

Normal
Malignant

105.00
102.59

0
18

7
36

Prostate

Hyperplasia
Malignant

134.20
120.69

0
25

3
28
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While a majority of staining was limited to malignant tissue, there were instances within normal
lung and breast tissue where there was significant HPRT staining (Table 7-1). As HPRT is a
housekeeping gene present within all somatic tissue, we expected to have a basal level of
staining within normal tissue, and all analysis were performed against normal tissue staining to
highlight any upregulation. Upon further analysis with protein expression data from clinical
samples in TCGA, we found that there was a significant overall upregulation of HPRT within all

Figure 7-2. Expression of HPRT within TCGA tumor and normal samples. Clinical samples from 1119 patients with
various cancer types were evaluated for HPRT elevation in malignant samples when compared to normal tissue. All
cancer evaluated showed a significant shift in the population of malignant samples (green) when compared to
normal controls (red).

cancer types evaluated when compared to normal controls (Figure 7-2). Samples from
1119 breast invasive carcinoma, 483 colon adenocarcinoma, 541 lung adenocarcinoma, 502 lung
squamous carcinoma, and 502 prostate adenocarcinoma patients were compared to normal
individuals and showed significant shifts in the expression of HPRT in malignant tumors, with
lung samples showing the highest shift. Within each of the cancer types evaluated we observed
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the same pattern of ‘HPRT high’ and ‘HPRT low’ populations in the patient cohorts. Several
patients with malignancy had expression levels of HPRT comparable to normal samples,
however, there was a population of patients that had elevated HPRT beyond that of normal tissue
staining. This data exhibited a very standard normal distribution and there were some healthy
patients with relatively high HPRT expression. These results indicate that there is a subset of
patients that experience unusually high levels of HPRT expression, which could be used to
further characterize tumors and provide a means for early detection of malignancy.
Table 7-2. Distribution of HPRT staining in malignant breast tissue and normal breast tissue.

Tissue Type
Adenocarcinoma High

Number of Patients
10

Age Range
29-68

Overall Gray Intensity
76.32

Adenocarcinoma Low

8

29-61

88.79

Normal Breast Tissue

11

43-69

91.91

Hyperplasia

3

49-68

100.87

Adenosis

7

28-61

89.91

Collagen Fiber Tissue

3

47-49

97.30

Marginal Tissue

21

32-74

90.07

Evaluation of HPRT within breast cancers tissue demonstrates its potential as a biomarker for
malignancy
Of the 18 malignant breast tissues evaluated, 10 patients experienced a significant (p = 0.0025)
increase in HPRT expression with an average total gray intensity of 76.32 when compared to
normal breast tissue, which had an average gray intensity of 91.91 (Table 7-2). Normal and
malignant tissue stained for HPRT were significant when compared to GAPDH positive and
Isotype negative controls (Figure 7-3A). In addition to normal breast tissues, adenosis, fiber
tissue, and hyperplasia were evaluated and showed insignificant upregulation compared to
normal samples (Figure 7-3B & 7-3D). As a majority of the malignant tissue
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Figure 7-3. Statistical evaluation of breast tissue. A) Malignant and normal breast HPRT staining compared to
GAPDH and Isotype controls. GAPDH and Isotype samples were not statistically significant between malignant and
normal tissue. HPRT samples had a significant increase in expression when comparing malignant tissue to normal
tissue. B) HPRT expression analysis between various tissue types. There were 10 patients who had significant
HPRT elevation and are labeled ‘Ductal Carcinoma High’, while the remainder 8 patients are labeled ‘Ductal
Carcinoma Low’ as they had staining similar to normal controls. C) Overall HPRT staining results of malignant and
normal tissue within all samples. D) Tissue images of HPRT staining in various breast tissue samples.
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experienced an upregulation of HPRT, there was still a significant (p=0.0026) difference
between normal tissue and malignant samples when ‘HPRT low’ tissue was included within the
analysis (Figure 7-3C).
In addition to evaluating malignant tissue, marginal tissue was analyzed to determine
whether HPRT could be used to indicate unusual cell proliferation around the tumor. This
analysis revealed that there was a distribution within the marginal tissue in regards to HPRT
expression. We found that 6 marginal tissues were ‘HPRT high’ and 10 samples were ‘HPRT
low’ (Figure 7-4). Each tissue showed variability, and demonstrates the ability of HPRT to aid in
distinguishing potentially malignant tissue. Marginal tissue elevated in HPRT expression may
indicate signs of malignancy and proliferative capacity.
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Figure 7-4. HPRT analysis of margin of carcinoma tissue. Margin of breast carcinoma tissue that stains A) ‘HPRT
High’; B) ‘HPRT low’; and C) ‘HPRT intermediate’ staining. D) graphical representation of the quantity of patient
samples within each HPRT staining level.
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Interestingly, we found that in normal tissue HPRT expression was localized to the ductal
tissue. There was clear staining within the inner lining of the lactiferous ducts of the breast with
minimal staining in other portions of the tissue (Figure 7-5). This expression is localized and
may indicate HPRT involvement in cell proliferation.

Figure 7-5. Normal breast tissue stained for HPRT. A) Within normal tissue we found minimal HPRT staining. B)
While normal tissue showed no significant HPRT expression, ductal openings of normal breast tissue had unusually
high staining. This may point to the involvement of HPRT in cellular proliferation.

Lung cancer shows insignificant variability of HPRT expression between cancer types and
stage.
Multiple different lung malignancies were evaluated to determine if there were any differences between
the cancer types as they have significantly different origins within the lung itself. All samples were
evaluated against corresponding normal, isotype controls, and GAPDH positive controls to compare
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expression (Figure 7-6A). We found that there was no statistically relevant difference between the
malignant lung samples in regards to HPRT expression (Figure 7-6B).

Figure 7-6. Statistical evaluation of HPRT expression in lung cancer. A) Malignant and normal lung tissue stained
with HPRT, GAPDH, and Isotype controls. GAPDH and Isotype samples were not statistically significant between
malignant and normal. B) HPRT expression analysis between various tissue types. There was no significance
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between lung cancer types in regards to HPRT expression. C) There were 6 patients that had elevated HPRT labeled
‘Lung Carcinoma High’ and 12 patients that had insignificant HPRT expression labeled ‘Lung Carcinoma Low’. D)
Tissue images of HPRT expression in various lung cancers.

Adenosquamous samples had the highest average HPRT expression with a mean gray
intensity of 94.12, while large cell carcinoma samples had the lowest average HPRT expression
with a mean gray intensity of 104.24 (Table 7-3 & Figure 7-3D). These values were not
statistically significant and indicate that there was no difference between the cancer types.
Within malignant samples 33% of patients experienced significant upregulation when compared
to normal tissue controls as 6 patients had expression characterized as ‘HPRT High’ (Figure 76C).
Table 7-3. Distribution of HPRT staining in malignant lung tissue and normal lung tissue.
Tissue Type
Squamous Carcinoma

Number of Patients
3

Grade Range
2-3

Age Range
46-58

M/F
3/0

Overall Gray Intensity
101.68

Large Cell Carcinoma

3

2-3

30-66

3/0

104.24

Adenocarcinoma

6

1-3

46-77

5/1

102.56

Alveolar Carcinoma

2

NA

39-59

1/1

96.26

Adenosquamous Carcinoma

2

3

60-69

2/0

94.12

Other Carcinomas

2

3

59-69

0/2

95.45

Normal Lung Tissue

18

-

39-77

14/4

101.08

Marginal Tissue

18

-

30-77

14/4

100.74

M/F; Male/Female patients.

Lung tissue was the only organ that we observed a stage-dependent increase in HPRT
expression (Figure 7-7). As there was only one stage I tissue to analyze, the significance
observed was between stage II and stage III tissue, where there was a significant increase in
HPRT expression in stage III tissue (p = 0.05). As this pattern was not observed within any other
organ, we hypothesize it may be an artifact of the small cohort size and a larger sample size is
needed to determine any relevant significance.
HPRT elevation in metastatic colon tumors was significant when compared to primary tumors.
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Within colon cancer tissue, there was a population (n = 18) that had a significant upregulation of HPRT
when compared to isotype controls (Figure 7-8A). With an average gray intensity of 92.00 (Table 7-4),
this was significant when compared to both the normal colon

Figure 7-7. Stage Evaluation of malignant lung tissue. Lung tissue showed significant variations in HPRT
expression in relation to stage. Stage I, II, and III tissue are evaluated and imaged to show any variations between
tissue intensity.
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Figure 7-8. HPRT expression within colon primary tumors, metastatic tumors from the colon, and normal colon
tissue. A) Malignant and normal tissue analysis in tissue stained with HPRT, GAPDH, and an Isotype antibody. B)
HPRT staining within all colon sample tissues. C) 16 primary tumor samples and 11 metastatic tumor samples
experienced ‘HPRT High’ staining.

166

tissue controls (p < 0.0001) and isotype controls (p < 0.0001). Additionally, we also
evaluated primary and metastatic colon tumors to determine whether there was any difference
in HPRT expression between aggressive, malignant cells that had successfully metastasized and
primary tumor cells.
Table 7-4. Distribution of HPRT staining in malignant colon tissue and normal colon tissue.
Tissue Type
Adenocarcinoma

Number of Patients
30

Grade Range
1-3

Age Range
31-79

M/F Overall Gray Intensity
104.81
14/16

Metastatic Adenocarcinoma

30

2-3

30-79

17/13

100.37

Tubular Adenoma

10

-

31-69

6/4

99.09

Cancer Adjacent Normal Colon Tissue

20

-

32-81

16/4

103.01

Normal Colon Tissue

10

-

29-42

10/0

105.00

M/F; Male/Female patients.

We found a similar pattern to other primary tumors evaluated where a subset of patients
were ‘HPRT High’ and a subset of patients who had similar levels to normal controls and were
labeled ‘HPRT Low’ (Figure 7-8B&D). We also found that metastatic samples had an overall
increase in HPRT compared to primary tumors (p = 0.014), indicating that metastatic cells may
express more HPRT (Figure 7-8C).
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Prostate cancer tissue exhibits significant HPRT expression that is not dependent on stage or
grade.

Figure 7-9. Stage analysis of HPRT expression in prostate cancer stage. Tissue images of A) Stage I; B) Stage II;
and C) Stage III Prostate cancer tissue stained with HPRT. D) Staining of prostate tissue with HPRT, GAPDH, and
Isotype antibodies. E, Stage evaluation of prostate tissue stained with HPRT shows no statistically relevant
differences between cancer stage.

Of the 53 malignant patients analyzed (Table 7-4) we found a high percentage (55%) of
the prostate patient cohort analyzed that were elevated in HPRT when compared to controls
(Figure 7-9). Following a stage evaluation, we found no statistically relevant correlation between
HPRT expression and the cancer stage even though there appears to be a slight average decrease
in gray intensity within the samples (Figure 7-9E). This data, along with data presented in Figure
7-2 indicates there is a significant population of prostate cancer patients that experience an
upregulation of this gene.
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Discussion
As an enzyme that is significantly upregulated in several malignant tumors, HPRT has the
potential to become an additional biomarker for the characterization of several cancers. As
Figure 7-2 indicates, there is significant variability within patients in regards to their relative
expression of HPRT both in normal and malignant tissue with the overall trend showing
upregulation of the protein in cancerous tissue. We have evaluated this expression profile in
several of the most common malignancies including lung, colon, breast, and prostate cancer with
each showing a similar pattern of expression. This leads us to believe this general upregulation
within a subset of patients may be a common trend in several cancer types. While there is a basal
level of expression due to the housekeeping nature of HPRT, this expression was generally weak
in normal tissue (Table 7-1) and patients who experienced an upregulation had significantly
elevated HPRT orders of magnitude higher than isotype controls. Any upregulation that was
observed was also independent of cancer grade or stage with the exception of Lung cancer. With
this in mind, HPRT could be utilized as an early biomarker because it appears to be upregulated
in all stages of cancer, including Stage I. This study has expanded the role HPRT currently has as
a mutational biomarker to also encompass a possible involvement in cancer development within
some patients49,521.
Table 7-5. Distribution of HPRT staining in malignant prostate tissue and normal prostate tissue.

Tissue Type
Number of Patients
Adenocarcinoma High
25

Age Range
66-85

Overall Gray Intensity
110.77

Adenocarcinoma Low

28

60-82

129.56

Hyperplasia

3

63-75

134.20

Of interesting note is the use HPRT currently plays as a common endogenous control for
several cancer-related studies. Due to its housekeeping nature, HPRT is often utilized as a
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control for expressional studies and transcriptional analysis in a variety of studies502–507,522,523.
Yet, the literature is inconsistent when reporting HPRT expression levels within cancer. After
comparing various housekeeping genes such as GAPDH, β-2 microglobulin, 18s ribosomal
RNA, etc., some researchers have reported HPRT as the most consistent endogenous control523.
Meanwhile, other researchers have reported HPRT levels to be significantly lower than other
controls in cancer tissue524. Finally, other studies have reported HPRT as an unsuitable standard
in certain cell types due to varying expression in response to growth factor stimuli525. Recently,
Homey et al. reported the expression of HPRT was detectable in cultured cancer cells, primary
tumors, and metastatic tumors, but was found undetectable in normal lung tissue60. This data
supports our observations and indicates that HPRT has widely variable expression that would
deem it unsuitable as a transcriptional control standard.
Conclusions
Our results indicate that HPRT expression has significantly higher expression in
malignant tissue when compared to normal controls, and has potential as a biomarker for the
characterization of several malignancies including breast, lung, prostate, and colon cancers.
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Abstract
HPRT is a housekeeping enzyme involved in recycling guanine and inosine in the purine
salvage pathway. As a housekeeping gene, HPRT has been widely used as an endogenous
control for molecular studies evaluating changes in gene expression. Yet, recent evidence has
shown that HPRT exhibits high variability within malignant samples with a trend of elevated
expression. To determine whether this observed upregulation is found for other molecular
techniques and in other organs, we designed this study to thoroughly evaluate the expression of
HPRT within both malignant and normal tissues to determine whether it is suitable as an
endogenous control. Utilizing protein and RNA-seq expression, we found that malignant and
normal patient samples vary significantly both within the same tissue type and across organ sites.
Upon staining for HPRT expression via immunohistochemistry, we found that expression is
highly variable in malignant samples (Lung; 89.2-111.8, Breast; 66.7-98.3, Colon; 85.3-129.7,
Prostate; 90.8-155.4, Pancreas; 74.1-132.1). Similarly, we observed high variability across cell
lines via western blotting (p<0.0001). RNA sequencing further confirmed these findings; we
observed clear variability in expression across 90 different cell lines from five organ sites.
Comparing normal and malignant patient samples, we observed consistent upregulation of HPRT
expression within malignant samples relative to normal samples (p-value = 0.0001). These data
indicate that HPRT is unsuitable as an endogenous control for cancer-related studies because its
expression is highly variable and exceeds that of an appropriate control; therefore, we
recommend its discontinued use as a normalization gene.
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Introduction
Nucleotides provide the essential building blocks to support DNA replication and cell
growth 1. As cell division is controlled by a balance of external factors, the processes that control
nucleotide production are tightly regulated 4. The salvage pathway is a nucleotide synthesis
pathway that operates by recycling nucleotides and supplies the majority of the nucleotide pool
needed during the s-phase of the cell cycle 9. Hypoxanthine Guanine Phosphoribosyltransferase
(HPRT) is a salvage pathway enzyme involved in the synthesis of both Guanine and Inosine and
is responsible for the majority of Guanine production, as 90% of free purines in humans are
recycled 10,11. The enzyme transfers phosphoribose from phosphoribosyl pyrophosphate (PRPP)
to hypoxanthine or guanine bases to form IMP and GMP, respectively 10,12. Due to the constant
requirement for GTP, as both a nucleotide for DNA synthesis and as energy currency throughout
the cell, HPRT is reliably produced as a housekeeping gene and is found in all somatic tissue in
low levels 19–21.
Due to its housekeeping nature, HPRT is commonly used as a standard endogenous
control for transcriptional and protein-level analysis 502,504–507,522. Yet, the literature is
inconsistent when reporting HPRT expression levels, particularly in cancer. After comparing
various housekeeping genes such as GAPDH, β-2 Microglobulin, 18s ribosomal RNA, etc., some
researchers have reported HPRT as the most consistent endogenous control 523, while others have
reported HPRT levels to be significantly lower than other controls in cancer tissue 503. Further
studies have reported HPRT as an unsuitable standard in certain cell types due to varying
expression in response to growth factor stimuli 525. Other sources have reported HPRT to be
expressed in breast carcinoma cell lines, primary tumors, and metastatic lungs, but undetectable
in healthy lung tissue 60. In addition, further evidence shows that HPRT demonstrates significant
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variability between normal patients and those with cancer 61,62. The inconsistency present in the
literature is concerning as HPRT is widely used to standardize both RNA and protein levels.
This study was designed to investigate the use of HPRT as a suitable endogenous control
for cancer-related studies. The most essential characteristic of endogenous controls is their
relatively constant expression in all cells regardless of experimental conditions. As a critical
component of several molecular techniques evaluating small discrepancies in mRNA and protein
content, using accurate endogenous controls to standardize expression is paramount in correctly
representing data.
Results
HPRT expression varies widely between cancer patients
Due to the housekeeping status of HPRT, protein expression within patient tissue was
directly compared against normal tissue samples to highlight additional upregulation above that
of normal cells. We found significant variability between normal and malignant patient samples
with an overall trend of elevated HPRT expression upon malignancy (Table 8-1). This variability
is seen across several different organ types with prostate cancer patients exhibiting the highest
discrepancy between normal, 154.93 average gray value, and malignant, 120.83 average gray
value. Most notably, the range of staining intensity greatly varied amongst the malignant samples
(lung; 89.2-111.8, breast; 66.7-98.3, colon; 85.3-129.7, prostate; 90.8-155.4, pancreas; 74.1132.1) demonstrating that within each organ type, HPRT expression is significantly variable.
This same variability was greatly reduced within the normal tissue samples as the overall range
of average gray intensity decreased (lung; 93.0-107.6, breast; 81.6-105.1, colon; 101.5-108.7,
prostate; 129.4-136.9, pancreas; 51.0-103.6). Pancreatic tissue showed an inverse relationship
when compared to all organ types, as HPRT expression was generally reduced (p<0.0001) in
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malignant tissue, 154.95 average gray value, when compared to normal tissue, 137.33 average
gray value (Figure 8-1).
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Figure 8-1. Immunohistochemistry staining of HPRT compared to GAPDH in a variety of organ types. Lung, Breast,
Colon, Prostate, and Pancreatic malignant and normal tissue were stained with antibodies against HPRT and
GAPDH to determine any trends in expression between cancerous and healthy tissue. Tissues were quantified on a
gray scale and lower values indicate a darker stain and higher protein binding. A, HPRT showed a significant
variability between malignant and normal tissue samples with an overall trend of increased HPRT upon malignancy.
B, GAPDH had significantly elevated levels of expression in both malignant and normal tissue samples.

Additionally, upon comparing HPRT expression across malignant organ types, we found
significant variation with breast tissue showing the highest average HPRT (97.33) and prostate
tissue showing the lowest average HPRT (120.83). The discrepancy between the different organ
sites was also experienced within normal tissue, but with less severity (Figure 8-2). Breast and
colon samples showed significant (p=0.0183) changes in HPRT expression, while pancreatic
samples were significantly lower than other organ sites (p<0.0001). These data indicate that not
only is HPRT expression inconsistent between healthy and malignant tissue, but also shows that
there is significant variability between various tissue types. On average, the marginal tissue had
intermediate HPRT expression between normal levels and malignant levels, which is consistent
with our analysis indicating a general trend of increased HPRT expression with cancer
development.
Less variability was observed in the box plots of GAPDH samples when compared to the
HPRT box plots as they were generally tighter in prostate, colon, and breast samples. GAPDH
also showed some significance between normal tissue, but was not as severe as the variability
observed in malignant samples.
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Figure 8-2. Statistical analysis of HPRT and GAPDH expression in patient tissue. Tissues were quantified on a gray
scale and lower values indicate darker staining. Both GAPDH and HPRT had significant variability between organ
systems. HPRT showed less significance within normal tissue, with pancreatic tissue showing the greatest
significance from other tissue types (p<0.001). In malignant samples, HPRT showed more significant variability
with all organs showing significance from each other with the exception of Colon and Pancreatic tissue samples.
GAPDH showed similar patterns as HPRT with significant expression between malignant organ sites.

Protein expression varies significantly between cell lines
We found that the expression of HPRT protein varied significantly between various cell
lines from a variety of organ origins. As protein volumes were standardized against GAPDH, we
found that EEF2 had no significant differences in protein expression between cell lines. B2M
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showed similar consistent expression, with the exception of Jurkat cells which had significantly
(p=0.0012) lower expression from other cell line samples. While both B2M, TBP, and GAPDH
show very small changes in total protein expression, HPRT had significant variability between
all cell types (Figure 8-3). Consistent with tissue data, normal PBMC cells had the lowest total
amount of protein (p<0.0001), while A549 and U937 cells had the highest total protein content
(p<0.0001).

Figure 8-3. Protein expression between cell lines shows significant variability in HPRT when compared to other
endogenous controls. Samples were originally standardized to GAPDH expression and B2M, EEF2, and HPRT were
measured in comparison to that standard. Cell lysates were isolated for 2 cell lines from each organ tissue type. We
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find that HPRT expression varies significantly in comparison to both EEF2 and B2M expression when standardized
against GAPDH.

PC3 and DU145 prostate cancer cell lines had equal HPRT expression (p>0.999), along
with H460 and A549 lung cancer cells (p=0.87). All other organ pairs had significant differences
in expression. SW620 and HT29 colon cancer cells (p=0.043), MDA-MB-231 and MCF7 breast
cancer cells (p=0.043) all show significant differences in HPRT expression. When comparing
normal PBMC lysate to other mononuclear cells, we found Raji cells (p=0.0007), Jurkat cells
(p=0.0212), and U937 cells (p=0.0007) each show significant elevation. These data also show
that HPRT protein levels within cancer cells are significantly different from one another,
especially when compared to other endogenous proteins.

Figure 8-4. RNA expression in cell lines show a range of HPRT expression. RNA expression of HPRT was plotted in
a range of malignant cell lines (7-25 cell lines) from five different organs sites. The horizontal lines are the average
expression levels across all cell lines within a given organ type, which is corresponded to the labeled organ color.
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These data show the significant variability in HPRT expression between various cancer cell lines in regards to RNA
levels.

RNA levels are inconsistent between various cancer cell lines
To determine whether HPRT was suitable as a control in terms of RNA expression, we
evaluated RNA levels of 90 cancer cell lines from a variety of different organ origins (lung,
breast, colon, prostate, pancreas). We found statistically significant variability in expression not
only between different cancer cell lines within the same organ site, but also found variation
between different organ sites (Figure 8-4). The highest expressing cell lines according to RNA
expression were QGP-1 (pancreas), DV-90 (lung), and OUMS-23 (colon), while the lowest
expressing cell lines were LoVo (colon), COR-L105 (lung), and SNU-213 (pancreas). Although
the overall average levels of all cell lines evaluated from each tissue type show some similarity,
as indicated by the horizontal lines, the variability between the individual cell lines within and
between each organ type is significant.
Table 8-1. Patient tissue quantification.
Organ
Lung
Breast
Colon
Prostate
Pancreas

Tissue Type
Normal
Marginal
Malignant
Normal
Marginal
Malignant
Normal
Marginal
Malignant
Normal
Malignant
Normal
Marginal
Malignant

Grade Range
1-3
1-3
1-3
1-3

Number of Patients
18
18
18
24
21
18
8
18
53
3
53
10
10
54

Age Range Male/Female
30-77

14/4

28-69
32-74
29-68
29-42
32-81
30-79
63-75
60-85
19-40
49-73
40-84

0/24
0/21
0/18
8/0
15/3
27/26
3/0
53/0
29/28
6/4
4/6

Overall gray intensity
101.08
100.74
100.26
113.04
107.90
97.33
104.37
103.30
102.59
134.2
120.83
154.93
137.33
154.95
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Figure 8-5. RNA expression in normal and malignant patient tissue. RNA expression of 10 different endogenous
control genes was graphed between tumor and normal samples. We found significant variability between several of
the control genes in regard to expression in normal and tumor samples.

Endogenous control variation is dependent on the original organ tissue
We also evaluated RNA expression levels between malignant and normal samples to
determine if the same variability observed within cell line data also existed within patient
samples. We found that there was an overall significant increase in HPRT upon malignancy, as
was observed in other assays (p-value = 0.0007, Prostate adenocarcinoma; 0.0001, lung
squamous carcinoma; 0.0001, Lung adenocarcinoma; 0.0001, Colon adenocarcinoma; 0.0001,
Breast invasive carcinoma). The most significant difference was found within lung squamous
cell carcinoma patients. Upon analyzing 9 other endogenous control genes we found that their
expression levels also varied, but this was according to the organ tissue type (Figure 8-5). ACTB
and TBP generally were elevated in normal patients when compared to malignant patients but
showed relatively consistent expression across samples (p-values ACTB: 0.8178, colon
adenocarcinoma; 0.4614, lung adenocarcinoma; 0.9974, lung squamous carcinoma; TBP:
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0.2615, lung adenocarcinoma; 0.3142, prostate adenocarcinoma). Meanwhile GAPDH, GUSB,
PGK1, PP1A, RPLPO, and B2M all generally showed elevation of expression in malignant
tumors. TFRC was the only gene that had a variation of elevation, with lung adenocarcinoma and
prostate adenocarcinoma patients showing elevated levels in normal samples and lung squamous
cell carcinoma, colon adenocarcinomas, and breast carcinoma showing elevation in tumors.
To show how HPRT variability can affect experimental results and conclusions we
mapped the other endogenous control genes utilizing either normal HPRT as the standard or
malignant HPRT as the standard. Here we see that gene expression can vary. TFRC goes from
showing an elevation when normalized to normal HPRT to a decrease in protein expression
when standardized to malignant HPRT. This demonstrates that utilizing HPRT in malignant
samples does not provide an adequate representation of gene elevation or reduction compared to
normal cells (Figure 8-6).
Discussion
This study analyzed the gene expression of HPRT to determine whether the protein is
suitable as a normalized control for cancer-related studies. Because HPRT has been used
extensively as an endogenous control for a several studies, it is important to provide a clear
understanding of how it’s expression changes in a cancerous setting 526–532. Here we have shown
that HPRT is not a suitable control in cancer-related experiments as it exhibits expression
variability at both protein and transcriptional levels. When comparing normal samples to
malignant samples, HPRT showed variation that is not consistent with a good normalized
control. Additionally, the levels of HPRT also varied across different organ tissue in malignant
samples and, to a lesser extent, normal samples.
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Figure 8-6. Impact of using HPRT as a normalization standard on gene expression. Normal and malignant HPRT
levels were used as a normalization to compare the expression of the remaining 9 endogenous control genes. We
found that when utilizing either normal or malignant HPRT levels there was significant variability in the other
endogenous control gene expression profiles.
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HPRT has been utilized as the sole housekeeping standard for several studies involving
cancer 533,534. As there is a significant increase in HPRT expression in most tissue types upon
developing malignancy, the increased target gene expression observed in several studies may be
more significant than originally detected, as some increases in gene expression may be masked
by the concomitant increase in malignant HPRT expression. This inherent elevation of HPRT
may also conceal genes with increased expression that would have otherwise been significant if a
different endogenous control was chosen for the analysis. With this in mind, we would
recommend research utilizing HPRT as a single standard to re-evaluate their data to determine if
a different control would result in more accurate results. In addition, we propose the discontinued
use of HPRT as a standard control as the variability seen within malignant patients renders it
unsuitable for normalization.
When comparing 10 different common endogenous controls, we found that their relative
expression between malignant and normal tissue was dependent on the originating organ. TBP
showed insignificant differences between malignant and normal cells in lung adenocarcinoma
but exhibited significant differences in lung squamous cell carcinoma. Some genes also had
inverted expression depending on the tissue type. PGK1 had elevated levels in normal prostate,
but also had elevated levels in colon adenocarcinoma. These results indicate that it may be in the
best interest of the researcher to select the endogenous control genes based upon previously
determined expression levels and change the selected control gene according to the experimental
conditions and tissue used.
Previous work has already shown that HPRT is an unsuitable endogenous control in some
experimental systems, such as embryonic stem cells 525, and has pseudogenes that affect gene
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normalization in QPCR 535. Considering this previous data and the results obtained in our
evaluation, HPRT appears to be unsuitable as an endogenous control for cancer-related studies.
Methods
Chemicals/Reagents
Anti-HPRT rabbit polyclonal antibody (ab10479) used for Western blot analysis were
purchased from Abcam (Cambridge, United Kingdom) and stored at 4°C. Western bright
western blotting detection kit was purchased from Advansta (Menlo Park, CA, USA) and stored
at room temperature. DIVA Decloaker 10x, Background Sniper, Mach 4 HRP polymer, DAB
Peroxidase, Hematoxylin, Hydrophobic pen, and Universal Negative antibodies were all
obtained from Biocare Medical, Concord, CA. GAPDH polyclonal antibody (One World Labs,
San Diego CA) was aliquoted and stored at -20°C. Tween20 (Fisher Reagents, Waltham MA)
was stored at room temperature. Hydrogen Peroxide, 30% (Fisher Reagents, Waltham MA) was
stored at 4°C.
Lysate Preparation
Raji, HT-29, Jurkat, U937, PC3, DU145, NCI-H460, SW620, MCF-7, MDA-MB-231,
and A549 human cell lines were obtained from the American Type Culture Collection
(Rockville, MD, USA). Raji, HT-29, Jurkat, U937, PC3, DU145 and NCI-H460 cells were
grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 2mM LGlutamine. SW620, MCF-7, and MDA-MB-231 cells were grown in DMEM medium
supplemented with 10% FBS and 4mM L-Glutamine (Gibco, MD, USA). A549 cells were grown
in F-12K medium supplemented with 10% FBS and 2mM L-Glutamine. Cell media was replaced
every 48 hours to maintain exponential conditions. Cell viability was evaluated using trypan blue
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staining. All cells were grown at 37°C and 5% CO2. Cell lines were authenticated in May of
2016 by the University of Arizona Genetics Core.
Whole blood was collected from healthy volunteers under IRB approval (BYU X090281)
with written informed consent. Blood was further diluted with PBS at a 1:1 ratio and layered on
Lymphocyte Separation Medium (LSM) (Corning Incorporated, Corning, NY, USA) before
being centrifuged for 30 minutes at 400xg. The buffy layer was collected and treated with a red
blood cell lysis buffer before used for experimentation.
Once confluent, cells were washed with cold PBS and added to a RIPA buffer solution
with freshly added protease and phosphatase inhibitor (Thermo Fisher Scientific, MA, USA).
Cells were then thoroughly vortexed and incubated on ice for 30 minutes with an additional
vortex step performed every 10 minutes. The lysed solution was then pelleted at 15,000xg for 15
minutes at 4°C and aliquoted to avoid freeze-thawing samples. All lysates were stored at -80°C.
Immunohistochemistry
Tissue microarrays were purchased from Biomax. Patient details and information are
found in Table 8-1 and include lung, prostate, colon, breast, and pancreatic cancer patients and
corresponding normal samples.
HPRT levels were assessed using standard immunohistochemistry staining. Following
treatment with Histoclear (National Diagnostics, Charlotte, North Carolina), tissues were
rehydrated with a series of ethanol washes. To retrieve antigen, tissues were treated with a DIVA
Decloaker. Tissues were washed with a hydrogen peroxide solution followed by a Tris Buffered
Saline-Tween20 (TBST) wash. Following washing, tissues were incubated with a blocking
Background Sniper solution to reduce non-specific antibody binding. Following blocking,
primary antibody was added at a 1:100 dilution and incubated overnight at 4°C. Tissues were
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then washed and treated with secondary HRP conjugated antibodies and incubated for an hour.
DAB peroxidase was added to the tissues along with hematoxylin to highlight target protein and
the cell nuclei, respectively. A universal negative antibody was used as the negative control for
background binding, and GAPDH was utilized as a positive control to ensure protocol
functionality.
Tissue Quantification
Quantification of tissues was carried out using ImageJ software. An IHC toolbox ImageJ
plugin with the DAB more option was chosen and tissues were removed of all non-DAB stain.
Following this modification, the image was converted to a grayscale and a threshold was applied
to eliminate areas of negative space. This same threshold was applied to all tissue samples within
the same organ to ensure consistency and reduce sample bias.
Western Blot and quantification
Cell lysates were blotted for GAPDH, B2M, EEF2, and HPRT expression utilizing
standard Western Blotting techniques described in Sewda et al., with minor modifications [22].
Briefly, each sample was boiled for 5 minutes prior to running on a 12% polyacrylamide gel
under reducing conditions. Gels were then transferred to a nitrocellulose membrane (Biorad
Laboratories Hercules, CA, USA), blocked, and treated with primary antibody overnight at 4°C
on a shaker. Following primary antibody treatment, membranes were washed and treated with
secondary HRP antibodies (Abcam, Cambridge, United Kingdom) for 1 hour at room
temperature. Membranes were then washed and treated with a Western Bright (Advansta,
California, USA) HRP substrate before capturing the image with X-ray film. Western images
were imported into ImageJ and converted to an 8-bit image. Lanes were then selected and
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plotted. The area under the individual bands were calculated to determine the relative protein
expression of the samples.
Transcriptomic analysis
We evaluated expression levels for 90 cell lines from the Cancer Cell Line Encyclopedia
using data that had been generated using Illumina-based RNA-Sequencing536,537. The data values
were originally calculated at the isoform level using the kallisto software538; we calculated genelevel values by summing the isoform values for each gene. Next we log-transformed these values
and converted them to transcripts-per-million values. We sorted the cell lines according to
HPRT1 expression level, from high to low expression per sample.
We obtained gene-level expression values for tumors and normal tissues from The
Cancer Genome Atlas539. The Illumina-based, RNA-Sequencing data had been prepared
previously using the featureCounts algorithm and the Rsubread package540–542. In cases where
RNA expression had been profiled for the same patient multiple times, we averaged expression
on a per-gene basis across the replicates. Next, we log-transformed the data and normalized the
data to transcripts-per-million values. The normal data came from tissue of the same organ type
or from blood samples; however, these samples did not necessarily come from the same patients
as the tumor samples.
We preprocessed the RNA expression data using scripts written in the Python
programming language (https://python.org, v.3.6.1). To make graphs for this analysis, we used
the ggplot2 package (v.2.2.1) and the Superheat package (v.0.1.0) implemented for the R
(v.3.4.3) statistical software543–545.
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Statistical analysis
ANOVA using the multiple comparison method was used to determine significance
differences between patient tissue samples in immunohistochemistry staining and western
blotting data. These statistical analyses were evaluated using GraphPad Prism 7 software.
In calculating differences in transcriptome between tumor and normal samples, we used a
permutation-based test. For a given gene, we repeatedly (n = 10,000) permuted the tumor/normal
labels and calculated the difference in mean expression; then we compared the actual difference
in expression for a given gene against its respective permuted distribution; lastly, we calculated
an empirical p-value by determining the proportion of times that the actual difference was greater
than the permuted differences. Differences were considered significant when the p value was <
0.05. These tests were performed using the R (v.3.4.3) statistical software.
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Biomarkers Research.
The following chapter is taken from an article submitted in Biomarkers Research. All content
and figures have been formatted for this dissertation.
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Abstract
Background: The aim of this study is to determine whether Hypoxanthine Guanine
Phosphoribosyltransferase (HPRT) could be used as a biomarker for the diagnosis and treatment
of B cell malignancies. With 4.3% of all new cancers diagnosed as Non-Hodgkin lymphoma,
finding new biomarkers for the treatment of B cell cancers is an ongoing pursuit. HPRT is a
nucleotide salvage pathway enzyme responsible for the synthesis of guanine and inosine
throughout the cell cycle.
Methods: Raji cells were used for this analysis due to their high HPRT internal expression.
Internal expression was evaluated utilizing western blotting and RNA sequencing. Surface
localization was analyzed using flow cytometry, confocal microscopy, and membrane
biotinylation. To determine the source of HPRT surface expression, a CRISPR knockdown of
HPRT was generated and confirmed using western blotting. To determine clinical significance,
patient blood samples were collected and analyzed for HPRT surface localization.
Results: We found surface localization of HPRT on both Raji cancer cells and in 77% of the
malignant ALL samples analyzed and observed no significant expression in healthy cells.
Surface expression was confirmed in Raji cells with confocal microscopy, where a direct overlap
between HPRT specific antibodies and a membrane-specific dye was observed. HPRT was also
detected in biotinylated membranes of Raji cells. Upon HPRT knockdown in Raji cells, we
found a significant reduction in surface expression, which shows that the HPRT found on the
surface originates from the cells themselves. Finally, we found that cells that had elevated levels
of HPRT had a direct correlation to XRCC2, BRCA1, PIK3CA, MSH2, MSH6, WDYHV1,
AK7, and BLMH expression and an inverse correlation to PRKD2, PTGS2, TCF7L2, CDH1,
IL6R, MC1R, AMPD1, TLR6, and BAK1 expression. Of the 17 genes with significant
correlation, 9 are involved in cellular proliferation and DNA synthesis, regulation, and repair.
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Conclusions: As a surface biomarker that is found on malignant cells and not on healthy cells,
HPRT could be used as a surface antigen for targeted immunotherapy. In addition, the gene
correlations show that HPRT may have an additional role in regulation of cancer proliferation
that has not been previously discovered.
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Introduction
Non-Hodgkin lymphomas (NHL) and lymphocytic leukemia (Chronic Lymphoblastic
Leukemia and Acute Lymphoblastic Leukemia) are hematological cancers that include more
than 30 different cancers of B and T lymphocytes 546. Non-Hodgkin lymphoma diagnoses made
up 4.3% of all new cancer cases in 2017, demonstrating the prevalence of the disease in the
United States 547. In addition, leukemia is the most common malignancy in children, with ALL
comprising approximately 26% of all childhood cancers 548,549.
Cancer biomarkers are typically categorized as diagnostic, prognostic, or predictive.
While diagnostic biomarkers identify the onset or presence of cancer, prognostic biomarkers
inform physicians of clinical outcomes for their patients throughout treatment, and predictive
biomarkers suggest how patients will respond to various treatment regimens 550. A new category
of surface biomarkers has emerged; these biomarkers function as targets for immunotherapy 551–
555

. Currently, the most prominent immunotherapy biomarker for B cell malignancies is CD19

180,556–559

. CD19 is a type I transmembrane protein expressed in normal and neoplastic B cells,

and follicular dendritic cells 560. CD19 has been used as a direct target for chimeric antigen
receptors (CARs) as well as an antibody in bi-specific T-cell that directs cytotoxic T-cells to
CD19 expressing B cells 560. Currently, the only FDA approved CAR therapy targets are against
CD19; these include Yescarta and Kymriah 561. A disadvantage of utilizing this biomarker target
is that patients’ healthy B cell populations decrease because CD19 is not specific to cancer cells.
Another disadvantage of targeting CD19 is that some tumors experience antigen loss which
confers resistance to CD-19-targeted immunotherapy, and approximately 10%-20% of patients
relapse following treatment with CD19-CAR therapy 562,563. To aid in reducing antigen loss,
researchers seek to identify new immunotherapy biomarkers that can be targeted to eliminate B
cell malignancies. New targets such as CD22, CD20, andROR1 have all shown promise in
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eliminating certain B cell malignancies, but further research is needed to expand targetable
antigens on the surface of malignant B cells 564–567.
Previous studies have found that there is variability in regards to hypoxanthine guanine
phosphoribosyltransferase (HPRT) expression within malignant tissue 61, and as such it has been
suggested that HPRT could be used as targetable biomarker for some solid malignancies 62. We
have designed this study to determine whether HPRT could be used as a targetable biomarker in
the treatment of B cell malignancies 61,514. In doing this, we hope to identify additional
biomarkers options to lessen the growing concern of antigen loss.
Materials and Methods
Chemicals
Anti-HPRT mouse monoclonal antibody (MA5-15274) used for flow cytometry was
aliquoted and stored at -20°C (Thermo Fischer Scientific, Waltham, MA, USA). Anti-HPRT
rabbit polyclonal antibody (ab10479) used for Western blot analysis were purchased from
Abcam (Cambridge, United Kingdom) and stored at 4°C. Anti-Mouse-FITC and anti-RabbitFITC antibodies (Sigma Aldrich, St. Louis, MO, USA) were stored at 4°C and were used in dark
conditions. Goat-anti-rabbit-HRP secondary antibody was purchased from Abcam and stored at
4°C. NF-κB polyclonal antibody (Bioss Antibodies, Wodburn, MA, USA) was stored at 4°C and
used as an internal negative control for surface expression. CD44 monoclonal antibody and
GAPDH polyclonal antibody (One World Lab, San Diego, CA) were stored at -20°C and used as
positive control and negative controls for surface expression, respectively. Propidium Iodide
(Sigma Aldrich Inc., Milwaukee, WI, USA) was stored at 4°C and aliquoted for use. Fc Block
was purchased from Biolegend (San Diego, CA, USA) and stored at 4°C. An APC-Conjugation

195

Kit (Abcam, Cambridge, United Kingdom) was stored at -20°C and following conjugation,
antibodies were stored at 4°C.
Cell Culture Conditions
The Raji (CCL-86- human Burkitt’s B cell lymphoma) cell line was obtained from the
American Type Culture Collection (Rockville, MD, USA). Raji cells were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS) and 2mM L-Glutamine (all from
Hyclone, Logan, UT, USA). Cell media was replaced, and cells were cut to maintain exponential
conditions throughout experimentation. Cell viability was evaluated using trypan blue staining,
and cells were utilized for all applications when viability exceeded 98%. All cells were grown at
37°C and 5% CO2. Raji cells were authenticated in May of 2016 by the University of Arizona
Genetics Core.
Flow Cytometry
The surface presence of HPRT was evaluated by measuring the fluorescence intensity of
antibodies against the enzyme. All samples were analyzed on a Blue/Red Attune (Applied
Biosystems), and 25,000-50,000 events were recorded per sample. Briefly, 3-5x105 cells were
incubated with 200µL of PBS containing 1µg of primary antibody for 15 minutes at 4°C. Cells
were then labelled with FITC-conjugated secondary (mouse or rabbit) antibody for 15 minutes
4°C. Isotypic IgG and unstained cells served as negative controls to ensure correct cell gating.
The forward/side-scatter plots were used to gate out cell doublets, dead cells, and cell debris.
Using unstained and isotype controls as guides, the positive population was determined by the
overall shift in the fluorescent intensity. Each cell line was independently analyzed and the data
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was plotted using FlowJo Software (FlowJo Enterprise). Cells were washed appropriately after
each step of the protocol.
Mononuclear cell separation
Whole blood was collected from healthy volunteers under IRB approval (BYU X090281)
with written informed consent. Blood was further diluted with PBS at a 1:1 ratio and layered on
top of Lymphocyte Separation Medium (LSM) (Corning Incorporated, Corning, NY, USA)
before being centrifuged for 30 minutes at 400xg. The buffy layer was collected and treated with
a red blood cell lysis buffer before used for experimentation.
ALL Patient Samples
Acute lymphoblastic leukemia (ALL) samples were collected at diagnosis or relapse from
patients after informed consent utilizing a biobank protocol at the Huntsman Cancer Institute in
Salt Lake City, UT. Samples were frozen with dimethyl sulfoxide (DMSO) and albumin and
further aliquoted for analysis. Following sufficient thawing at 37°C, samples were washed with
Dulbecco’s phosphate-buffered saline (DPBS). After careful washing, cells were used for flow
cytometry analysis and stained with similar procedures as previously described.
Surface Biotinylation and Western Blot Analysis
Cells were analyzed for surface presence of HPRT along with general expression within
the cell using the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific, Waltam, MA,
USA). Briefly, 3 flasks of Raji cells were grown to 95% confluency and normal lymphocytes
were obtained from healthy donors under appropriate IRB approval (#090281). These cells were
washed and treated with a biotin solution. Following rocking on a shaker for 30 minutes at 4°C,
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the cells were treated with a quenching solution. Then, cells were treated with a lysis solution
and incubated for 30 minutes at 4°C. Cell lysate was added to a neutravidin gel and incubated for
60 minutes at room temperature. This solution was then run through a filter and proteins bound
to biotin were trapped within the column. The neutravidin gel was washed 4 times and the flow
through was collected and labelled “cytosolic fraction”. The biotin-labelled protein was then
eluted from the column utilizing a 50mM DTT solution and labelled “membrane fraction”.
Both membrane and cytosolic fractions were evaluated for HPRT presence using
standard Western Blotting techniques described in Sewda et al. with slight modifications [22].
Briefly, each sample was boiled for 5 minutes prior to running on a 12% polyacrylamide gel
under reducing conditions. Gels were then transferred to a nitrocellulose membrane (Biorad
Laboratories Hercules, CA, USA), blocked, and treated with an anti-HPRT polyclonal antibody
overnight at 4°C on a shaker. Following primary antibody treatment, membranes were washed
and treated with a goat anti-rabbit HRP antibody (Abcam, Cambridge, United Kingdom) for 1
hour at room temperature. Membranes were then washed and treated with a Western Bright
(Advansta, California, USA) HRP substrate and the image was captured with X-ray film.
Confocal Microscopy
Image processing was carried out with Laser Sharp Computer Software (Bio Rad
Laboratories). Cells were incubated in 200uL of PBS containing 1µg of anti-HPRT monoclonal
antibody for 15 minutes at 4°C. Cells were then labelled with 1µg of FITC-conjugated secondary
antibody for 15 minutes at 4°C. Then, cells were incubated at 37°C for 10 minutes with a 1:1000
dilution of a Cell Mask Deep Red plasma membrane dye (Fisher Scientific, Waltham, MA,
USA). Cells were imaged using an epiflourescence microscope (Olympus, Tokoyo, Japan)
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equipped with a 15mW Krypton/Argon laser (Bio-Rad Laboratories, Hercules, CA). Images
were captured and processed using Laser Sharp Computer Software (Bio Rad Laboratories).
HPRT knockdown
The pSpCas9(BB)-2a- GFP CRISPR vector was purchased from Addgene (Cambridge,
MA, USA) and guide RNA design was conducted using the CRISPR Design tool created by MIT
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. Briefly, Raji cells were grown to a concentration of 4x105 cells per mL and seeded in a 6-

well plate. Following 24 hours of growth, cells were transfected with a lipofectamine LTX
reagent (Invitrogen Waltam, MA, USA). Briefly, 150µL of Opti-MEM (Gibco, Gaithersburg,
MD) was incubated with 5-7µL of Lipofectamine LTX reagent while 250µL of Opti-MEM was
incubated with approximately 2x103ng of the CRISPR vector. The solutions were mixed
together and incubated at room temperature for 30 minutes. The lipofectamine-DNA solution
was then added to the Raji cells in a drop-wise fashion. Cells were grown for 3 days and then
treated with media containing 6-Thioguanine (6-TG) at a final concentration of 10µg/µL. 6-TG
is a nucleoside analog that is toxic to cells with a functional HPRT gene. Cells that survived the
6-TG treatment were grown to sufficient quantities to produce cell extract. This extract was
analyzed by Western blotting using similar techniques described previously, to confirm surviving
cells were HPRT-/-.
Bioinformatic gene expression analysis of malignant B cell lines
We evaluated gene-expression levels for 105 genes across 79 cell lines from the Broad
Institute’s Cancer Cell Line Encyclopedia 537. We used RNA-Sequencing data for protein-coding
transcripts that had been generated using Illumina-based, short-read sequencing. These data had
been processed using the kallisto software 538, then log- transformed and converted to transcripts199

per- million values 536. This data can be found at https://osf.io/gqrz9/files/
(matrices/CCLE/CCLE_tpm.tsv.gz). We summed the transcript-level values to gene-level values
and sorted the cell lines according to HPRT expression level, from high to low expression per
sample. We parsed and prepared the data using Python (https://python.org, v.3.6.1) scripts. In
making the heat map, we used the R (v.3.4.3) statistical package 569 and the Superheat package
(v.0.1.0) 543.
Statistical analysis
ANOVA statistical analysis with the Tukey-Kramer multiple comparison method were
used to analyze the flow cytometry data from all cell lines, representing the differential surface
expression of HPRT for the various treatments. In addition, two-way ANOVA tests were
performed to compare the mean expression of HPRT between wild type Raji and knockdown
cells. All statistical analyses were performed using GraphPad Prism 7 software. Differences were
considered significant when a p value was <0.05.
When assessing relationships between HPRT expression and other genes, we used a
Spearman correlation test to calculate correlation coefficients and two-sided p-values. In
performing these calculations, we used the cor.test function in the stats package of the R (v.3.4.3)
statistical software.
Results
Raji cells show a significant increase in HPRT localization on the plasma membrane while
healthy cells have insignificant expression.
Raji cells treated with antibodies against HPRT had an average fluorescent population
shift of 81.39% which was significantly different (p-value < 0.0001) from the isotype controls,
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which only experienced a 1.50% shift in the fluorescent population (Figure 9-1A&C).
Lymphocytes from healthy donors treated with antibodies against HPRT had insignificant
fluorescent shifts in the population (1.53%) when compared to isotype controls (p-value =
0.98)(Figure 9-1B&D). These results indicate that HPRT has substantial presence on the surface
of Raji cells and has insignificant presence on the surface of their normal counterparts.
To confirm surface localization, malignant and normal cells were analyzed using
confocal microscopy to visualize direct overlap between the plasma membrane and HPRT
binding. Raji cells had a direct overlap between the membrane specific dye and the FITC
conjugated HPRT antibody resulting in a yellow merged image (Figure 9-2B). This same overlap
was not observed in normal lymphocytes as the HPRT binding was similar to that of the isotype
control, showing that these cells had minimal HPRT expression (Figure 9-2A). This analysis
shows that HPRT associates strongly with the plasma membrane and has a significant surface
presence on malignant Raji cells.
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Biotinylated surface proteins show HPRT bound to the plasma membrane of Raji cells.

Figure 9-1. HPRT surface localization in Raji and normal cells. A, Raji cells treated with a fluorescent anti-HPRT
antibody experienced a significant shift (p-value < 0.0001) when compared to isotype controls. B, Normal
lymphocytes from healthy donors treated with fluorescent anti-HPRT antibodies did not experience a significant
shift in the fluorescent population when compared to isotype controls. C, Statistical analysis reveals a significant
elevation of HPRT expression on the surface of Raji cells, and D, an insignificant elevation of HPRT on healthy
lymphocytes.
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To further confirm whether HPRT was bound to the plasma membrane of Raji cells, we
biotinylated the surface proteins of Raji cells and normal cells, and probed for HPRT presence.
This analysis revealed a band in the Raji membrane biotin sample that was absent from the
normal lymphocyte membrane biotin sample and all other membrane controls. As expected, the
band observed in the membrane fraction was smaller than that of the cytosolic fraction as the
amount of HPRT on the cell surface would be significantly less than the internal levels of the
protein (Figure 9-3). This analysis further confirmed the localization of HPRT on the cell surface
of Raji cells and the absence of the enzyme on normal cells.

Figure 9-2. HPRT directly overlaps with the plasma membrane of Raji cells. Fluorescent HPRT antibodies were
compared against a membrane specific dye to highlight overlap in binding. CD19 and CD44 were used as positive
controls and isotype controls were used as negative controls to highlight nonspecific antibody binding A, Healthy
lymphocytes did not have a significant presence of HPRT on the cell surface and levels were similar to isotype
controls. B, Raji cells showed a clear increase in fluorescence when analyzed for HPRT and there was a direct
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overlap between the membrane dye and the antibody treatment, indicating that HPRT is co-localized with the
plasma membrane of Raji cells.

HPRT knockdown cells exhibited reduced levels of surface HPRT expression.
To help confirm that the surface HPRT originated from the cells themselves, we created
a knockdown of HPRT in Raji cells using a CRISPR system. Following adequate selection, we
determined that there was sufficient reduction of HPRT within the cells for analysis (Figure 4).
The average relative expression of the enzyme went from 47,628 in wild type Raji cells to 2,254
in knockdown cells (p-value = 0.0002). In conducting this analysis, we also observed that the
HPRT expression within Raji cells was significantly different than the expression within normal
PBMCs. This further demonstrates the variability of HPRT expression between malignant and
normal samples.

Figure 9-3. Biotinylated surface proteins reveal HPRT presence and confirms surface presence of the protein.
‘Membrane Fraction’ shows the total surface proteins on both lymphocytes and Raji samples. ‘Cytosolic Fraction’
shows the total HPRT within the cell. A band is observed in the ‘Raji Biotinylation’ sample as the membrane
fraction of Raji cells and healthy lymphocytes are probed for HPRT presence.
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When evaluating HPRT knockdown cells for surface expression we found a significant
(p-value = 0.039) decrease in the presence of the protein on the surface compared to the WT Raji
counterparts (Figure 5). We observed a shoulder in the population that we hypothesize are a
result of the sample not being a true knockout, but a knockdown. While the knockdown cells did
show slight significance in expression when compared to isotype controls (p-value = 0.029), this
was far less than the surface expression of HPRT in WT Raji cells (p-value = 0.0001). The
overall average reduction in HPRT expression upon protein knockdown was approximately 20%.
Further analysis with a true knockdown cell line will need to be evaluated to confirm these initial
findings, but these data indicate that surface HPRT is in some way directly produced within the
cells.

Figure 9-4. HPRT knockdown confirmation. Following knockdown of HPRT, a western blot was performed to both
confirm knockdown status and to also quantify the expression of HPRT within Raji cells and healthy PBMC.
Knockdown cells had significantly decreased levels of HPRT in total cell lysate, indicating successful knockdown
(p-value = 0.0002). Healthy PBMCs had significantly lower total HPRT than Raji samples.

Analysis of patient samples shows that HPRT surface expression has clinical relevance.
To determine whether the presence of HPRT was an artifact of cell culturing conditions or cell
immortalization, we analyzed samples from patients with ALL to determine whether the
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phenomenon was also found within these patients. We found that 7 out of the 9 patient samples
were positive for elevated HPRT on the cell’s surface and we saw an overall increase in
fluorescence (p-value < 0.0001) upon anti- HPRT treatment when compared to isotype controls.
The highest expression observed was approximately 34%, while the lowest expression was 6.7%,
with the average fluorescence shift around 25% for ALL patients (Figure 9-6). This analysis
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showed that HPRT has relevance within a proportion of patients. This analysis also confirmed

Figure 9-5. Flow analysis of HPRT knockdown Raji cells reveal a reduction in surface binding. Following
knockdown of the HPRT gene in Raji cells, we analyzed surface HPRT expression in both knockdown Raji and
wild type Raji cells. We found that there was a significant decrease in HPRT surface localization in the
knockdown when compared to the wild type Raji cells.
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that HPRT surface localization is not a universal characteristic of malignant cells and patients
should be evaluated on an individual basis.

Figure 9-6. ALL patients show elevated surface HPRT. Patient samples were stained with PI to discriminate against
dead cells. APC was used to stain proteins of interest. Upon evaluation of 9 ALL patient samples, we found that 7 of
them had elevated HPRT surface localization with an average fluorescent population shift of 25%. This indicates
that the surface localization observed in Raji cells is also found within patients.
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Differential gene expression between HPRT low and HPRT high expressing cancer cells.
As we found variability between normal cells and malignant cells in regard to their
relative HPRT expression, we further evaluated changes in gene expression between highexpressing and low-expressing cells to determine whether HPRT could have any potential
influence on other cancer-associated genes. We assessed 79 different malignant B cell lines and
ranked them according to their relative HPRT expression. Raji cells had the third highest
expression of all cell lines evaluated, which we predicted, as there is significant surface
presentation of the enzyme in Raji cells.
Many other genes experienced a significant trend correlating to HPRT expression (Table
9-1). Genes that showed a direct positive correlation to HPRT were XRCC2 (p-value = 0.0045),
BRCA1 (p-value = 0.0032), PIK3CA (p-value = =0.0034), MSH2 (p-value = 0.0445), MSH6 (pvalue = 0.019), WDYHV1 (p-value = 0.0066), AK7 (p-value = 0.0452), and BLMH (p-value =
0.0498). Genes that showed an inverse correlative relationship to HPRT were PRKD2 (p-value =
0.0109), PTGS2 (p-value = 0.0046), TCF7L2 (p-value = 0.0032), CDH1 (p-value = 0.0201),
IL6R (p-value = 0.0054), MC1R (p-value = 0.0487), AMPD1 (p-value = 0.0227), TLR6 (p-value
= 0.0401), and BAK1 (p-value = 0.0052). Although HPRT is not the sole contributor to these
changes in gene expression, there may be a cascading relationship between HPRT levels and
these genes as there are general trends either towards higher expression or lower expression
when HPRT is elevated within the cells.
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Table 9-1. HPRT gene correlations.
Gene Name

Gene

Breast cancer type 1 susceptibility protein

XRCC2
BRCA1

Phosphatidylinositol 4,5-bisphosphate 3-kinase
catalytic subunit alpha

PIK3CA

Protein N-terminal glutamine amidohydrolase
Adenylate kinase 7

MSH2
MSH6
WDYHV1
AK7

Bleomycin hydrolase

BLMH

Serine/threonine-protein kinase D2
Prostaglandin G/H synthase 2

PRKD2
PTGS2
TCF7L2
CDH1
IL6R
MC1R
AMPD1
TLR6
BAK1

Cadherin-1
Interleukin-6 receptor
Melanocyte-stimulating hormone receptor
AMP deaminase 1
Toll-like receptor 6
Brassinosteroid insensitive 1-associated receptor
kinase 1

General Function
Direct Correlation
DNA repair protein involved in homologous recombination.
Tumor suppressor gene that maintains genomic stability via DNA damage repair, chromatin
remodeling, transcriptional regulation and apoptosis.
Involved in cell growth, survival, proliferation, motility and morphology. Also participates in
cellular signaling in response to growth factors.
Involved in mismatch repair system.
Involved in mismatch repair system.
Involved in the N-end rule pathway in protein degradation.
Nucleoside monophosphate kinase that transfers phosphate groups between nucleoside
triphosphates and monophosphates.
Cysteine peptidase, hydrolyzes homocysteine thiolactone
Inverse Correlation
Regulation of cell proliferation via MAP1/3 signaling.
Production of inflammatory prostaglandins
Involved in the Wnt signaling pathway and modulates MYC expression.
Involved in mechanisms regulating cell-cell adhesion, mobility, and proliferation.
Potent pleiotropic pro-inflammatory cytokine that regulates cell growth and differentiation.
Produces melanin pigment
Energy metabolism
Innate immune response to Gram-positive bacteria and fungi
Controls the expression of genes associated with innate immunity in the absence of
pathogens or elicitors.

p-value
0.0045
0.0032
0.0034
0.0445
0.019
0.0066
0.0452
0.0598
0.0109
0.0046
0.0032
0.0201
0.0054
0.0487
0.0227
0.0401
0.0052
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Figure 9-7. Gene-expression evaluation of HPRT high vs HPRT low expression B cell lines. 79 Cancerous B cell
lines are ranked on the Y-axis according to their relative HPRT expression, which is portrayed on the right-hand Yaxis. The expression of 105 cancer-associated genes are labeled on the X-axis. The expression of each of these genes
is portrayed with higher expression scaled to darker color. We found significant variability within B cell lines in
terms of HPRT expression and also identified correlative relationships between the gene expression of HPRT and
other cancer-associated genes.
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Discussion
HPRT is an enzyme that plays a critical role in the cell cycle by providing essential
nucleotides that support cell division and DNA replication. We have shown that HPRT is
significantly elevated in some patient malignancies. This elevation appears to manifest via colocalization to the plasma membrane of the cell. Yet, this surface expression is not found on all
malignant cells and we have shown that many cell lines have significant variation in regard to
their expression of HPRT. As cell cycle regulation is a common target for mutation in malignant
cells, we hypothesize that enzymes controlling the cell cycle are the most likely contributing
factor to the differential HPRT expression within these cells 500,570. Additionally, we hypothesize
that surface presence of the enzyme is related to an overabundance of the protein internally, and
we predict that cell lines with an unusually high level of HPRT will have significant surface
expression.
As a protein that is presented on the surface of malignant cells and absent on the surface
of normal cells, HPRT could be used as a cancer-associated epitope for immunotherapy
targeting. New epitopes are required as cancer is an evolving disease and adapts to avoid
immune detection 554. There has been unprecedented success using CD19 Chimeric Antigen
Receptors to target and kill malignant B cells 556–558,560. Yet, this therapy is not cancer-specific
and targets healthy cells as well. As a protein that appears to be found only on malignant cells,
HPRT could serve as a safer target for patients with B cell malignancies, as they may maintain
their healthy supply of B cells. HPRT could also serve as a novel biomarker to aid in increasing
numbers of CD19-resistent cancers 71,562. Targeting HPRT could serve as an additional treatment
to target cells that become resistant to current treatment regimes.
While HPRT is present on the surface of Raji cells, we hypothesize that only cells with
significantly elevated HPRT production express the enzyme on the plasma membrane. Screening
212

patients for surface HPRT would be feasible; a simple blood test would confirm whether a
patient was positive or negative. Our data indicates that HPRT surface localization is a relatively
common occurrence in these B cell malignancies and could be a valuable biomarker in future
therapeutic treatments. Future work will need to be conducted using a larger number of patient
samples to determine whether targeting HPRT would be technically feasible and beneficial from
a therapeutic standpoint.
While the surface expression of HPRT may be useful as a biomarker for diagnosis and
treatment, novel correlations between HPRT and other genes may highlight possible regulatory
roles that HPRT play within the cell. Of the 17 genes that had a significant correlation to HPRT
expression, 9 are involved in cellular proliferation and DNA synthesis/repair. With this is mind,
HPRT may be responsible for additional regulation of cellular proliferation outside of nucleotide
synthesis and may interact or direct other genes. Another possibility is that the same genes that
are regulating cellular proliferation in these genes may also influence HPRT expression. On an
interesting note, of the 9 genes with an inverse correlative relationship with HPRT expression, 4
genes (PTGS2, IL6R, TLR6, and BAK1) are involved in the regulation and activation of the
immune system. This may suggest that the upregulation of HPRT could have a side effect of
downregulating the immune system.
In addition, we also noted some interesting cell lines that have gene profiles significantly
different from any other cell line. SUDHL4, AMO1, and L428 cells appear to have inverse gene
expression to the average B cell line. This highlights that any observed correlations between
gene expression are the result of several different contributing factors, and not just HPRT
expression within these cells.
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Conclusions
Because HPRT is localized to the surface of malignant lymphocytes, it has the potential
to be used as a targetable biomarker for immunotherapy. As antigen escape is emerging as a
significant concern with targeted immunotherapy, the need to find and use new biomarkers is
always increasing. In addition, the genes that are correlated with HPRT expression may elucidate
a new role of HPRT in cancer proliferation.
List of abbreviations
HPRT; hypoxanthine guanine phosphoribosyltransferase, ALL; acute lymphoblastic leukemia,
CLL; chronic lymphoblastic leukemia, BRCA1; Breast cancer type 1 susceptibility protein,
PIK3CA; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha, WDYHV1;
Protein N-terminal glutamine amidohydrolase, AK7; Adenylate kinase 7, BLMH; Bleomycin
hydrolase, PRKD2; Serine/threonine-protein kinase D2, PTGS2; Prostaglandin G/H synthase 2,
CDH1; Cadherin-1, IL6R; Interleukin-6 receptor subunit alpha, MC1R; Melanocyte-stimulating
hormone receptor, AMPD1; AMP deaminase 1, TLR6; Toll-like receptor 6, BAK1;
Brassinosteroid insensitive 1-associated receptor kinase 1
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Abstract
Background: Incidence of endometrial cancer are rising both in the United States and worldwide.
As endometrial cancer becomes more prominent, the need to develop and characterize
biomarkers for early stage diagnosis and the treatment of endometrial cancer has become an
important priority. Several biomarkers currently used to diagnose endometrial cancer are directly
related to obesity. Epigenetic and mutational biomarkers have been identified for endometrial
cancer, and have resulted in treatment options for patients with specific aberrations, but many
tumors who do not harbor those specific aberrations. A promising alternative is to develop
biomarkers based on differential gene expression, which can be used to estimate prognosis.
There remains a need to identify additional biomarkers to help physicians identify and
characterize endometrial cancer and to optimize patient treatments.
Objective: Due to their significant elevation within other cancer types, we have evaluated
expression levels of JAG2, AURKA, PGK1, and HPRT1 in endometrial tumors to determine
whether they show promise as diagnostic, prognostic, or treatment biomarkers.
Study Design: We evaluated 589 patients to determine differential expression between normal
and malignant patient samples. We then supplemented these evaluations with
immunohistochemistry staining of endometrial tumors and normal tissues. Additionally, we used
the Library of Integrated Network-based Cellular Signatures to evaluate the effects of 1769
chemotherapy drugs on 26 cell lines to determine the effects of each drug on HPRT1 and
AURKA expression.
Results: Expression of all four genes was elevated when compared to normal samples, and
HPRT1 and PGK1 showed a stepwise elevation in expression that was significantly related to
cancer grade. To determine the prognostic potential of these genes, we evaluated patient outcome
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and found that levels of both HPRT1 and AURKA were significantly correlated with overall
patient survival. When evaluating drugs that had the most significant effect on lowering the
expression of HPRT1 and AURKA, we found that Topo I and MEK inhibitors were most
effective at reducing HPRT1 expression. Meanwhile, drugs that were effective at reducing
AURKA expression were more diverse (MEK, Topo I, MELK, HDAC, etc.). The responses of
these drugs on the expression of HPRT1 and AURKA provides insight into their role within
cellular maintenance.
Conclusions: Collectively, these data show that JAG2, AURKA, PGK1, and HRPT1 have the
potential to be used independently as diagnostic, prognostic, or treatment biomarkers in
endometrial cancer. Expression levels of these genes may provide physicians with insight into
tumor aggressiveness and chemotherapy drugs that are well suited to individual patients.
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Introduction
Endometrial cancer is the fourth most common cancer in women with 12,990 new
diagnoses and 4,120 deaths in 2016 in the United States417. Over 710,200 women are living with
endometrial cancer in the United States, and approximately 2.8% of women will be diagnosed
with the disease at some point during their lifetime. As the most significant risk factor for
endometrial cancer is obesity, a majority of the biomarkers used to detect and monitor
endometrial cancer development are related to metabolic and endocrine alterations571.
Androgens, estrogens, prolactin, thyroid stimulating hormone, leptin, and adiponectin are a few
of the biomarkers utilized to highlight risk of endometrial cancer development. While these
biomarkers can be useful, they are oftentimes somewhat subjective as the levels of these
hormones fluctuate naturally, are generally elevated with obesity, and are not necessarily unique
to cancer development571,572. In order to find new biomarkers that may act as diagnostic
biomarkers for endometrial cancer, we evaluated Jagged2 (JAG2), Aurora Kinase A (AURKA),
Phosphoglycerate Kinase 1 (PGK1), and Hypoxanthine Guanine Phosphoribosyltransferase
1(HPRT1) due to their role in cellular proliferation and cancer development. We evaluated these
genes because of their upregulation and diagnostic potential in other cancer types61,573–577.
JAG2 is a notch transmembrane ligand. Notch signaling is a conserved signaling pathway
linked to the development of several cancers due to its role in cell fate, cellular proliferation
regulation, and cell death578. This is exemplified by the fact that Notch signaling regulates stem
cell proliferation and differentiation579. Within cancer, Notch signaling mediates hypoxia,
invasion, and chemoresistance580, and JAG2 expression in primary tumors has been correlated
with vascular development and angiogenesis581. In addition, elevated levels of JAG2 result in
significant chemoresistance, and when JAG2 is knocked down in mice, tumor cells become
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sensitive to chemotherapeutics (doxorubicin)576. Notch signaling has been identified as an
important pathway for carcinogenesis of the endometrium582. Additionally, JAG2 has been
shown to be a promising target in several cancer cell lines, as specific antibody-drug conjugate
have resulted in tumor reduction583.
AURKA is a cell-cycle regulated kinase that functions in spindle formation and
chromosome segregation during the M phase of the cell cycle. AURKA has been shown to be a
downstream target of MAPK1, which is a major force in cellular proliferation in several cancer
cells584. The protein is also elevated in a variety of cancer and has a significant association with
disease recurrence574,575. Because AURKA is upregulated in cancers, efforts have been made to
target the protein to aid in tumor reduction. Upon AURKA suppression, cancer cells become
sensitive to chemotherapeutics and overall tumor growth is suppressed in a variety of cancer
cells (docetaxel & taxane)585,586. The role AURKA may play as a diagnostic biomarker in
endometrial cancer has not been well studied, although it has shown promising results in other
cancer types575,587–590.
PGK1 is involved in the glycolysis pathway and functions by transferring a phosphate
group from 1,3-bisphosphoglycerate to ADP to form ATP591,592. As an enzyme involved in
generating valuable energy for the cell, especially in hypoxic conditions, PGK1 has been
correlated with cancer development and progression in a variety of tumor types577,593,594. It’s role
in promoting tumor proliferation is linked to PGK1’s ability to promote tumor
angiogenesis595,596, DNA replication and repair597598, and cancer metastasis594,599. While the
protein is elevated internally in several cancers, it is also actively secreted from tumor cells,
where it cleaves plasminogen to create angiostatin600. PGK1 has been shown to be upregulated in
several cancer types, but has not been evaluated for upregulation in endometrial cancer594,601.
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HPRT1 is a nucleotide salvage enzyme involved in the cell cycle498,514. This enzyme is a
transferase responsible for producing guanine and inosine nucleotides by transferring a
phosphoribose from PRPP to guanine and inosine bases, respectively, during cellular
maintenance10,28. As cells rapidly divide, the need for nucleotides increases, and subsequently
HPRT1, has been shown to be elevated in several malignant settings61,62. As the enzyme shows
upregulation in malignant tissue while maintaining stable levels in normal tissue, it has the
potential to be used as a biomarker for cancer development in several cancer types.
We decided to evaluate these enzymes in endometrial cancer because they have all shown
promising diagnostic potential in other tissue types as biomarkers for disease development and
progression but have not been evaluated in endometrial cancer. As malignant endometrial
biomarkers are less established, we hope to identify additional markers for malignancy to aid in
the early diagnosis and possible treatment of endometrial cancer.
Materials and Methods
Chemicals/Reagents
DIVA Decloaker 10x, Background Sniper, Mach 4 HRP polymer, DAB Peroxidase,
Hematoxylin, Hydrophobic pen, and Universal Negative antibodies were all obtained from
Biocare Medical, Concord, CA. Anti-JAG2 (LifeSpan Biosciences, Inc. Seattle, USA), AntiAURKA (Sigma-Aldrich, St. Louis, USA), and anti-PGK1 (Abcam, Cambridge, UK) were
stored at -20°C. Anti-HPRT monoclonal antibody (Abcam, Cambridge, UK) was aliquoted and
stored at -20°C. GAPDH polyclonal antibody (Cell signaling) was aliquoted and stored at -20°C.
Tween20 (Fisher Reagents, Waltham MA) was stored at room temperature. 30% Hydrogen
Peroxide (Fisher Reagents, Waltham MA) was stored at 4°C.
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Tissue Microarray Samples
Tissue microarrays were obtained from Biomax and stained for GAPDH, HPRT, JAG2,
AURKA, PGK1, and with an isotype control. Patients were all female and ranged in age from 21
to 63. Normal (n=9), cancer adjacent (n=9), and malignant tissue (n=54) (grade 1-3) were
included in the analysis (Table 1).
Immunohistochemistry
Protein levels were assessed using protocols described by Townsend et al. with slight
modifications61. Briefly, tissues were rehydrated, washed, and treated with DIVA Decloaker.
Following a hydrogen peroxide wash, tissues were treated with a Background Sniper followed by
a primary antibody (1:100 dilution). After a series of washes, the tissues were treated with DAB
Peroxidase and hematoxylin and imaged using a standard light microscope.
Tissue Quantification
ImageJ software was utilized to quantify staining intensity602. An IHC toolbox plugin was
selected with the “DAB (more brown)” option to remove staining that is not resulting from DAB.
After this modification, the images were converted to a grayscale and a threshold was applied to
eliminate areas of negative space that could potentially bias the results. Once a universal
threshold was applied, the average gray intensity of the tissue was collected.
Tumor Gene-expression Analysis
We obtained RNA-Sequencing and clinical outcomes data for Uterine Corpus
Endometrial Carcinoma (UCEC) samples from The Cancer Genome Atlas (TCGA)540. We used
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transcripts-per-million values, summarized at the gene level. These data were derived from
tumor and normal samples.
Survival was calculated using a Cox proportional hazard model. Inaddition to gene
expression (primary variable), covariates included gene expression and clinical factors such as
age, race, and tumor purity. Kaplan-Meier curves were generated to compare survival of patients
with the highest 20% of target gene expression against those with the lowest 20% of target gene
expression. The statistical analyses and curve generations were calculated utilizing the TIMER
program developed by Li et al. 603.
Drug Response Analyses
We evaluated the effects of chemotherapy treatments on cell lines using two publicly
available databases. First, we examined data from the Cancer Cell Line Encyclopedia (CCLE)537.
We obtained treatment-response data for 24 drugs that were available from the CCLE portal and
used the area above the fitted dose-response curve (ActArea) as a metric of treatment
response604. We obtained transcript-level expression levels for CCLE536 and summed proteincoding transcript values to gene-level values using a custom Python script (https://python.org).
For each of four genes (HPRT1, AURKA, JAG2, and PGK1), we identified cell lines for which
drug-response and gene-expression data were available and then ranked the cell lines according
to expression of the respective genes. Next, we selected the lowest- and highest-expressing cell
lines for each gene and used a Mann-Whitney U test to evaluate differences in ActArea values
between these cell-line groups. To perform these calculations, we used the R statistical software
(version 3.4.3)569.
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Second, we evaluated data from the Library of Integrated Network-based Cellular
Signatures, which contains gene-expression profiles for cell lines after drug perturbations. We
wrote a Python (version 3.6.5) script to extract HPRT1 and AURKA expression values from the
LINCS database for samples from 26 cell lines for which data were available. We used the Level
5 data, which were generated using the L1000 platform605, normalized using a z-score
methodology within each plate, and averaged across replicates. Using the R (version 3.4.4)569
statistical software and the readr package (version 1.1.1)606, we parsed the metadata file to
identify experiments where the cell lines had been treated with chemotherapeutic compounds
(pert_type = "trt_cp"). The summarized data values indicate relative gene-expression levels for
cells treated with a given compound relative to control-treated cells. To perform this filtering and
data transformation, we used the dplyr (version 0.7.4)607 and reshape2 (version 1.4.3) packages
608

. Before plotting the data, we grouped the values for each cell line by compound name. We

identified the median value for each group and sorted the values from lowest to highest. Then we
used the superheat package (version 1.0.0) to create heatmaps with data from the seven cell lines
with the most treatment data 543. The code and data we used for this analysis can be found at
https://bitbucket.org/alyssaparker99/lincs-heatmaps
Statistical Analysis
Staining intensity between tissue samples were analyzed using an ANOVA test with the
multiple comparison method. Additionally, unpaired t tests were utilized in conjunction to
confirm statistical significance. These statistical tests were performed in GraphPad Prism 7
software. Differences were considered significant when the p value was < 0.05. Asterisks were
used in figures to indicate levels of significance with ns = P > 0.5, * = P ≤ 0.05, ** = P ≤ 0.01,
*** = P ≤ 0.001, and **** = P ≤ 0.0001.
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Results
JAG2, AURKA, PGK1, and HPRT1 had significant upregulation in malignant samples when
compared to normal.

Figure 10-1. Gene expression in patient samples. HPRT, PGK1, JAG2, and AURKA were analyzed for gene
expression in both normal (red line) and malignant (blue histogram) samples. Relative protein expression is
quantified on the X-axis (represented as transcripts per million), while the frequency of the expression is plotted on
the Y-axis.
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We evaluated gene-expression levels for AURKA, JAG2, HPRT1, and PGK1 in tumors
and normal tissues from TCGA. Upon comparing malignant and normal samples, we observed a
consistent elevation of each of the genes in malignant tissues (Figure 1). JAG2 had the smallest
elevation overall (p-value = 4.6x10-3), while AURKA showed the largest increase (p-value =
1.2x10-21). This upregulation indicates that these genes may be useful as diagnostic markers of
endometrial cancer, as they have differential expression between normal and malignant samples.
When analyzing protein levels in tissue microarrarys from a separate cohort, we again
found that all four genes were significantly elevated within malignant samples (Figure 2). This
confirmed the initial analysis with gene expression data. In addition, we found that PGK1 and
HPRT1 both showed significant differences between grades as there was a stepwise elevation of
protein expression corresponding to grade. This indicates that HPRT1 and PGK1 may have a
grade dependency, and could serve as biomarkers for tumor aggressiveness. All four genes
showed a range of protein expression in both malignant and normal samples (Figure 3).
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Figure 10-2. Tissue evaluation of AURKA, JAG2, PGK1, and HPRT. Tissues were quantified on a gray scale with
lower values indicating darker staining intensity. A, AURKA expression and B, JAG2 expression was significant
between malignant and normal samples, but showed no significance between cancer grade. C, PGK1 expression and
D, HPRT expression showed significance both between normal and malignant samples in addition to between
cancer grade.
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Figure 10-3. Gene expression between normal and malignant patient samples. Tissues were quantified on a gray
scale with lower values indicating darker staining intensity. Across malignant samples, patients had a variety of
expression of each of the genes evaluated that were all significant from each other with the exception of JAG2 and
HPRT expression. In addition, normal samples also showed a variety of expression of the genes, with PGK1
showing the highest expression and AURKA showing the lowest expression.

To determine whether elevated expression of these genes occurred in the same patients,
we plotted expression values for each patient jointly for all four genes. There was no pattern of
concordant elevation across PGK1, AURKA, JAG2, and HPRT1. For example, patients with
elevated levels of AURKA did not share the same high levels of HPRT1 or of the other genes
(Figure 4). This was observed in all cancer stages. For example, there were cases where the
patient with the lowest expression of AURKA (patient 7 in Stage 2) also had the highest
expression of HPRT1. This indicates that these biomarkers may be useful in identifying different
patients and that each biomarker may be independently used to benefit further characterization of
individual patient cancer types.
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Figure 10-4. Individual patient expression of biomarkers. Each biomarker and their relative expression is plotted
according to the patient. Relative expression is represented on the Y-axis, while the protein evaluated is represented
on the X-axis. Individual patients did not show a pattern of biomarker elevation consistently in any of the stages
evaluated.

AURKA and HPRT1 elevation have a significant impact on patient survival.
We evaluated overall patient survival in patients with the highest 20% of biomarker
expression and patients with the lowest 20% biomarker expression to determine whether the
elevation of these genes had any impact on survival. Both PGK1 (p-value=0.589) and JAG2 (pvalue=0.46) showed insignificant differences in survival over the course of 100 months between
high and low expressors. While there may be elevation of these genes within cancer, they do not
seem to contribute to survival outcomes. Interestingly, both AURKA and HPRT1 showed
significant differences in survival in high vs low expressing patients. Following 100 months,
patients with the highest 20% of AURKA expression showed significant (p-value<0.0001)
decreases in survival and AURKA elevation correlated with a lower survival rates (Figure 5).
This same pattern was also observed for patients with elevated HPRT1 expression, as patients
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with the highest 20% HPRT expression had significantly (p-value=0.041) decreased survival
compared to their lower expressing counterparts. This shows that both AURKA and HPRT1 may
have significance beyond diagnostic; they also may be useful, as prognostic biomarkers for
uterine corpus endometrial cancer.

Figure 10-5. Survival of patients with elevated levels of JAG2, AURKA, PGK1, and HPRT1. We plotted the survival
of patients with the highest 20% expression of each respective biomarker (red line) and compared them to the
patients with the lowest 20% expression (blue line) over the course of 100 months. We found no statistically
significant difference in survival in regards to high and low expression of PGK1 or JAG2, but found significant
decreases in survival in patients with an elevation of AURKA (p-value <0.0001) and HPRT1 (p-value=0.041).
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Drug treatments of cell lines with high and low target gene expression.
To determine whether these genes could be utilized as biomarkers for physicians when
deciding treatment options, we analyzed the effects of 24 drugs on cell lines with relatively high
and low expression of AURKA, JAG2, PGK1, and HPRT1. Cell lines were ranked according to
their expression of each gene and highest and lowest expressing cell lines were chosen for
analysis (Figure 6). Although there was no significance observed, there were some responses that
appeared to have a larger impact than others. Drugs with the largest differences were PD0325901 (MEK inhibitor), TAE684 (ALK inhibitor), AEW541 (IGF-1R inhibitor), and Nilotinib
(tyrosine kinase inhibitor) in JAG2, PGK1, HPRT1, and AURKA, respectively. Several of the
drug responses were negligible as the mean ActArea was almost identical in a majority of the
responses between the high and low expression cell lines (Figures 7-10).
Table 10-1. Protein expression within patient tissue.

Protein

n

General Function

HPRT
PGK1
AURKA
Jag2

68
71
72
72

Nucleotide Salvage
Glycolytic Enzyme
Cycle-regulated Kinase
Protein Coding

Average gray
value Malignant
157.206
107.273
209.994
143.635

Average Gray
Value CAT
186.176
154.437
236.147
194.297

Average Gray
Value Normal
223.207
171.748
244.352
186.269

Note. CAT; Cancer Adjacent Tissue
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Figure 10-6. Cell lines ranked by their relative expression of JAG2, AURKA, PGK1, and HPRT1. Cell lines were
ranked according to their gene expression level (transcripts per million) and the 10 highest expressing and 10 lowest
expressing cell lines are shown.
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Drugs with the largest impact on AURKA and HPRT1 expression.
As HPRT1 and AURKA elevation showed prognostic significance (Figure 5), we
analyzed data from the LINCS, a publicly available resource that contains gene-expression
responses signatures for 1769 chemotherapy drugs and 26 cell lines. We searched for drug
treatments that caused significant declines in HPRT1 and/or AURKA expression. These
responses varied widely across drug treatments and cell lines with some drugs increasing the
expression of the genes and, other decreasing expression. The vast majority of drug treatments
had no impact on HPRT1 or AURKA expression. We focused on seven cell lines for which data
were most available (Figure 11). For both genes, over 12,000 drug-cell line interactions resulted
in no effect. When evaluating AURKA expression, 78 interactions resulted in a severe reduction,
396 resulted in an intermediate reduction, while 14 resulted in a severe elevation and 141
resulted in an intermediate elevation of the gene. When evaluating HPRT1 expression 13
interactions resulted in a severe reduction, 233 resulted in an intermediate reduction, while 15
resulted in an intermediate elevation of the gene (Table 2). This indicates that AURKA may be a
better prognostic biomarker than HPRT1 as there is a larger number of events where the protein
was significantly decreased upon treatment.
Table 10-2. Impact of drug treatment on AURKA and HPRT expression.

AURKA

HPRT1

Description
Severe Reduction
Intermediate Reduction
No Effect
Intermediate Elevation
Severe Elevation

PTEZ Score Range
-10  -6
-6  -2
-2  2
26
6  10

# samples
78
396
14,174
141
14

Severe Reduction
Intermediate Reduction
No Effect
Intermediate Elevation
Severe Elevation

-10  -6
-6  -2
-2  2
26
6  10

13
233
14553
15
0

Note. PTEZ; Post-treatment expression z-score
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Figure 10-7. Drug responses to cell lines with elevated JAG2. The 20 cell lines with the highest and lowest
expression for each target gene from the previous analysis in Figure 6 (X-axis) were evaluated via their Activity
Area (ActArea) in response to drug treatments. Drug responses are represented by individual graphs with the mean
ActArea plotted on the Y-axis. Drugs with a high ActArea indicate sensitivity, while drugs with a low ActArea
indicate resistance. The mean ActArea is represented by a line within the figure to indicate the average increase or
reduction between the high expressing and low expressing cell lines.

233

Figure 10-8. Drug responses to cell lines with elevated PGK1. The 20 cell lines from the previous analysis in Figure
6 were evaluated via their ActArea in response to drug treatments. The mean ActArea is represented by a line within
the figure to indicate the average increase or reduction between the high expressing and low expressing cell lines.
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Figure 10-9. Drug responses to cell lines with elevated HPRT1. The 20 cell lines from the previous analysis in
Figure 6 were evaluated via their ActArea in response to drug treatments. The mean ActArea is represented by a line
within the figure to indicate the average increase or reduction between the high expressing and low expressing cell
lines.
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Figure 10-10. Drug responses to cell lines with elevated AURKA. The 20 cell lines from the previous analysis in
Figure 6 were evaluated via their ActArea in response to drug treatments. The mean ActArea is represented by a line
within the figure to indicate the average increase or reduction between the high expressing and low expressing cell
lines.

236

The ten drugs with the largest reduction in AURKA expression were Ro-4987655, Genz644282, OTS-167, Vorinostat, Pralatrexate, Epirubicin, Ro-4987655, Pralatrexate, JNJ26481585, and R-547. Each of these drugs has a different mechanism of action but most ware
involved in DNA synthesis and regulation. Of note, when analyzing the drugs that resulted in an
increase in AURKA expression, we found that 9 of 10 drugs were directly involved in inhibiting
microtubule function or inhibited PLK. This was consistent throughout our analysis and indicates
AURKA may be connected in a regulatory fashion to these cellular mechanisms (Table 3).
Table 10-3. Effective drugs for the reduction of AURKA.

Cell Line

Drug

Inhibition Target

Target
Symbol
Drugs with significant reduction in AURKA expression post treatment
Ro-4987655
Mitogen-Activated Protein Kinase
MEK
A375
Genz-644282
Topoisomerase I
Topo I
A375
OTS-167
Maternal Embryonic Leucine-Zipper MELK
HUES3

PTEZ Score

Vorinostat
HUES3
Pralatrexate
A375
Epirubicin
MCF7
Ro-4987655
HT29
Pralatrexate
MCF7
JNJ-26481585
A375
R-547
HT29
Drugs with an increase in AURKA expression post treatment
BIIB-021
Heat Shock Protein 90
PC3
NMS-1286937
Polo-like Kinase 1
HT29
NMS-1286937
Polo-like Kinase 1
HELA
Docetaxel
Microtubule Function
HT29
Epothilone-b
Microtubule Function
HT29
Indibulin
Microtubule Function
HT29
Dolastatin-10
Microtubule Function
HELA
Volasertib
Polo-like Kinase 1
HELA
Epothilone-b
Microtubule Function
HT29
Combretastatin-A-4 Microtubule Function
HELA

HDAC
Topo II
MEK
HDAC
CDK

-10
-9.838
-9.471
-9.284
-9.259
-9.206
-8.938

HSP90
PLK
PLK
PLK
-

6.298
6.407
6.426
6.458
6.518
6.552
6.666
6.732
6.898
7.007

Kinase
Histone Deacetylase
DNA synthesis
Topoisomerase II
Mitogen-Activated Protein Kinase
Metabolic
Histone Deacetylase
Cyclin Dependent Kinase

-10
-10
-10

Note. PTEZ; Post-treatment expression z-score
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Drugs that resulted in the highest reduction in HPRT1 expression were AS-703026, OTS167, BGT-226, genz-644282, AS-703026, SN-38, SN-38, TAK-733, paclitaxel, and KX2-391.
Of these, six were of either Topoisomerase I (Topo I) or MEK. This may indicate a relationship
between HPRT1 regulation and regulation of Topo I or the MEK pathway (Table 4).
Table 10-4. Effective drugs for the reduction of HPRT1.

Cell
Drug
Inhibition Target
Target
Line
Symbol
Drugs with significant reduction in HPRT1 expression post treatment
AS-703026
Mitogen-Activated Protein Kinase
MEK
HT29
Maternal Embryonic Leucine-Zipper
MELK
HUES3 OTS-167

PTEZ
Score

Jurkat BGT-226
MCF7 genz-644282
AS-703026
A375
MCF7 SN-38
SN-38
A375
TAK-733
HT29
MCF7 paclitaxel
MCF7 KX2-391
Drugs with an increase in HPRT1 expression post treatment
Cyclin Dependent Kinase
MNEU dinaciclib
SB-939
Histone Deacetylase
NPC
MNEU mitoxantrone Topoisomerase II
ischemin
P53 Transcription
NEU
mitoxantrone Inflammation
ASC
NVP-BGJ398
Fibroblast Growth Factor Receptor
NEU
Jurkat tanespimycin Heat Shock Protein
dinaciclib
Cyclin Dependent Kinase
SKL
dinaciclib
Cyclin Dependent Kinase
ASC
Cyclin Dependent Kinase
Jurkat dinaciclib

P13K
Topo I
MEK
Topo I
Topo I
MEK
Src

-8.533
-7.601
-7.119
-6.904
-6.702
-6.594
-6.537
-6.366

CDK
HDAC
Topo II
FGFR
HSP
CDK
CDK
CDK

2.362
2.39
2.412
2.454
2.551
2.668
2.72
3.137
3.195
5.414

Kinase
Phosphoinositide 3-Kinase
Topoisomerase I
Mitogen-Activated Protein Kinase
Topoisomerase I
Topoisomerase I
Mitogen-Activated Protein Kinase
Microtubule Function
Sarcome

-9.822
-9.707

Note. PTEZ; Post-treatment expression z-score
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Discussion
We have determined that there is a significant elevation of JAG2, HPRT1, AURKA, and
PGK1 expressionin endometrial cancer. With elevated expression upon malignancy, these genes
can be utilized as a companion diagnostic tool to both identify and characterize endometrial
cancer. As cancer specific biomarkers, these genes may serve as useful markers when analyzing
endometrial cancer development within patient tissue. Additionally, HPRT and PGK1 show
additional promise as possible biomarkers for cancer grade as the levels of the proteins elevated
in a stepwise manner with higher cancer grade. These biomarkers have already shown utility in
other cancer types 61,573,574,576,577,584 and we have shown that their use may also extend to
endometrial cancer.
While there are several epigenetic biomarkers for endometrial cancer (p52, KRAS,
VEGF. PTEN, etc.)609,610, there remains a need to find suitable protein biomarkers for not only
endometrial diagnosis, but also as possible targets for future therapies. Future directions to this
work include evaluating a larger cohort of patients to determine whether the expression of these
biomarkers could have clinical application. Especially in the case of both HPRT1 and AURKA,
it may be beneficial to develop therapies to reduce their expression, thereby determining whether
these genes play a critical role in cancer survival and proliferation as they show significant
impact on overall patient survival.
In addition, the conserved pathways that HPRT1 and AURKA have in terms of drugs that
inhibit or induce their expression, may indicate a regulatory relationship between the inhibited
pathway and the proteins that have not yet been identified. The merit of this hypothesis is
demonstrated as AURKA has a reciprocal regulation with PLK1 in mitotic entry and within
spindle assembly611. This corresponds to the data we have observed as the drugs with the largest
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impact on AURKA elevation with the highest consistency are inhibitors of PLK1 and
microtubule formation. Yet, the consistent relationship between drugs that inhibit HPRT1
expression are both inhibitors of Topo I and the MEK pathway. There has not been any
investigation into the relationship between HPRT1 and these proteins/pathways and our initial
data show that a possible link exists. With this in mind, this potential relationship merits further
examination and could potentially elucidate novel gene interactions specific to cancer.

Figure 10-11. Drugs that lower the expression of JAG2, HPRT1, AURKA, and PGK1. Cell lines (x-axis) were
evaluated for their expression of AURKA and HPRT1 pre and post treatment with drugs (y-axis). The relative
changes in protein expression is indicated by the heat map legend and show the variety of responses to various
drugs. The events and their effects on target gene expression are indicated by the bar graphs.
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APPENDIX 1
HPRT surface localization in malignant prostate cancer cells and the influence of gain of
function p53 mutations on HPRT expression.
Michelle H. Townsend, Abigail M. Felsted, Zac E. Ence, Weston Burrup, John E. Lattin, Stephen
R. Piccolo, Richard A. Robison, and Kim L. O’Neill
The following data contains data published in an abstract in Cancer Research and presented at
the American Association for Cancer Research Annual Meeting in 2018. This appendix contains
data for a manuscript in preparation for publication and all contents and figures have been
formatted for this dissertation.
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Abstract
Prostate cancer is the second most lethal cancer in men, and an estimated 26,730 men
will die from the disease in 2017. We chose to evaluate the HPRT enzyme due to its involvement
in nucleotide synthesis and cell cycle progression. Two prostate cancer cell lines were used for
this analysis (PC3 and DU145) along with malignant tissue. The surface localization of HPRT
was determined utilizing flow cytometry and scanning electron microscopy, while upregulation
within tissue was assessed using immunohistochemistry. Additionally, RNA-seq data was used
to evaluate general HPRT upregulation in patients with prostate cancer (n = 502) when compared
to healthy individuals (n = 52). Throughout our investigation, we found a significant association
between HPRT and the plasma membrane of DU145 cells, but found no presence on PC3 cells.
Flow cytometry showed insignificant (p = 0.14) changes in fluorescence when PC3 cells were
exposed to HPRT antibodies, while there was a significant increase in fluorescence on DU145
cells (p = 0.0004). To determine the distribution of HPRT across the membrane, gold conjugated
antibodies were used for analysis with an electron microscope. The distribution of the gold on
the cell surface showed random HPRT binding across the membrane with no patterns of
localization. This analysis aided in confirming HPRT surface presence as the gold weight % of
DU145 cells increased significantly when exposed to HPRT antibodies (p < 0.0001). In addition
to being presented on the surface of DU145 cells, tissue samples revealed variable HPRT
expression as approximately 53% of prostate cancer patients had elevated levels of HPRT
compared to normal controls, while 47% of patients had no upregulation. TCGA data revealed a
significant (p = 1.53x10-4) increase in HPRT levels upon malignancy. While some patients had
levels consistent with healthy controls, there was a significant number of patients with increased
protein expression upon cancer development. The control of HPRT expression within these
cancer cells has been linked preliminarily to p53 functionality. While PC3 cells are null for p53,
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DU145 cells have a p53 mutation than may exhibit gain of function (GOF) properties. GOF p53
mutations are known to influence salvage pathway enzyme expression and is an influential gene
in HPRT expression in these cancer cells. These results strongly indicate a unique relationship
between prostate cancer cells and HPRT and suggest the protein as a possible biomarker for the
detection and treatment of patients with prostate cancer.
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Introduction
As the second leading cause of cancer related deaths in males, prostate cancer is a
principal health concern. In 2018, approximately 164,690 new cases of prostate cancer are
estimated and 29,430 men are expected to die in the United States612. This is the second most
frequently diagnosed cancer in males following lung cancer462. While incidence rates in younger
men are relatively low, rates increase by 2.8% every year after the age of 65512. While many
environmental factors, such as diet and hormone treatments, have shown to lower the risk of
cancer development by 25% in some cases, there is a need to find suitable biomarkers for cancer
diagnosis and treatment.
Currently, the most routine diagnostic methods for prostate screening are measuring
prostate-specific antigens (PSA), conducting digital rectal examinations, and histological
examinations of biopsied prostate tissue613. PSA, a kallikrein serine protease encoded by the
KLK3 gene, is the routinely tested antigen when screening for prostate cancer. As PSA levels are
often elevated in the blood of prostate cancer patients, measuring PSA can aid physicians in
determining the risk of cancer along with the stage of developed tumors. Yet, these evaluations
can be subjective and variable between patients, making diagnosis difficult when considering
assay sensitivity and specificity614. Another drawback from PSA screening is the lack of
specificity for prostate cancer which results in negative biopsies and over diagnosis615. Although
measuring PSA is a useful tool for the early identification of prostate cancer, there are many
shortcomings that make it less than ideal for several patients613,616,617.
In addition to PSA characterization, several prostate cancer specific antigens have been
identified as autoantibodies present in the serum of patients through phage microarrary
analysis618. This method of screening measures patient antibodies against 22 tumor associated
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peptides, and can detect tumor development with 88.2% accuracy and a sensitivity of 81.6%. In
comparison to PSA tests, these antibody screenings have significantly increased performance619.
Additionally, other overexpressed antibodies have been used in the identification of prostate
cancers such as huntingtin interacting protein-1, prostasomes, and human kallikrein-related
peptidase 2 620–622. Antibodies towards these antigens show a definitive increase in patients with
prostate cancer and are used to improve diagnosis often in combination with PSA screening.
mRNA-based biomarkers have also been shown as dependable biomarkers for prostate
detection. PCA3 (Prostate cancer antigen 3) and ERG (ETS-related gene) are both mRNA
biomarkers that are shown elevated expression in prostate cancer. PCA3 is a prostate-specific
gene that encodes a non-coding mRNA, and the overexpression of the gene was observed in 95%
of prostate cancer patients623,624. ERG gene fusions between TMPRSS2, SLC45A3 or NDGR1
with ERG, and are also extremely common as 50% of prostate cancer patients have the
fusion625,626. This gene fusion results in increased expression of ERG oncogene and high levels
of ERG transcripts615.
Several different surface expressed protein have been identified for their potential
therapeutic use in prostate cancer. Prostate-specific membrane antigen (PSMA) are found on the
surface of prostate cancer cells and are useful for both diagnosis and treatment627. There are
currently several clinical trials investigating PSMA as a target for CAR T cell therapy
(NCT03356795, NCT03089203, NCT03185468, NCT01140373). PSCA is a glycoprotein that is
expressed on the cellular surface of prostate cancer and is detected via immunohistochemistry624.
PSCA also serves as a direct target for CAR T cell therapy and there are three clinical trials
testing the efficacy and safety of anti-PSMA CAR T cells (NCT03198052, NCT02744287,
NCT03267173). Hepsin is a membrane-bound serine protease that is widely expressed
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throughout the body, but is upregulated in malignant prostate tissue and is used as a diagnostic
tool628. There are several other surface antigens, such as Sca-1, CD133, and CXCR4, used to
identify cancer stem cells that possess progenitor cell properties and can serve as targets for
initiating prostate tumorigenesis629,630.
Because the characterization of prostate cancer cells is so integral to the effective
treatment of the disease, we designed this project to identify possible cancer biomarkers that
could be used diagnostically as well as therapeutically. Hypoxanthine Guanine
Phosphoribosyltransferase (HPRT1) has been shown to have potential as a surface antigen in
lung cancer, colorectal cancer, and Burkitt’s lymphoma and has also showed elevated expression
within malignant tissue61,62,388,573,631. HPRT is a salvage enzyme involved in nucleotide recycling
and production throughout the cell cycle28,632,633. We evaluated the expression of HPRT in
prostate cancer to determine if it had a similar potential.
Materials and Methods
Chemicals
Mouse-anti-human HPRT monoclonal antibody clone 1F8D11 (Thermo Fischer
Scientific, Waltham, MA) was aliquoted and stored at -20°C. Anti-mouse-FITC and anti-rabbitFITC antibodies (Sigma Aldrich, St. Louis, MO) were stored at 4°C and were used in minimal
light conditions. Bovine Serum Albumin (Sigma Aldrich, St. Louis, MO) and sodium thiol
sulfate (Macron Fine Chemicals, Center Valley, PA) were dissolved in PBS at a 1-3%
concentration and stored at 4°C. A 50% Glutaraldehyde stock solution (Electron Microscopy
Sciences, Hatfield, PA) was stored at -20°C and workable solutions were diluted to 0.25% in
PBS and stored at 4°C. Glycine (Thermo Fischer Scientific, Waltham, MA) was diluted to
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0.2mM in PBS and stored at 4°C. NF-κB polyclonal antibody (Bioss Antibodies, Wodburn, MA)
was stored at -20°C. GAPDH polyclonal antibody and CD44 monoclonal antibody (One World
Lab, San Diego, CA) were stored at -20°C.
Cell Culture Conditions
The human prostate cancer cell lines PC3 and DU145 were obtained from the American
Type Culture Collection (Rockville, MD). Both cell lines were grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 2mM L-Glutamine (all from Hyclone, Logan,
UT). Cell media was replaced every 48 hours and cells were trypsinized and cut upon 90%
confluency. Cells were treated with Acutase (Stemcell Technologies, Vancouver, Canada) when
utilized for flow cytometry, and when plated for all other applications. Cells were grown at 37°C
and 5% CO2. Cell lines were authenticated in May of 2016 by the University of Arizona
Genetics Core. Cell viability was assessed using trypan blue staining and only cell samples with
a viability over 98% were used for testing.
Immunohistochemistry
Prostate tissue arrays were obtained from Cybrdi. The expression of HPRT was assessed
utilizing standard immunohistochemistry staining outlined in Townsend et al. 62. Briefly, tissues
were soaked in histoclear to remove paraffin, rehydrated in ethanol, and treated with a DIVA
solution to retrieve antigen. Slides were incubated in block and subsequently treated with
primary antibody overnight at 4°C. Tissues were then washed and treated with secondary HRP
conjugated antibodies followed by a DAB peroxidase solution to highlight areas of antibody
binding. A universal negative antibody and a GAPDH antibody were used as the negative and
positive controls, respectively.
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Tissue arrays were imaged blind to ensure each tissue core was accurately represented
without bias. Tissues were then quantified utilizing ImageJ software. All images were evaluated
using the IHC toolbox ImageJ plugin. The DAB option is chosen and the tissue image is
removed of all other staining. Following this analysis, the image is converted to a grayscale and a
threshold is applied in order to eliminate areas of negative space inherit within the tissue. Once
the threshold is applied, the average gray value of the tissue is collected. The same threshold is
applied to all tissue samples in order to ensure consistency.
Flow Cytometry
To evaluate HPRT surface localization on cultured cells (DU145 and PC3), fluorescent
antibodies were used to label target proteins. Briefly, approximately 250,000 cells per sample
were incubated with 1µg of primary antibody at 4°C after washing. Cells were then labeled with
FITC-conjugated secondary (mouse or rabbit) antibodies for 15 minutes at 4°C. Isotype IgG and
NF- κB served as negative controls to account for non-specific antibody binding. CD44 was used
as a positive control. Forward/side scatter plots were used to gate out cell doublets and the
resulting data was analyzed and plotted using FlowJo Software (FlowJo Enterprise).
Confocal Microscopy
Cultured cells were also analyzed using an epifluorescence microscope (Olympus,
Tokyo, Japan) under a laser confocal system (Bio-Rad Laboratories, Hercules, CA) using a
15mW krypton/argon laser. Image processing was conducted using Laser Sharp Computer
Software (Bio Rad Laboratories). Briefly, cells were treated with acutase and plated at a
concentration of 4x105 cells/mL in a 6-well plate. Following one day of growth, cells were
washed and treated with 2.5µg of primary antibody and incubated at 4°C for 15 minutes on a
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shaker. Cells were then treated with FITC-conjugated secondary antibody under the same
conditions as primary antibody. Finally, cells were treated with a 1:1000 dilution of Cell Mask
Deep Red plasma membrane dye (Fisher Scientific, Waltham, MA) and incubated at 37°C for 10
minutes prior to imaging.
Scanning Electron Microscopy
Samples were analyzed under a scanning microscopy using procedures outlined by
Weagel et al. 389. In brief, cells were washed thoroughly with BSA, Sodium Thiol Sulfate, and
sodium azide, before treatment with biotin-labeled primary antibodies. Cells were then washed
and treated with gold-conjugated streptavidin. Following cell staining, the samples were fixed
with a 0.25% flutaraldehyde solution and treated with a gold enhancement kit. Finally, samples
were dehydrated in a series of ethanol washes before imaged in low vacuum conditions with a
Phillips XL-30 ESEM 15kV electron stream. A gaseous side electron detector (GSE) and Back
Scatter electron detector (BSE) were used to visualize gold particles on the surface of cell
samples. Due to the gold enhancement step, the background elemental gold percentage of gold
are approximately 8%
Once images for the cells were obtained, the elemental composition of the cells was
evaluated using energy dispersive spectroscopy (EDAX). EDAZ analysis provides a k-ratio, a Zvalue, an A-value, and an F-value. The k-ratio represents the element’s peak height compared to
a sample of the pure element collected under the same conditions. The Z value represents a
correction in the atomic number taking backscattered election yield of the pure element and the
sample. The A value represents a compensation for X-rays generated in the sample that are
cannot emit energy. The F value represents a correction for the generation of X-rays. We used
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these EDAX output values to normalize our samples gold weight percentages using the
following equation:
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =
Cell lysate preparation and Western Blot analysis

𝑘𝑘 − 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 ∗ 100
𝑍𝑍 ∗ 𝐴𝐴 ∗ 𝐹𝐹

DU145 and PC3 cells were grown to 95% confluency and trypsinized. Following
washing, cells were treated with a RIPA buffer with freshly added protease and phosphatase
inhibitor (all from Thermo Fisher Scientific, Waltham, MA). The solution was vortexed
thoroughly and incubated for 30 minutes on ice with an additional vortex step performed every
10 minutes. The lysed solution was then pelleted at 15,000xg for 15 minutes at 4°C and
aliquoted to eliminate freeze-thawing. All lysate were stored at -80°C.
Lysates were blotted for GAPDH, HPRT, and p53 expression utilizing standard western
blotting techiques described by Sewda et al., with minor modifications634. Each sample was
boiled for 5 minutes prior to running on a 12% polyacrylamide gel under reducing conditions.
Gels were then transferred to a nitrocellulose membrane (Biorad Laboratories Hercules, CA,
USA), blocked, and treated with primary antibody overnight at 4°C on a shaker. The, HRP
conjugated secondary antibodies (Abcam, Cambridge, United Kingdom) were incubated with the
membrane for 1 hour at room temperature. Membranes were washed and treated with Western
Bright (Advansta, California, USA) HRP substrate before capturing the image with X-ray film.
Films were imported into ImageJ and converted to an 8-bit image. Lanes were selected and
plotted. The area under the individual bands were calculated to determine the relative protein
expression of the samples.
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Statistical Analysis
Standard ANOVA statistical analysis with the multiple comparison method was used to
determine the differential surface expression of the various treatments for flow cytometry data on
both PC3 and DU145 cells. In addition, two-way ANOVA tests were performed to compare the
means of HPRT expression between PC3 and DU145 cells. EDAX data was analyzed using an
ANOVA with the multiple comparison method in addition to unpaired t tests to determine
significance between samples. All statistical analysis was evaluated using GraphPad Prism 7
software. Differences were considered significant when the p value was <0.05.
Results
Patients with prostate adenocarcinoma have variable levels of HPRT expression with an overall
trend of elevated expression upon malignancy.
We found that variability in prostate cancer tissue regarding HPRT expression with an
overall trend of increased expression within malignant samples. When compared to normal
samples, there was a statistically significant increase in overall HPRT expression within
malignant samples (p-value < 0.0023). While there was an overall increase in HPRT expression
within cancerous samples, there was a separation between the patients with some individuals
showing unusually high levels of HPRT (“High Adenocarcinoma”) while other patients showed
levels similar to normal controls (“Low Adenocarcinoma”). Of the patients evaluated 47%
showed a ‘high adenocarcinoma’ profile (Figure A1-1B) while 53% of the patients experienced
normal levels of HPRT and were ‘low adenocarcinoma’. Within malignant samples, when
separated, ‘low’ patients were statistically significant from ‘high’ patients (p-value < 0.0001).
This differentiation between patients was observed in all stage levels, as Figure 1A&B show that
within stage III tissue some patients have normal levels of HPRT (Figure 11-1A), while other
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patients have a severe upregulation of the protein in lower, stage II, cancers (Figure A1-1B). This
indicates that the expression of HPRT within tumors is considerably varied between patients. As
there appeared to be no stage dependence, we hypothesized that the increase in HPRT within
some individuals was mutational in cause, as it did not relate to the proliferative state of the
tumor.
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Figure A1-1. HPRT expression in malignant and normal tissue demonstrate variability of expression. Tissues were
evaluated for HPRT expression along with GAPDH as a positive control and an isotype as a negative control.
Images were quantified using a gray scale with lower values indicating a darker stain. A, Sample from a 62-year-old
male with stage III prostate adenocarcinoma had very low levels of HPRT expression similar to those seen in normal
controls. B, Sample from an 81-year-old male with stage II prostate adenocarcinoma had elevated levels of HPRT
that were significant from normal controls. C, Sample from a 63-year-old normal male showed the expected low
levels of HPRT expression within healthy adults. D, Statistical evaluation of HPRT expression along with controls.
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HPRT is co-localized to the surface of DU145 cells, but not PC3 cells.
DU145 cells show statistically significant HPRT expression on the surface of the cell.
There is a statistically significant (p-value < 0.0001) increase in the average fluorescent shift in
the population (33.4%) when cells are exposed to fluorescent anti-HPRT antibodies when
compared to isotype controls (Figure A1-2). This expression is not observed in PC3 cells and
there is no statistically significant shift in the fluorescent population when cells are treated with
anti-HPRT fluorescent antibodies (p-value =0.998). These results are similar to results found in
patient tissue, as some cells have an upregulation of HPRT, which results in surface presentation
of the protein, while other patients have lower levels of the protein that results in no surface
localization.
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Figure A1-2. Surface localization of HPRT in DU145 and PC3 cells. Following treatment with fluorescent
antibodies towards the target proteins, the resulting shifts in the fluorescent population were diagramed. Isotype and
NF-κB were used as negative controls and CD44 was used as a positive control for expression. A, PC3 cells showed
no change in fluorescence upon anti-HPRT treatment while B, DU145 cells show a shift in the population towards a
higher fluorescence, indicating surface expression of the protein. C, Statistical evaluation of PC3 expression of
HPRT and all controls. D, Statistical evaluation of DU145 expression of HPRT and all controls.

To confirm surface expression, we also imaged individual cells and merged them to a
membrane specific dye. The overlap in these images confirms the association of HPRT to the
255

plasma membrane in DU145 cells and the lack of HPRT presence on the surface of PC3 cells.
PC3 cells showed similar staining intensity as isotype controls and did not show co-localization
with the membrane specific dye (Figure A1-3). DU145 cells showed a clear presence on the
surface of the cell that was directly overlapped with the membrane-specific dye (Figure A1-4).
This confirms the surface expression observed in flow cytometry.
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Figure A1-3. PC3 cell images reveal insignificant HPRT surface localization. Cells were treated with an isotype
antibody, HPRT, and CD44 antibodies along with an unstained control. Each sample was imaged separately to
highlight the cell membrane (“membrane”) and the target (“FITC”). Both images were merged to show any overlap
(“Merge”).
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Figure A1-4. DU145 cell images reveal significant HPRT surface localization. Cells were treated with an isotype
antibody, HPRT, and CD44 antibodies along with an unstained control. Each sample was imaged separately to
highlight the cell membrane (“membrane”) and the target (“FITC”). Both images were merged to show any overlap
(“Merge”).
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To further determine the exact location of the HPRT protein on the cell surface, we
performed scanning electron microscopy to visualize the exact position of antibody binding. We
found that the unstained, isotype, and negative control all showed no distinguishable gold
particles, indicating no antibody binding. Yet, both anti-HPRT and anti-CD44 treated cells
showed distinct particles, highlighted in pink, that pinpoints the exact location of antibody
binding on the cellular surface. Anti-CD44 shows some localization of binding as the antibodies
appear to cluster. Anti-HPRT treated cells do not show this same pattern and gold particles are
randomly dispersed across the cell (Figure A1-5).
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Figure A1-5. Exact position of HPRT binding on the surface of DU145 cells. Cells labelled with gold towards the
respective antibody treatment were evaluated for gold weight percentage. The size scale shown in each image
represents a 2μm distance. Images were obtained using a GSE detector to show cell morphology and correct
structure and cellular integrity. Images were also obtained using a BSE detector which images heavy metals within
the samples. EDAX analysis was also utilized to show the elemental composition of each sample. The gold
elemental peak is indicated by a gold arrow.
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When compared to isotype controls, there was a significant increase in HPRT expression on the
surface of DU145 cells (p-value < 0.0001) as determined by increases in gold elemental weight
percentage of the samples. The average gold percentage of anti-HPRT treated samples was
11.63%, while the average gold percentage of isotype controls was 8.58%. This increase in
elemental gold shows the increase in gold binding, and subsequently anti-HPRT binding to the
surface of the cells (Figure A1-6).

Figure A1-6. Gold weight percentage of DU145 cells. The gold weight percentage of each sample was calculated
and compared to controls. Cells treated with anti-HPRT antibodies had a significant elevation in gold weight% when
compared to isotype controls.

Influence of p53 mutations on HPRT expression.
In an effort to determine the molecular mechanism of HPRT elevation and surface
expression we evaluated the differences in transcriptional regulation of the hprt gene between
PC3, DU145, and other cell lines previously determined to have surface expression of the
protein. We determined that cell lines with elevated levels of HPRT on the cell membrane all
have a gain of function (GOF) mutation in p53, a transcription factor of the hprt gene. As GOF
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p53 mutations have already shown to influence salvage enzyme expression, we hypothesized that
this mutation may have an influence on HPRT expression and resulting surface localization,
especially considering our initial hypothesis that the overexpression of HPRT in patients was
mutational in origin. We utilized a protein that showed a historical strong correlation with GOF
mutations (TK1) as our ‘positive’ control for increases in protein levels upon GOF mutations33.
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Figure A1-7. TK1 expression between GOF, LOF, WT, and normal patients. Patient samples were evaluated for
their p53 status and plotted according to ‘GOF’ mutations (G245C, P151S, R175H, R248Q, R249S, R273H,
R282W), ‘LOF’ mutations, and ‘no mutations’ (WT). Each diagram has been log2 transformed to better represent
the data. We evaluated 14 different cancer types for expression changes in TK1 upon p53 mutation. TK1 expression
was evaluated in transcripts per million.
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We evaluated RNA-sequencing data and compared the relative expression of HPRT and
TK1 between GOF mutations, Loss of function (LOF) mutations, WT (‘no mutation’), and
normal samples. This analysis led to conflicting results. We found very little change in TK1, our
positive control, expression between GOF and LOF mutations within several cancer types
(Figure A1-7). Throughout our analysis, only one cancer type showed statistical significance in
TK1 expression between GOF and LOF mutations (Uterine Endometrial Carcinoma; p-value =
0.037). As such, it was difficult to evaluate the influence of GOF p53 mutations on HPRT
expression as our results deviated from previous work. This discrepancy may be due to a small
sample size, as gain of function mutations are somewhat infrequent within patient populations.
In our evaluation of HPRT expression, we found there were only 2 cancer types (diffuse
large B-cell lymphoma & liver hepatocellular carcinoma) that had a significant difference
between the expression of HPRT between LOF p53 mutations and GOF mutations (p-value =
0.0335 & 0.0236, respectively). Several cancer types did show a significant difference between
GOF mutations and no p53 mutation (breast invasive carcinoma; p-value = 0.0028, colon
adenocarcinoma; p-value = 0.0255, bladder urothelial carcinoma; p-value = 0.0052, liver
hepatocellular carcinoma; p-value = 0.0024, and rectum adenocarcinoma; p-value = 0.0067),
showing that mutations in p53 do impact the overall expression of HPRT in some cancer (Figure
A1-8). In addition, a promising observation is in each cancer type regardless of p53 status, HPRT
was significantly elevated between normal and malignant samples (p-value < 0.0001).
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Figure A1-8. HPRT expression between GOF, LOF, WT, and normal patients. All diagrams were log2 transformed
to better represent the data. GOF mutations (G245C, P151S, R175H, R248Q, R249S, R273H, R282W) were
compared to other mutations for variations in HPRT expression upon mutation. HPRT expression was evaluated in
transcripts per million.
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Discussion
We have determined that HPRT has a significant elevation in prostate cancer both within
certain patient tissue and also on the surface of some prostate cancer cells. It would appear that
this overexpression is not a universal event in cancer, and is patient specific. The molecular
mechanism has been preliminarily linked to gain of function p53 functionality within these cells.
The exact mechanism behind the elevation and surface expression of HPRT will require further
study and presents an opportunity to discover new molecular functions and/or control of the
HPRT1 gene within cancer.
HPRT is already known to have a regulatory function as its role in neural development is
critical for healthy growth as patients with a deficiency of the protein suffer from Lesch-Nyhan
syndrome. This regulatory role may extend to a possible advantageous function within cancer
cells, which may explain its subsequent upregulation in approximately 50% of prostate cancer
patients.
Although an exact mechanism is not known, HPRT shows significant surface localization
with prostate cancer cells in some patients and could serve as a biomarker for targeted
immunotherapy, such as CAR T cell therapy. Especially, as HPRT is not found in normal
patients at high levels it may be a beneficial target to limit on-target, off-tumor cytotoxicity.
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APPENDIX 2
HPRT elevation has a direct impact on Guanosine production within cancer cells and induces a
decrease in cytokine production in the tumor microenvironment.
Michelle H. Townsend, Claudia M. Tellez Freitas, Dallas Larsen, Stephen R. Piccolo, K. Scott
Weber, Richard A. Robison, and Kim L. O’Neill

This appendix contains data for a manuscript in preparation for publication and all contents and
figures have been formatted for this dissertation.
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Introduction
Guanosine is a guanine nucleoside that has an important role in regulating inflammation
within the central nervous system (CNS). Both guanosine and adenosine are aromatic organic
molecules that present with one or more phosphates to form components of nucleotides essential
for cellular survival. In addition to their basic role within cellular maintenance, both adenosine
and guanosine act as intercellular messenger molecules.
Adenosine is established as a potent anti-inflammatory molecule that affects the
activation of neutrophils, by inhibiting stimulated cell adhesions to the vascular
endothelium635,636, macrophages, by suppressing chemokine/cytokine production637–639, and T
cells. T regulatory cells (Tregs) express CD39 and CD73 on their cell surface, which produce
adenosine to mediate anti-inflammatory regulatory effects on effector T cells636,640,641. These
anti-inflammatory properties of adenosine have made it an attractive target for therapy in chronic
inflammatory diseases642–644.
Guanine and its derivatives have been identified as modulators of G-protein function,
which are essential in signal transduction645,646. In addition, they have also shown a regulatory
role in small monomeric G-proteins (Ras, Rab Ef-Tu, etc.)647. Guanosine itself has shown antiinflammatory properties specifically within the brain and acts as a neuroprotectant. Specifically,
guanosine has shown to inhibit LPS-induced pro-inflammatory responses648 and reduce NF-kB
signaling pathway and pro-inflammatory cytokine production649. Additionally, guanosine
reduces apoptosis650 and activates cell survival pathways, including P13K/Akt/PKB signaling in
neural cells651–653. Extracellular guanosine has a regulatory role and controls the levels of
extracellular adenosine654,655. An increase in guanosine leads to an increased level of adenosine
and guanosine has been implicates as a potential therapeutic target for reducing inflammation654.
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We have previously shown that a salvage enzyme hypoxanthine guanine
phosphoribosyltransferase (HPRT) is upregulated within several cancer types61. HPRT is
responsible for salvaging GTP and is involved in the production of guanine and its derivatives632.
We hypothesized that an increase in guanosine production within tumors may be persistent
because of the immune protection it provides the tumor as guanosine has shown antiinflammatory properties in the CNS. In addition, as the levels of guanosine have shown to
elevate in hypoxic and hypoglycemic conditions, we believe the increase in HPRT expression
within these tumors has a direct relationship with the conditions present within tumor
microenvironment, which often supports a hypoxic and hypoglycemic state656–660.
Materials and Methods
Cell Culture
Raji, Jurkat, and THP-1 human cell lines were obtained from the American Type Culture
Collection (Rockville, MD, USA). All cells were grown and maintained in RPMI-1640 medium
supplemented with 10% fetal bovine serum and 2mM L-glutamine. Cells were grown at 37°C
and 5% CO2 and were fed every 24-48 hours according to their proliferation. Cell lines were
authenticated in May of 2016 by the University of Arizona Genetics Core.
HPRT Knockdown Raji cells
The pSpCas9(BB)-2a- GFP CRISPR vector was purchased from Addgene (Cambridge,
MA, USA) and guide RNA design was conducted using the CRISPR Design tool created by
MIT568. Briefly, Raji cells were grown to a concentration of 4x105 cells per mL and seeded in a
6-well plate. Following 24 hours of growth, cells were transfected with a lipofectamine LTX
reagent (Invitrogen Waltam, MA, USA). Briefly, 150µL of Opti-MEM (Gibco, Gaithersburg,
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MD) was incubated with 5-7µL of Lipofectamine LTX reagent while 250µL of Opti-MEM was
incubated with approximately 2x103ng of the CRISPR vector. The solutions were mixed
together and incubated at room temperature for 30 minutes. The lipofectamine-DNA solution
was then added to the Raji cells in a drop-wise fashion. Cells were grown for 3 days and then
treated with media containing 6-Thioguanine (6-TG) at a final concentration of 10µg/µL. 6-TG
is a nucleoside analog that is toxic to cells with a functional hprt gene. Cells that survived the 6TG treatment were grown to sufficient quantities to produce cell extract. This extract was
analyzed by western blotting to confirm surviving cells were HPRT-/-.
Calcium Signaling Activation
Calcium mobilization was measured using flow cytometry and the high affinity calcium
indicator Fluo-4 (ex:470–490 nm and em: 520–540 nm). Cells were loaded for 30 mins as
previously published with pluronic acid and 1mM Fluo-4-acetoxymethyl ester (Invitrogen) in
Ringer solution (150 mM NaCl, 10 mM glucose, 5 mM of HEPES, 5 mM of KCl, 1 mM MgCl2,
and 2 mM CaCl2, pH 7.4). Intracellular calcium mobilization was initiated by adding 50 ng/ml
of PMA (phorbol 12-myristate 13-acetate) and 1 μg/mml of ionomycin. For further analysis done
in FlowJo, intracellular calcium flux was measured in the cell lines e using the FlowJo kinetics
tool.
Kaplan-Meier Curves
Survival was calculated utilizing a Cox proportional hazard model. Covariates included
gene expression and clinical factors such as age, race, and tumor purity. Uterine Corpus
Endometrial Carcinoma (UCEC) samples were obtained from The Cancer Genome Atlas
(TCGA)539 and Kaplan-Meier curves were generated to compare survival of patients with the
270

highest 30% of target gene expression to those with the lowest 30% of target gene expression.
The statistical analyses and curve generations were calculated utilizing the TIMER program
developed by Li et al. 603.
Immune Infiltration and Gene correlations
The correlation of HPRT expression to each immune cell subset infiltration and with
other tumor associated genes was generated using the TIMER program developed by Li et al. 603.
Gene-level expression values for tumor samples was obtained from The Cancer Genome
Atlas536,540. Samples were purity-corrected and the Spearman’s correlation and statistical
significance were calculated.
Gene expression correlations
We used RNA-Sequencing data for protein-coding transcripts that had been generated
using Illumina-based, short-read sequencing. These data had been processed using the kallisto
software538, then log- transformed and converted to transcripts-per- million values536. We
summed the transcript-level values to gene-level values and sorted the cell lines according to
HPRT expression level, from high to low expression per sample. We parsed and prepared the
data using Python (https://python.org, v.3.6.1) scripts. In making the heat map, we used the R
(v.3.4.3) statistical package569 and the Superheat package (v.0.1.0)543.
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Figure A2-1. Impact of HPRT elevation on immune gene expression. We evaluated patients with lung squamous cell
carcinoma and ranked them according to their relative expression of HPRT which is represented above the graph.
Cytokine gene expression is organized into ‘pro-inflammatory cytokines’, ‘pro-inflammatory and anti-inflammatory
cytokines’ and ‘anti-inflammatory cytokines’. We found an overall trend of decreasing cytokine expression upon
increased HPRT expression within all cytokine categories.
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Table A2-1. Gene correlations with HPRT expression.
Gene
CD27
CD40
CD40LG
CD70
EDA
EDA2R
EDAR
FAS
FASLG
IL11
IL11RA
IL18BP
IL18R1
IL18RAP
IL1F10
IL1R1
IL1RAPL1
IL1RAPL2

p-value
2.18x10-14
6.29x10-6
5.17x10-16
5.71x10-13
0.007857
1.6x10-15
0.000857
0.000486
0.003111
0.0001
9.49x10-9
1.38x10-9
1.66x10-6
8.2x10-6
0.00325
1.48x10-13
4x10-08
1.17x10-7

Correlation
+
+

Gene
CCL1
CCL11
CCL13
CCL14
CCL15
CCL16
CCL17
CCL18
CCL19
CCL20
CCL21
CCL22
CCL23
CCL25
CCL26
CCL3
CCL4
CCL5
CCL7

p-value
0.000048
0.015893
0.000508
5.69x10-8
1.23x10-5
2.14x10-15
4.3x10-6
0.000121
8.32x10-9
0.00038
3.3x10-16
7.22x10-13
9.37x10-13
0.000173
3x10-16
0.007677
0.000144
4.02x10-6
0.002324

Correlation
+
-

Gene
DCN
DPT
ENG
IL10
IL10Rα
IL10Rβ
IL13
IL20
IL22
IL22Rα1
TNFRSF17

p-value
1.41x10-11
2.33x10-14
0
2.93x10-11
0
0.029185
0.013039
6.38x10-9
3.39x10-11
0.009197
1.37x10-8

Correlation
+
-

Anti-inflammatory and Pro-inflammatory
Gene
p-value
Correlation
LEP
0.001091
LEPR
1.66Ex10-7
LIF
0.000363
LIFR
1.73x10-5
LTA
1.55x10-11
LTBR
0.047026
+
OSM
1.24x10-5
OSMR
0.041817
RELT
3.91x10-5
SIGIRR
6.44x10-9
TNF
8.82x10-11
TNFRSF10B
6.34x10-6
TNFRSF10C
0
TNFRSF13C
0.014051
TNFRSF1A
0.041936
0
TNFRSF1B
TNFRSF21
0.001233
TNFRSF6B
1.02x10-19
Pro-inflammatory
p-value
Correlation
Gene
CNTF
0.000363
CXCL10
0.035549
CXCL11
0.016643
CXCL12
1.38x10-9
CXCL13
4.46x10-7
0.047987
CXCL14
CXCL16
4.46x10-7
CXCL17
8.99x10-5
CXCL2
6.77x10-8
CXCL3
0.001412
CXCR1
1.52x10-7
1.04x10-8
CXCR2
CXCR3
1.84x10-12
CXCR4
1.58x10-13
CXCR5
3.62x10-14
5.61x10-7
CXCR6
CXCR7
0.001016
+
FAM19A1
3.11x10-8
FAM19A2
9.01x10-11
Anti-inflammatory
Gene
p-value
Correlation
IL22Rα2
5.39x10-8
IL24
0.009718
IL29
0.026208
IL4
2.56x10-5
IL5
0.024097
LTB
4.53x10-18
SMAD5
0.034756
+
STAT2
1.76x10-8
STAT3
9.86x10-8
STAT4
8.23x10-17
TNFRSF19
4.27x10-6
-

Gene
IL1RN
IL31
IL33
IL36B
IL36RN
IL6R
TNFSF8
TNFSF9
TNFRSF8
TNFRSF9
TNFSF11
TNFSF12
TNFSF13
TNFSF13B
TNFSF14
TNFSF15
IL1RL1
TNFRSF8

p-value
0.003788
0.025384
2.76x10-5
0.00013
0.041797
3.63x10-5
9.33x10-17
0.025906
7.49x10-13
4.32x10-9
3.06x10-11
1.08x10-12
9.48x10-14
3.31x10-7
1.21x10-13
0.000132
5.8x10-9
7.49x10-13

Correlation
+
+
+
+
-

Gene
IFNA5
IFNAR1
IFNAR2
TNFRSF10D
TNFRSF4
TNFSF4
CCR4
CCR5
CCR6
CCR7
CCR8
CCRL1
FAM19A3
FAM195A5
IFNA14
CCR1
CCR2
CCR3

p-value
0.004918
2.25x10-10
0
4.14x10-14
0
6.7x10-6
2.09x10-17
2.07x10-11
0
4.1x10-14
1.12x10-10
7.84x10-6
8.78x10-11
3.56x10-5
0.009756
1.56x10-9
8.12x10-15
0.000869

Correlation
-

Gene
STAT5A
STAT6
TGFβ1
TGFβ2
TGFβ3
TGFBR2
TNFRSF11B
TNFRSF12A
TNFRSF13B
TNFRSF14
TNFRSF25

p-value
0
1.08x10-5
2.26x10-8
4.46x10-9
6.74x10-13
0
1.73x10-5
2.55x10-6
5.58x10-15
0
3.56x10-8

Correlation
-
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Results
HPRT expression showed an overall negative correlation to genes involved in immune function.
As HPRT levels vary significantly among patients, we evaluated the changes in immune
gene expression in patients with high expression and compared them to patients with lower
expression. For this analysis we evaluated lung squamous carcinoma as it showed the most
distinct elevation of HPRT when compared to normal lung tissue61,62. Of the 194 total genes
evaluated we found a that 68% were negatively correlated with HPRT elevation (31 of 49 antiinflammatory, 54 of 67 anti-inflammatory and pro-inflammatory, and 47 of 78 proinflammatory). Interestingly, there was an overall decrease in both ant-inflammatory and proinflammatory cytokines with elevates expression of HPRT (Figure A2-1). Genes with a
statistically relevant correlation are found in table 1 and show the significant effect elevated
levels of HPRT have in the expression of immune-related genes. Of the genes that did show a
statistically significant positive correlation to HPRT expression seven were pro-inflammatory
(12% of total), two were anti-inflammatory and pro-inflammatory (3.6% of total), and two were
anti-inflammatory (6% of total) in function (Table A2-1).
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Figure A2-2. HPRT influence on patient survival. Patients were divided into the highest expressing 30% and lowest
expressing 30% in regards to HPRT. Patient survival was monitored over an extended time (varied depending on the
cancer as data permitted) and the percent survival was evaluated on the y-axis.
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HPRT elevation has a significant impact on patient survival in several cancer types.
When comparing patients with the highest 30% and the lowest 30% of HPRT expression
we found that low expressing patients had a significant increase in overall survival over a long
term period in several cancer types (Figure A2-2). Most notable, head and neck squamous cell
carcinoma experienced one of the most significant differences between patients. This is
interesting because HPRT is involved in guanosine processing and guanosine is most influential
in the CNS.
Increased HPRT expression correlates to decreased tumor infiltration by immune cell subsets.
We found that in several cancer types there was a significant negative correlation
between HPRT expression and the immune infiltration of B cells, CD8+ T cells, D4+ T cells,
macrophages, neutrophils, and dendritic cells (Figure A2-3). Within prostate adenocarcinoma
(PRAD), lung squamous cell carcinoma (LUSC), and thyroid carcinoma (THCA) the tumor
infiltration of all immune cell types were lessened upon HPRT elevation, with the exception of
CD8+ T cells in THCA cancer. This shows that the expression of HPRT is significantly
associated with the ability of immune cell subsets to penetrate and infiltrate the tumor
microenvironment. Of the immune cell types evaluated, macrophages (42% of cancers) showed
the least change in infiltration, while CD4+ T cells showed the most significant change (62.5%
of cancers). Cancers that seemed to experience no changes in immune infiltration upon HPRT
elevation were esophageal carcinoma (ESCA), kidney chromophobe (KICH), and uterine
carcinosarcoma (UCS) (Table A2-2). In addition, when evaluating the immune infiltration of
immune cells with a change in the copy number of the HPRT gene we found that in several
cancer types there was a significant decrease in immune infiltration in ‘arm-level gain’ and ‘armlevel loss’ patients when compared to ‘normal’ patients (Figure A2-4).
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Figure A2-3. Immune cell infiltration is decreased with high levels of HPRT. HPRT expression levels is represented
on the Y-axis and the infiltration level of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and
dendritic cells is represented on the X-axis. Each cancer type is displayed on the right hand side. These data indicate
that HPRT expression has a significant negative correlation with immune infiltration.
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Table A2-2. Immune cell infiltration according to cancer type and HPRT expression.

Cancer Type
ACC
CESC
COAD
DLBC
ESCA
GBM
HNSC
KICH
KIRP
LIHC
LUAD
OV
MESO
PAAD
SKCM
STAD
UCEC
UCS
BLCA
LUSC
PRAD
THCA
BRCA
KIRC

cor
0.12
0.17
0.03
0.42
0.18
-0.21
0.18
0.15
0.09
0.17
-0.07
-0.06
-0.08
0.13
-0.10
0.06
-0.04
-0.06
0.01
0.23
0.19
0.03
0.23
0.13

Purity

p
0.29
4.4x10-3
0.52
6.1x10-3
0.02
1.5x10-5
7.0x10-7
0.24
0.16
1.5x10-3
0.12
0.17
0.46
0.096
0.04
0.23
0.49
0.68
0.80
5.7x10-7
8.9x10-5
0.46
8.9x10-15
4.7x10-3

B Cell
CD8+ T Cell
cor
p
cor
p
-0.18
-0.22
0.064
0.13
-0.10
-0.15
0.012
0.14
0.09
0.076
0.044
0.38
-0.09
-0.01
0.76
0.96
-0.06
0.40
0.10
0.17
-0.12
-0.10
0.045
0.02
0.01
-0.18 6.8x10-5 0.12
0.03
0.82
0.01
0.94
0.19 2.3x10-3 0.32 1.6x10-7
0.05
0.10
0.076
0.11
-0.07
0.028
0.14
0.1
0.07
0.12
0.02
0.65
0.08
0.48
0.11
0.33
-0.21 6.5x10-3 -0.22 4.1x10-3
-0.04
0.47
0.14 4.6x10-3
-0.19 2.9x10-4 -0.008
0.87
0.047
-0.03
0.62
0.12
0.04
0.76
0.14
0.33
-0.17 9.2x10-4 0.25 1.8x10-6
-0.22 2.3x10-6 -0.13 3.8x10-3
-0.14 5.3x10-3 -0.21 2.6x10-5
-0.20 8.1x10-6 0.24 1.1x10-7
-0.1
1.8x10-3
-0.01
0.88
-0.12
0.014
-0.02
0.64

CD4+ T Cells
cor
p
-0.15
0.21
-0.18 2.2x10-3
-0.30 1.3x10-9
-0.68 6.9x10-4
-0.12
0.11
-0.04
0.39
-0.17 1.8x10-4
-0.08
0.54
-0.17 6.3x10-3
0.02
0.73
-0.15 8.5x10-4
0.07
0.13
0.21
0.051
-0.34 5.6x10-6
-0.19 4.3x10-5
-0.38 6.4x10-14
-0.17 4.5x10-3
-0.12
0.40
0.07
0.20
-0.49 7.2x10-30
0.043
-0.1
-0.39 2.3x10-19
-0.19 3.5x10-9
-0.23 8.9x10-7

Macrophage
cor
p
-0.38 8.0x10-4
-0.15
0.014
0.001
0.98
0.16
0.48
0.06
0.46
0.02
0.61
-0.04
0.38
0.04
0.77
-0.04
0.54
-0.01
0.82
-0.03
0.49
0.02
0.61
0.048
0.66
-0.39 1.5x10-7
0.004
0.94
-0.28 3.7x10-8
-0.05
0.43
-0.04
0.77
-0.15 4.2x10-3
-0.31 6.1x10-12
-0.26 5.8x10-8
-0.31 4.4x10-12
-0.17 1.7x10-7
-0.16 7.7x10-4

Nuetrophil
cor
p
0.04
-0.24
-0.04
0.55
-0.05
0.28
-0.40
0.07
-0.08
0.28
0.042
0.1
-0.12 9.3x10-3
-0.18
0.15
-0.03
0.61
-0.03
0.56
0.034
0.10
1.7x10-6
0.22
-0.15
0.19
-0.38 2.6x10-7
1.4x10-5
0.20
0.004
0.95
0.11
0.061
-0.01
0.93
2.1x10-4
0.19
-0.28 3.7x10-10
-0.17 6.2x10-4
-0.19 2.8x10-5
-0.06
0.06
-0.22 3.0x10-6

Dendritic Cell
cor
p
-0.13
0.27
-0.06
0.34
5.5x10-4
-0.17
0.004
0.98
-0.06
0.42
3.2x10-8
0.27
1.2x10-3
-0.15
-0.23
0.064
0.10
0.10
0.07
0.18
0.08
0.09
3.3x10-4
0.16
3.7x10-4
0.38
7.7x10-6
-0.34
-0.03
0.54
-0.12
0.019
-0.008
0.89
0.074
0.60
1.5x10-9
0.31
-0.34 5.1x10-12
9.1x10-3
-0.13
0.017
-0.11
0.03
-0.07
4.3x10-3
-0.13

Note. Green boxes indicate statistically significant correlations between immune cell infiltration and HPRT
expression. Red boxes indicate samples with a negative correlation to HPRT expression.

Increased levels of HPRT correlate with decreased levels of costimulatory and coinhibitory
molecules.
When evaluating the effect HPRT levels may have on immune activation, we found that
elevated levels of the protein have a significant negative correlation to molecules involved in costimulation or co-inhibition. These results mirror those found in the initial evaluation of proinflammatory and anti-inflammatory cytokines. It appears that the increased expression of HPRT
has a down-regulatory effect on all inflammatory molecules (Figure A2-5).
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Figure A2-5. Effects of high HPRT on coinhibitory and costimulatory signals. The expression of HPRT was
correlated to the expression of five coinhibitory molecules and five costimulatory molecules to determine relevance
of HPRT expression in checkpoint immunotherapy. We found that HPRT had a statistically significant negative
correlation to all molecules evaluated.

Guanosine has a significant impact on immune cell activation
When evaluating the impact on guanosine on immune cell activation, we found that
guanosine significantly decreases the activation of Raji B cells. We found no significant change
in activation in Jurkat T cells or THP-1 macrophages.
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Figure A2-6. Immune cell activation upon treatment with guanosine and adenosine. Jurkat (T cells), Raji (B cells),
THP-1 (macrophages), and a Raji HPRT knockdown were evaluated for their activation upon treatment with
guanosine and adenosine. The normalized representation of the activation and the activation curve are shown for
each respective cell type.
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Conclusion
These data indicate that HPRT has a regulatory role in immune regulation in cancer cells
that may stem back to the immuno-protective role it plays in the CNS to protect neurons from
hypoxic and hypoglycemic conditions which are also common within the tumor
microenvironment.
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